WO2003063771A2 - N4-acylcytosine nucleosides for treatment of viral iinfections - Google Patents

N4-acylcytosine nucleosides for treatment of viral iinfections Download PDF

Info

Publication number
WO2003063771A2
WO2003063771A2 PCT/US2002/040081 US0240081W WO03063771A2 WO 2003063771 A2 WO2003063771 A2 WO 2003063771A2 US 0240081 W US0240081 W US 0240081W WO 03063771 A2 WO03063771 A2 WO 03063771A2
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
dideoxy
fluorine
pharmaceutically acceptable
fluorocytidine
Prior art date
Application number
PCT/US2002/040081
Other languages
French (fr)
Other versions
WO2003063771A3 (en
Inventor
Kyoichi A. Watanabe
Junxing Shi
Michael J. Otto
Original Assignee
Pharmasset Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Ltd. filed Critical Pharmasset Ltd.
Priority to JP2003563467A priority Critical patent/JP2005519916A/en
Priority to KR1020047009263A priority patent/KR100978904B1/en
Priority to MXPA04005779A priority patent/MXPA04005779A/en
Priority to AU2002365234A priority patent/AU2002365234B2/en
Priority to CA2470255A priority patent/CA2470255C/en
Priority to EP02804833A priority patent/EP1569652A4/en
Priority to BR0214944-3A priority patent/BR0214944A/en
Publication of WO2003063771A2 publication Critical patent/WO2003063771A2/en
Publication of WO2003063771A3 publication Critical patent/WO2003063771A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Definitions

  • the present invention is directed to compounds, methods and compositions for the treatment or prevention of viral infections using nucleoside analogues. More specifically, the invention describes N 4 -acyl-substituted cytosine nucleoside analogues, pharmaceutically acceptable salts, prodrugs, or other derivatives thereof, and the use thereof in the treatment of a viral infection, and in particular a human immunodeficiency virus (HIV) or hepatitis B virus (HBV) infection.
  • HIV human immunodeficiency virus
  • HBV hepatitis B virus
  • HIV human immunodeficiency virus
  • HBV HBV is second only to tobacco as a cause of human cancer. The mechanism by which HBV induces cancer is unknown. It is postulated that it may directly trigger tumor development, or indirectly trigger tumor development through chronic inflammation, cirrhosis, and cell regeneration associated with the infection.
  • HBV infection can lead to acute hepatitis and liver damage, resulting in abdominal pain, jaundice and elevated blood levels of certain enzymes. HBV can cause fulminant hepatitis, a rapidly progressive, often fatal form of the disease in which large sections of the liver are destroyed. Patients typically recover from the acute phase of HBV infection. In some patients, however, high levels of viral antigen persist in the blood for an extended, or indefinite, period, causing a chronic infection. Chronic infections can lead to chronic persistent hepatitis. Patients infected with chronic persistent HBV are most common in developing countries. By mid-1991, there were approximately 225 million chronic carriers of HBV in Asia alone, and worldwide, almost 300 million carriers. Chronic persistent hepatitis can cause fatigue, cirrhosis of the liver, and hepatocellular carcinoma, a primary liver cancer.
  • HBV is very similar to that of HIV/AIDS, which is a reason why HBV infection is common among patients infected with HIV or suffering from AIDS. However, HBV is more contagious than HIV.
  • DNA causing chain termination, because they lack a 3 '-hydroxyl group.
  • Some nucleosides also inhibit the viral enzyme reverse transcriptase.
  • 3TC (lamivudine) and interferon are currently the only FDA-approved drugs for the treatment of HBV infection. Viral resistance develops within 6 months of 3TC treatment in about 14% of patients.
  • Cis-2-hydroxymethyl-5-(5-fluorocytosin-l-yl)-l,3-oxathiolane is currently in clinical trials for the treatment of HIV and separately for HBV by Triangle Pharmaceuticals, Inc. See Schinazi et al. (1992) Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-l-[2- (hydroxymethyl)-l,3-oxathiolane-5-yl]cytosine. Antimicrob. Agents Chemother. 36,
  • A2 (Ajinomoto Co., Inc.). Netherlands Pat. No. 8901258 (Stichting Rega V.Z.W.) discloses generally 5-halogeno-2',3'-dideoxy-2',3'-didehydrocytidine derivatives for use in treating HIV and HBV. ⁇ -D- and ⁇ -L-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine were further described in US Pat. Nos. 5,703,058; 5.905,070; 6,232,300; and 5,561,120. US Pat. No.
  • 5,703,058 claims a method for the treatment of HIV and/or HBV infection that includes administering an effective amount of ⁇ -L-d4FC in combination or alternation with cis-2-hydroxymethyl-5-(5-fluorocytosin- 1 -yl)- 1 ,3-oxathiolane, cis-2-hydroxymethyl- 5-(cytosin- 1 -yl)- 1 ,3-oxathiolane, 9-[4-(hydroxymethyl)-2-cyclopenten- 1 -yl)-guanine
  • 5,905,070 claims a method for the treatment of HIV and HBV infection that includes administering an effective amount of ⁇ -D-d4FC in combination or alternation with cis-2-hydroxymethyl-5-(5-fluorocytosin-l-yl)-l,3-oxathiolane, cis-2- hydroxymethyl-5-(cytosin- 1 -yl)- 1 ,3-oxathiolane, 9-[4-(hydroxy-methyl)-2-cyclopenten- 1 - yl)-guanine (carbovir), 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir), interferon, 3'- deoxy-3 '-azido-thymidine (AZT), 2',3'-dideoxyinosine (ddl), 2',3'-dideoxycytidine (ddC), (-)-2'-fluoro-5-methyl- ⁇ -L-ara-uridine (L-FMAU) or 2
  • N 4 -acyl-cytosine nucleosides and in particular, N 4 - acyl-2',3'-dideoxy-5-fluorocytidine and N 4 -acyl-2',3'-didehydro-2',3'-dideoxy-5-fluoro- cytidine, show improved inhibitory activity against HIV and HBV. Therefore, a method for the treatment or prevention of HIV and/or HBV infection in a host, and in particular, a human, is provided that includes administering an effective amount of a N 4 -acyl-cytosine nucleoside.
  • the active compound is of formula (I) or (II):
  • R 1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to , C 2 , C 3 , C 4 , C 5 , and C 6 ), haloalkyl (including but not limited to , C 2 , C 3 , C ,O5, and C 6 ), alkenyl (including but not limited to C 2 , C 3 , C 4 , C 5 , and C 6 ), haloalkenyl (including but not limited to C 2 , C 3 , C , C 5 , and C 6 ), alkynyl (including but not limited to C 2 , C 3 , C , C 5 , and C 6 ), haloalkynyl (including but not limited to C 2 , C 3 , C , C 5 , and C 6 ), haloalkynyl (including but not limited to C 2 , C 3 , C , C 5 , and C 6 ), haloalkyny
  • R 2 is chosen from alkyl (including but not limited to , C 2 , C 3 , C , C 5 , C 6 , C 7 , C 8 , C 9 , C]Q, C ⁇ , C ⁇ , C ⁇ 3 , C ⁇ 4 , C15, C ⁇ 6 , C ⁇ , C 18 , C 1 9, C 2 o, C 21 , and C 22 ), alkenyl (including but not limited to
  • R 3 and R 3 are chosen independently from H, halogen (F, CI, Br, I), CN, CF 3 , N 3 , NO 2 , alkyl (including but not limited to Ci, C 2 , C 3 , C , C 5 , and C 6 ), alkenyl (including but not limited to C 2 , C 3 , C , C 5 , and C 6 ), alkenyl (including but not limited to C 2 , C 3 , C , C 5 , and C 6 ), alkynyl (including but not limited to C 2 , C 3 , C 4 , C5, and C 6 ), and aryl (including but not limited to C 6 , C 7 , C 8 , C 9 , and C10); v) R 3 and R 3 are chosen independently from H, halogen (F, CI, Br, I), CN, CF 3 , N 3 , NO 2 , alkyl (including but not limited to Ci, C 2 , C 3 , C
  • R 2 cannot be an alkyl, alkoxyalkyl (such as methoxymethyl), aralkyl (such as benzyl or substituted benzyl), aryloxyalkyl (such as phenoxymethyl) or aryl (including but not limited to a phenyl optionally substituted with halogen (F, CI, Br, I), alkyl (including but not limited to C t , C 2 , C 3 , and C 4 ) or alkoxy (including but not limited to , C 2 , C 3 , and C )).
  • alkoxyalkyl such as methoxymethyl
  • aralkyl such as benzyl or substituted benzyl
  • aryloxyalkyl such as phenoxymethyl
  • aryl including but not limited to a phenyl optionally substituted with halogen (F, CI, Br, I)
  • alkyl including but not limited to C t , C 2 , C 3 , and C 4
  • the compound of the present invention can be in the form of the isolated ⁇ -L- or ⁇ -D- configuration, or a mixture thereof, including but not limited to a racemic mixture.
  • Y is CH 2 and both R 3 and R 3 groups are hydrogen, forming a d2 nucleoside (i.e., a 2',3'-dideoxy nucleoside).
  • the active compound is ⁇ -D-N 4 -p-iodobenzoyl-2',3'-dideoxy- 5-fluorocytidine.
  • active compounds include ⁇ -D-N 4 -p-fluoro- benzoyl-2',3'-dideoxy-5-fluorocytidine, ⁇ -D-N -p-chlorobenzoyl-2',3'-dideoxy-5-fluoro- cytidine, ⁇ -D-N 4 -p-bromobenzoyl-2',3'-dideoxy-5-fluorocytidine, ⁇ -D-N 4 -p-ethyl- benzoyl-2 ' ,3 ' -dideoxy-5 -fluorocytidine, and ⁇ -D-N 4 -p-t-butylbenzoyl-2 ' ,3 '-dideoxy-5 - fluoro-cytidine.
  • the active compound is ⁇ -D- ⁇ -p-bromobenzoyl ⁇ ' ⁇ '- didehydro-2',3'-dideoxy-5-fluorocytidine.
  • active compounds include ⁇ -D-N 4 -p-fluorobenzoyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine, ⁇ -D-N 4 - ⁇ -chlorobenzoyl-2',3 '-didehydro-2'3 '-dideoxy-5 -fluorocytidine, ⁇ -D- ⁇ 4 -p-iodobenzoyl- 2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine, ⁇ -D-N 4 -p-ethylbenzoyl-2',3'-didehydro- 2',3'-dideoxy-5-fluorocytidine, and ⁇ -D-N 4 -p-
  • 2',3'-dideoxy-N 4 -acyl-cytosinenucleosides and 2',3'-didehydro- 2',3'-dideoxy-N 4 -acyl-cytosinenucleosides are inhibitors of HBV. Therefore, these compounds can also be used to treat patients that are co-infected with both HIV and HBV.
  • the present invention provides a compound, method and composition for treating an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • the present invention provides a compound, method and composition for preventing an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • the present invention provides a compound, method and composition for treating an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • the present invention provides a compound, method and composition for preventing an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • a pharmaceutical formulation comprising a compound of the invention in combination with a pharmaceutically acceptable carrier or excipient for the treatment of a host infected with HIV or HBV.
  • a compound, method and composition for treating or preventing an HIV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
  • a method and composition for treating or preventing an HBV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
  • Figure 1 is a non-limiting example of the synthesis of active compounds of the present invention, and in particular, the synthesis of ⁇ -D-N 4 -acyl-2',3'-dideoxy-5- fluorocytidine and ⁇ -D-N 4 -acyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine nucleosides.
  • Figure 2 is a graphic representation of the anti-HBV activity of selected N 4 -acyl- substituted ⁇ -D-2 ',3 '-dideoxy- and ⁇ -D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine analogues.
  • N 4 -acyl-cytosine nucleosides and in particular, N 4 -acyl-
  • a method for the treatment or prevention of a host, and in particular, a human, infected with HIV and/or HBV includes administering an effective amount of an N 4 - acyl-cytosine nucleosides.
  • the present invention also provides a method and composition for treating an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • the present invention provides a method and composition for preventing an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • the present invention provides a method and composition for treating an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • the present invention provides a method and composition for preventing an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
  • a pharmaceutical formulation comprising a compound of the invention in combination with a pharmaceutically acceptable carrier or excipient.
  • a method and composition for treating or preventing an HIV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
  • a method and composition for treating or preventing an HBV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
  • the active compound is of formula (I) or (II):
  • R 1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to Q, C 2 , C 3 , C 4 , C 5 , and C 6 ), haloalkyl (including but not limited to , C 2 , C 3 , C , C 5 , and C 6 ), alkenyl (including but not limited to C 2 , C 3 , C 4 , C5, and C 6 ), haloalkenyl (including but not limited to C 2 , C 3 , C 4 , C5, and C 6 ), alkynyl
  • R 2 is chosen from alkyl (including but not limited to C ⁇ , C 2 , C 3 , C 4 , C 5 , and C 6 ), haloalkynyl (including but not limited to C 2 , C 3 , C 4 , C 5 , and C 6 ), cycloalkyl (including but not limited to C 3 , C 4 , C 5 , C 6 , C 7 , and C 8 ), CN, CF 3 , N 3 , NO 2 , aryl (including but not limited to C 6 , C , C 8 , C9, and C 10 ), heteroaryl (including but not limited to C 4 , C 5 , C 6 , C 7 , Cs, C9, C 1 0, C ⁇ , and C 12 ) and acyl (including but not limited to C , C 3 , C 4 , C 5 , and C 6 ); iv) R 2 is chosen from alkyl (including but not limited to C ⁇ , C 2
  • R 6 is chosen from halogen (F, CI, Br, I), CN, CF 3 , N 3 , NO 2 , alkyl (including but not limited to Ci, C 2 , C 3 , C 4 , C 5 , and C 6 ), haloalkyl (including but not limited to Cj, C 2 , C 3 , C 4 ,
  • C 5 , and C 6 aminoalkyl (including but not limited to C ⁇ , C 2 , C 3 , C 4 , C 5 , and C 6 ), alkoxy (including but not limited to C ⁇ , C 2 , C 3 , C 4 , C 5 , and C 6 ), thioalkyl (including but not limited to C ⁇ , C 2 , C 3 , C 4 , C 5 , and C 6 ), alkenyl (including but not limited to C 2 , C 3 , C 4 , C 5 , and C 6 ), alkynyl (including but not limited to C 2 , C 3 , C 4 , C 5 , and C 6 ), and aryl (including but not limited to C 6 , C 7 , C 8 , C 9 , and
  • R 3 and R 3' are chosen independently from H, halogen (F, CI, Br, I), CN, CF 3 , N 3 , NO 2 , alkyl (including but not limited to C ls C 2 , C 3 , C , C 5 , and C 6 ), alkenyl (including but not limited to C , C 3 , C 4 , C 5 , and C 6 ), and alkynyl (including but not limited to C 2 , C 3 , C 4 , C 5 , and C 6 ); vi) R 4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to , C 2 , C 3 , C 4 , C 5 , and C 6 ), alkenyl (including but not limited to C , C 3 , C 4 , C 5 , and C 6 ), alkyny
  • R 5 is H, acyl, alkyl, alkenyl, alkynyl, or cycloalkyl.
  • the compound of the present invention can be in the form of the ⁇ -L- or ⁇ -D- configuration, or a racemic mixture.
  • R 2 cannot be an alkyl, alkoxyalkyl (such as methoxymethyl), aralkyl (such as benzyl or substituted benzyl), aryloxyalkyl (such as phenoxymethyl) or aryl (including but not limited to a phenyl optionally substituted with halogen (F, CI, Br, I), alkyl (including but not limited to Ci, C 2 , C 3 , and C ) or alkoxy (including but not limited to Ci, C 2 , C 3 , and C 4 )).
  • alkoxyalkyl such as methoxymethyl
  • aralkyl such as benzyl or substituted benzyl
  • aryloxyalkyl such as phenoxymethyl
  • aryl including but not limited to a phenyl optionally substituted with halogen (F, CI, Br, I)
  • alkyl including but not limited to Ci, C 2 , C 3 , and C
  • alkoxy including but not
  • the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) Y is CH 2 , CHF or CF 2 ; iii) R 1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to Ci, C 2 , C 3 , C 4 , C 5 , and C 6 ), haloalkyl (including but not limited to , C 2 , C 3 , C 4 , C 5 , and C 6 ), alkenyl (including but not limited to C 2 , C 3 , C , C 5 , and
  • C 6 haloalkenyl (including but not limited to C , C 3 , C 4 , C 5 , and C 6 ), alkynyl (including but not limited to C 2 , C 3 , C 4 , C 5 , and C 6 ), haloalkynyl (including but not limited to C 2 , C 3 , C 4 , Cs, and C 6 ), cycloalkyl (including but not limited to C 3 , C 4 , Cs, C 6 , C 7 , and Cs), CN, CF 3 , N3, NO , aryl (including but not limited to C ⁇ , C , C 8 , C 9 , and Cio), heteroaryl (including but not limited to C 4 , C 5 , C 6 , C 7 ,
  • R 2 is chosen from alkyl (including but not limited to Ci, C 2 , C3, C 4 , C 5 , C ⁇ , C 7 , C 8 , C 9 , Cio, C ⁇ , C 12 , Ci 3 , C 14 , C15, Ci6, C 17 , C 18 , C19, C 2 o, C 21 , and C 22 ), alkenyl (including but not limited to C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C9, Cio, Cn, C ⁇ 2 , C ⁇ 3 ,
  • alkynyl including but not limited to C 2 , C 3 , C 4 , C5, C ⁇ , C , C 8 , C9, Cio, C ⁇ , C ⁇ 2 , C13, C ⁇ 4 , C15, Ci ⁇ , C ⁇ , C] 8 , C 1 9, C 2 o, C 2 ⁇ , and C 22
  • cycloalkyl including but not limited to C 3 , C 4 , C 5 , C ⁇ , C ⁇ , and C 8
  • aminoalkyl including but not limited to C ⁇ , C 2 , C 3 , C , C5, and C 6
  • hydroxyalkyl including but not limited to C ⁇ , C 2 , C 3 , C 4 , C 5 , and C ⁇
  • haloalkyl including but not limited to , C 2 , C 3 , C 4 , C
  • C 2 , C3, C , C 5 , and C ⁇ haloalkyl (including but not limited to Ci, C 2 , C 3 , C 4 , C 5 , and Ce), aminoalkyl (including but not limited to , C 2 , C 3 , C 4 , C 5 , and C 6 ), alkoxy (including but not limited to d, C 2 , C 3 , C 4 , C 5 , and C ⁇ ), thioalkyl (including but not limited to , C 2 , C 3 , C 4 , C 5 , and C 6 ), alkenyl (including but not limited to C , C 3 , C 4 , C 5 , and C 6 ), alkynyl (including but not limited to C 2s
  • R 3 and R 3 are chosen independently from H, halogen (F, CI, Br, I), CN, CF 3 , N 3 , NO 2 , alkyl (including but not limited to C ⁇ , C 2 , C 3 , C 4 , C 5 , and C 6 ), alkenyl (including but not limited to C 2 , C3, C , C5, and C 6 ), and alkynyl (including but not limited to C 2 , C3, C 4 , C 5 , and C 6 ); and vi) R 4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to , C 2 , C 3 , C 4 , C5, and
  • a phospholipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol .
  • the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) Y is CH 2 , CHF or CF 2 ; iii) R 1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to Ci, C 2 , C3, C 4 , C 5 , and C 6 ), haloalkyl (including but not limited to C , C 2 , C 3 , C 4 , C 5 , and C 6 ), alkenyl (including but not limited to C 2 , C 3 , C , C 5 , and
  • R 2 is chosen from cycloalkyl (including but not limited to C 3 , C 4 , C 5 , C 6 , C ⁇ , and C 8 ), aminoalkyl (including but not limited to Ci, C 2 , C 3 , C 4 , C5, and Ce), haloalkyl (including but not limited to C ⁇ , C 2 , C 3 , C 4 , C 5 , and C 6 ), thioalkyl (including but not limited to Ci, C 2 , C 3 , C 3 , C 3 , C 4 , C 5 , and C 6 ), thioalkyl (including but not limited to Ci, C 2 , C 3 , C
  • Ci Ci, C 2 , C 3 , C 4 , C 5 , and C ⁇
  • alkoxy including but not limited to Cj, C 2 , C 3 , C 4 , C 5 , and C 6
  • thioalkyl including but not limited to C ⁇ , C 2 , C3, C 4 , C 5 , and C 6
  • alkenyl including but not limited to C 2 , C 3 , C , C 5 , and C ⁇
  • alkynyl including but not limited to C 2 , C 3 , C 4 , C 5 , and C ⁇
  • aryl including but not limited to v
  • R 3 and R 3 are chosen independently from H, halogen (F, CI, Br, I), CN, CF 3 , N3, NO 2 , alkyl (including but not limited to , C 2 , C3, C 4 , C 5 , and C 6 ), alkenyl (including but not limited to C 2 , C 3 , C 4 , C 5
  • a phospholipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) Y is CH 2 , CHF or CF 2 ; iii) R 1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to , C 2 , C 3 , C 4 , C 5 , and C 6 ), haloalkyl (including but not limited to , C 2 , C 3 , C 4 , C 5 , and C 6 ), alkenyl (including but not limited to C 2 , C 3 , C 4 , C 5 , and C ⁇ ), haloalkenyl (including but not limited to C 2 , C3, C 4 , Cs, and C 6 ), alkynyl (including but not limited to C 2 , C 3 , C 4 , C 5 , and C 6 ), haloal
  • R 3 and R 3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • R 3 and R 3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) Y is CH 2 , CHF or CF 2 ; iii) R 1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to Cj, C 2 , C 3 , C 4 , C 5 , and C 6 ), haloalkyl (including but not limited to Cj, C 2 , C 3 , C 4 , C 5 , and C ⁇ ), alkenyl (including but not limited to C 2 , C 3 , C 4 , C 5 , and C ⁇ ), haloalkenyl (including but not limited to C 2 , C 3 , C 4 , C5, and C 6 ), alkynyl
  • R 2 is CeHtR 6 where R 6 is chosen from CN, CF 3 , N 3 , NO 2 , haloalkyl (including but not limited to Ci, C 2 , C 3 , C 4 , C 5 , and C 6 ), aminoalkyl (including but not limited to , C 2 , C 3 , C , C 5 , and C 6 ), thioalkyl (including but not limited to Ci,
  • R 3 and R 3 are chosen independently from H, halogen (F, CI, Br, I), CN, CF 3 , N 3 , NO 2 , alkyl (including but not limited to C 1? C 2 , C 3 , C , C 5 , and C ⁇ ), alkenyl
  • R 4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to , C 2 , C3, C 4 , C 5 , and C 6 ), alkenyl
  • R 3 and R 3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) Y is CH 2 , CHF or CF 2 ; iii) R 1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to C ⁇ , C 2 , C 3 , C 4 , C 5 , and C 6 ), haloalkyl (including but not limited to , C 2 , C 3 , C 4 , C 5 , and C ⁇ ), alkenyl (including but not limited to C 2 , C 3 , C , C 5 , and C ⁇ ), haloalkenyl (including but not limited to C 2 , C 3 , C 4 , C5, and C 6 ), alkynyl (including but not limited to C 2 , C3, C 4 , C 5 , and C ⁇ ), haloalky
  • R 4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to C C 2 , C 3 , C 4 , C 5 , and C 6 ), alkenyl (including but not limited to C 2 , C 3 , C , C 5 , and C 6 ), alkynyl (including but not limited to C 2 , C 3 , C , C 5 , and C 6 ), aryl (including but not limited to C 6 ,
  • the active compound is of formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) R 1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to C ⁇ , C 2 , C3, C , C5, and C 6 ), haloalkyl (including but not limited to Ci,
  • alkenyl including but not limited to C 2 , C 3 , C , C 5 , and C ⁇
  • haloalkenyl including but not limited to C , C 3 , C 4 , C 5 , and C 6
  • alkynyl including but not limited to C 2 , C3, C 4 , C 5 , and C ⁇
  • haloalkynyl including but not limited to C 2 , C 3 , C , C 5 , and C 6
  • cycloalkyl including but not limited to ⁇ C 3 , C 4 , C 5 , C ⁇ , C ⁇ , and C 8
  • aryl including but not limited to
  • R 2 is chosen from cycloalkyl (including but not limited to C 3 , C 4 , C 5 , C 6 , C 7 , and C 8 ), aminoalkyl (including but not limited to Ci, C 2 , C3, C 4 , C 5 , and C ⁇ ), haloalkyl (including but not limited to Ci, C 2 , C 3 , C , C5, and C 6 ), thioalkyl
  • R 6 is chosen from halogen (F, CI, Br, I), CN, CF 3 , N 3 , NO 2 , alkyl (including but not limited to C , C 2 , C 3 , C , C 5 , and C ⁇ ), haloalkyl (including but not limited to , C 2 , C 3 , C 4 , C 5 , and C 6 ), aminoalkyl (including but not limited to d, C 2 , C 3 , C 4 , C 5 , and C 6 ), alkoxy (including but not limited to , C 2 , C 3 , C 4 ,
  • thioalkyl including but not limited to C ⁇ , C 2 , C 3 , C , C 5 , and Ce
  • alkenyl including but not limited to C 2 , C 3 , C 4 , C5, and C 6
  • alkynyl including but not limited to C 2 , C 3 , C 4 , C 5 , and C 6
  • aryl including but not limited to
  • R 3 and R 3' are chosen independently from H, halogen (F, CI, Br, I), CN, CF 3 , N 3 , NO 2 , alkyl (including but not limited to , C , C 3 , C 4 , C 5 , and C ⁇ ), alkenyl (including but not limited to C 2 , C3, C 4 , C 5 , and C 6 ), and alkynyl (including but not limited to C 2 , C 3 , C 4 , C 5 , and C 6 ); and v) R 4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to Ci, C 2 , C 3 , C 4 , C 5 , and C 6 ), alkenyl (including but not limited to C 2 , C 3 , C
  • a phospholipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • the active compound is of formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) R 1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to Ci, C 2 , C 3 , C 4 , C5, and C 6 ), haloalkyl (including but not limited to C ⁇ , C 2 , C 3 , C , C 5 , and C ⁇ ), alkenyl (including but not limited to C 2 , C 3 , C , C 5 , and C ⁇ ), haloalkenyl (including but not limited to C 2 , C 3 , C , C 5 , and C 6 ), alkynyl (including but not limited to C 2 , C , C , C 5 , and C 6 ), haloalkynyl (including but not limited to C 2 , C 3 , C 4
  • a phospholipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • the active compound is of formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) R 1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to , C 2 , C 3 , C 4 , C 5 , and C 6 ), haloalkyl (including but not limited to C ⁇ , C 2 , C 3 , C 4 , C5, and C 6 ), alkenyl (including but not limited to C 2 , C 3 , C 4 , C 5 , and C ⁇ ), haloalkenyl (including but not limited to C 2 , C 3 , C 4 , C 5 , and C ⁇ ), alkynyl (including but not limited to C 2 , C 3 , C 4 , C5, and C 6 ), haloalkynyl (including but not limited to C 2 , C 3 , C 4 , C5, and C 6 ), halo
  • R 3 and R 3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • R 3 and R 3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • the active compound is * of - formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) R 1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to , C 2 , C 3 , C , C 5 , and C 6 ), haloalkyl (including but not limited to , C 2 , C 3 , C 4 , C 5 , and Ce), alkenyl (including but not limited to C 2 , C 3 , C , C 5 , and C ⁇ ), haloalkenyl (including but not limited to C 2 , C 3 , C 4 , C5, and C 6 ), alkynyl
  • R 2 is CeH t R 6 where R 6 is chosen from CN, CF 3 , N 3 , NO 2 , haloalkyl (including but not limited to C 2 , C 3 , C 4 , C5, and C 6 ), cycloalkyl (including but not limited to C 3 , C 4 , C 5 , C ⁇ , C ⁇ , and C 8 ), CN, CF 3 , N 3 , NO 2 , aryl (including but not limited to C 6 , C ⁇ , C 8 , C 9 , and Cio), heteroaryl (including but not limited to C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , do, C ⁇ , and C ⁇ 2 ) and acyl (including but not limited to C 2 , C 3 , C , C 5 , and C 6 ); iii) R 2 is CeH t R 6 where R 6 is chosen from CN, CF 3 , N 3 , NO 2 , halo
  • a phospholipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I), CN, CF 3 , N 3 , NO 2 , alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the ortho position.
  • halogen F, CI, Br, I
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I) in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) ' R 2 is a phenyl moiety optionally substituted with Br in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with I in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with F in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CI in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with NO 2 in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • X is O; Y is CH 2 ; i) R 1 is fluorine or hydrogen; ii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and
  • R 2 is a phenyl moiety optionally substituted with methyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with ethyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R is a phenyl moiety optionally substituted with n-propyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with iso-propyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-butyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with sec-butyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with tert-butyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-pentyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with isopentyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3' are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with neopentyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with cyclopentyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-hexyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with a cyclohexyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CN in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CF 3 in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with N3 in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with haloalkyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with aminoalkyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R and R are independently hydrogen or fluorine; R is hydrogen; and iv) R is a phenyl moiety optionally substituted with alkoxy in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with thioalkyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkenyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkynyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R3 and R3' are independently hydrogen or fluorine; R4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with aryl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with benzyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with thiophenyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine ⁇ R 4 is hydrogen; and iv) R is a phenyl moiety optionally substituted with furanyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with naphthyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with benzoyl in the ortho position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I), CN, CF 3 ,
  • N 3 NO 2 , alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I) in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3' are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with Br in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with I in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with F in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CI in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with NO 2 in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with methyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with ethyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-propyl in the meta position.
  • the active compound is of formula , its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with iso-propyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-butyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with sec-butyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with tert-butyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-pentyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with isopentyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with neopentyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with cyclopentyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3' are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-hexyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with a cyclohexyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CN in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CF 3 in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with N 3 in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with haloalkyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with aminoalkyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is.hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkoxy in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with thioalkyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkenyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkynyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically,.acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with aryl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with benzyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with thiophenyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with furanyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with naphthyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with benzoyl in the meta position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I), CN, CF 3 , N 3 , NO 2 , alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the para position.
  • halogen F, CI, Br, I
  • the active compound is of formula
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with Br in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R3 and R3' are independently hydrogen or fluorine; R4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with I in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and .. iv) R 2 is a phenyl moiety optionally substituted with F in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CI in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with NO 2 in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkyl in the para position.
  • the active compound is of formula (I), its pharmaceutically. acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with methyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with ethyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-propyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii). R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen;..and * > iv) R 2 is a phenyl moiety optionally substituted with iso-propyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorin ⁇ ; R 4 is hydrogen; and
  • R is a phenyl moiety optionally substituted with n-butyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and , iv) R 2 is a phenyl moiety optionally substituted with sec-butyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with tert-butyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-pentyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with isopentyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with neopentyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) ,'J R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and, ,•- iv) R 2 is a phenyl moiety optionally substituted with cyclopentyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine 1 , R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-hexyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and , iv) R 2 is a phenyl moiety optionally substituted with a cyclohexyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y js CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CN in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable, salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CF 3 in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with N 3 in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with haloalkyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii): .; R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with aminoalkyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are Independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkoxy in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and ⁇ iv) R 2 is a phenyl .moiety optionally substituted with thioalkyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkenyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable, salts or prodrugs thereof, wherein: i) X is O; Y is GH 2 ; i) R 1 is fluorine or hydrogen; ii) R 3 and R 3' are independently hydrogen or fluorine; R 4 is hydrogen; and v) R 2 is a phenyl moiety optionally substituted with alkynyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with aryl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with benzyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii). -. :R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with thiophenyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with furanyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and ⁇ iv) R 2 is a phenyl moiety optionally substituted with naphthyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; . iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with benzoyl in the para position.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3-dihalo.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; , iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4-dihalo.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • X is O; Y is CH 2 ; ii) R .1 i •s fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,5-dihalo.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • X is O; Y is CH 2 ; i) R 1 is fluorine or hydrogen; ii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and v) R 2 is a phenyl moiety optionally substituted with 2,6-dihalo.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorinej R 4 is hydrogen; and iv) R is a phenyl moiety optionally substituted with 3,4-dihalo.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and , iv) R 2 is a phenyl moiety optionally substituted with 3,5-dihalo.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y ⁇ CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,4-trihalo.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,5-trihalo.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4,5-trihalo.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4,6-trihalo.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 -and.R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,5,6-trihalo.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R is a phenyl moiety optionally substituted with 3,4,5-trihalo.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and, iv) R 2 is a phenyl moiety optionally substituted with 2,3,4,5-tetrahalo.
  • the active compound is of
  • I' formula (I), its pharmaceutically acceptable salts or prodrugs thereof wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,4,5,6-pentahalo.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3' are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3-dialkyl.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4- dialkyl.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,5- dialkyl.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,6- dialkyl.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine ⁇ R 4 is hydrogen; and iv) R is a phenyl moiety optionally substituted with 3,4- dialkyl.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and , iv) R 2 is a phenyl moiety optionally substituted with 3,5- dialkyl.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and t iv) R 2 is a phenyl moiety optionally substituted with 2,3,4-trialkyl.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,5- trialkyl.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4,5- trialkyl.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4,6- trialkyl.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 . are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,5,6- trialkyl.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R are independently hydrogen or fluorine ⁇ R is hydrogen; and
  • R is a phenyl moiety optionally substituted with 3,4,5- trialkyl.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • X is O; Y is CH 2 ; i) R 1 is fluorine or hydrogen; ii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and , v) R 2 is a phenyl moiety optionally substituted with 2,3,4,5-tetraalkyl.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,4,5,6-pentaalkyl.
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3-di-NO 2 .
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4- di-NO 2 .
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R l is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,5- di-NO 2 .
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,6- di-NO 2 .
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; 1 R 4 is hydrogen; and iv) R 2 is a ph ' enyl moiety optionally substituted with 3,4- di-NO 2 .
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and , iv) R 2 is a phenyl moiety optionally substituted with 3,5- di-NO .
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,4- tri-NO 2 .
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,5- tri-NO 2 .
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4,5- tri-NO .
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4,6- tri-NO 2 .
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,5,6- tri-NO .
  • the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorinej R 4 is hydrogen; and
  • R 2 is a p 'henyl moiety optionally substituted with 3,4,5- tri-NO .
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and , iv) R 2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I), CN, CF 3 , N3, NO 2 , alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the ortho position.
  • halogen F, CI, Br, I
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
  • X is O; ii) R 1 is fluorine or hydrogen; iii) R and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I) in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with Br in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with I in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; i) R 1 is fluorine or hydrogen; ii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and v) R 2 is a phenyl moiety optionally substituted with F in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CI in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine 1 ; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with NO 2 in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and , iv) R 2 is a phenyl moiety optionally substituted with alkyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; , ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3' are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with methyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with ethyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-propyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with iso-propyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-butyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3' are independently hydrogen or fluorine;! R 4 is hydrogen; and
  • R is a phenyl moiety optionally substituted with sec-butyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and , iv) R 2 is a phenyl moiety optionally substituted with tert-butyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and , iv) R 2 is a phenyl moiety optionally substituted with n-pentyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3' are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with isopentyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with neopentyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with cyclopentyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-hexyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine ⁇ R 4 is hydrogen; and
  • R is a phenyl moiety optionally substituted with a cyclohexyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and
  • R 2 is a phenyl moiety optionally substituted with CN in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O;
  • R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CF 3 in the ortho position.
  • the active compound is of
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with haloalkyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with aminoalkyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkoxy in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3' are independently hydrogen or fluorine; 'R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with thioalkyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and , iv) R 2 is a phenyl, moiety optionally substituted with alkenyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkynyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with aryl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with benzyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with thiophenyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with furanyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with naphthyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with benzoyl in the ortho position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I), CN, CF3, N 3 , NO 2 , alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the meta position.
  • halogen F, CI, Br, I
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; i ⁇ ) R 3 and R 3' are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I) in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with Br in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with I in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with F in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CI in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with NO 2 in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; , iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkyl in the meta position,
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3' are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with methyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with ethyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-propyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with iso-propyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ⁇ ) R 1 is fluorine or hydrogen; iii) R 3 and R 3' are independently hydrogen or fluorine); R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-butyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine r hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and, iv) R 2 is a phenyl moiety optionally substituted with sec-butyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; r ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with tert-butyl in the meta position.
  • the active compound is of , . , formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: . i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-pentyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with isopentyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with neopentyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with cyclopentyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-hexyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with a cyclohexyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CN in the meta position.
  • the active compound is of ⁇ formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:.. '-> ⁇ _ i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CF 3 in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with N 3 in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with haloalkyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently, hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with aminoalkyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkoxy in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with thioalkyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkenyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: ... ,. «.. . i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkynyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with aryl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with benzyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with thiophenyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with furanyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with naphthyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with benzoyl in the meta position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I), CN, CF 3 , N 3 , NO 2 , alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the para position.
  • halogen F, CI, Br, I
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I) in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with Br in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with I in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with F in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CI in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with NO 2 in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) , X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with methyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with ethyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-propyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with iso-propyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-butyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with sec-butyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with tert-butyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-pentyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with isopentyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • X is O; i) R 1 is fluorine or hydrogen; ii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and v) R 2 is a phenyl moiety optionally substituted with neopentyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with cyclopentyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with n-hexyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with a cyclohexyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CN in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with CF3 in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with N 3 in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with haloalkyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with aminoalkyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkoxy in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with thioalkyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 andR 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkenyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with alkynyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with aryl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with benzyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with thiophenyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with furanyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with naphthyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with benzoyl in the para position.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3-dihalo.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4-dihalo.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,5-dihalo.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,6-dihalo.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 3,4-dihalo.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 3,5-dihalo.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,4-trihalo.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,5-trihalo.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4,5-trihalo.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4,6-trihalo.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,5,6-trihalo.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 3,4,5-trihalo.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,4,5-tetrahalo.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • X is O; i) R 1 is fluorine or hydrogen; ii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and v) R 2 is a phenyl moiety optionally substituted with 2,3,4,5,6-pentahalo.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3-dialkyl.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4- dialkyl.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,5- dialkyl.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,6- dialkyl.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 3,4- dialkyl.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen;
  • R and R are independently hydrogen or fluorine; R is hydrogen; and iv) R is a phenyl moiety optionally substituted with 3,5- dialkyl.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,4-trialkyl.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,5- trialkyl.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4,5- trialkyl.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; ⁇ i) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4,6- trialkyl.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,5,6- trialkyl.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) .
  • X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 3,4,5- trialkyl.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,4,5-tetraalkyl.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,4,5,6-pentaalkyl.
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
  • X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3-di-NO 2 .
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4- di-NO 2 .
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,5- di-NO 2 .
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,6- di-NO 2 .
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 3,4- di-NO 2 .
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 3,5- di-NO 2 .
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,4- tri-NO 2 .
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,3,5- tri-NO 2 .
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R and R are independently hydrogen or fluorine; R is hydrogen; and d iv) R 2 is a phenyl moiety optionally substituted with 2,4,5- tri-NO 2 .
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,4,6- tri-NO 2 .
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 2,5,6- tri-NO 2 .
  • the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a phenyl moiety optionally substituted with 3,4,5- tri-NO 2 .
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a thienyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 2- position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a thienyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 3- position or the 4-position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a benzothiophenyl optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl on the benzene ring.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a benzothiophenyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl on the thienyl ring.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a cyclohexyl optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 2 or 3- position.
  • the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH 2 ; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a cyclohexyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 4- position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a thienyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 2 or 3 position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R and R are independently hydrogen or fluorine; R is hydrogen; and iv) R 2 is a thienyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 4- position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a benzothiophenyl optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl on the benzene ring.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a benzothiophenyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl on the thienyl ring.
  • the active compound is of formula
  • R 1 is fluorine or hydrogen
  • R 3 and R 3 are independently hydrogen or fluorine
  • R 4 is hydrogen
  • R 2 is a cyclohexyl optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 2 or 3 position.
  • the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R 1 is fluorine or hydrogen; iii) R 3 and R 3 are independently hydrogen or fluorine; R 4 is hydrogen; and iv) R 2 is a cyclohexyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 4 position.
  • the active compound is ⁇ -D-2',3'-dideoxy-5-fluoro- N 4 -(4-iodobenzoyl)cytidine of the structure:
  • the active compound is ⁇ -D-2',3'-dideoxy-5- fluoro-N ⁇ 4 -(4-fluorobenzoyl)cytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(4- chlorobenzoyl)-2',3'-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(4-bromobenzoyl)- 2 ',3 '-dideoxy-5 -fluorocytidine of the structure:
  • the active compound is ⁇ -D-2',3 '-dideoxy-5- fluoro-N 4 -(3-fluorobenzoyl)cytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(3- chlorobenzoyl)-2',3'-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(3-bromobenzoyl)- 2',3'-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-2',3'-dideoxy-5- fluoro-N 4 -(4-nitrobenzoyl)cytidine of the structure:
  • the active compound is ⁇ -D-2',3 '-dideoxy- 5-fluoro-N 4 - »-toluoylcytidine of the structure:
  • the active compound is ⁇ -D-2',3 '-dideoxy-5-fluoro-
  • the active compound is ⁇ -D-2',3'-dideoxy-N 4 - (4-ethylbenzoyl)-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-2',3 '-dideoxy- 5-fluoro-N 4 -(4-propylbenzoyl)cytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(4-tert- butylbenzoyl)-2', 3 '-dideoxy-5 -fluorocytidine of the structure:
  • the active compound is ⁇ -D-2',3'-dideoxy- 5-fluoro-N -(2-thiophenecarbonyl)cytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(benzo-[b]-thiophene-2- carbonyl)-2',3'-dideoxy-5-fluorocytidine of the structure: or a pharmaceutically acceptable salt or prodrug thereof.
  • the active compound is ⁇ -D-N 4 -(cyclohexane-carbonyl)-
  • the active compound is ⁇ -D-2',3'-didehydro-2',3'- dideoxy-5-fluoro-N 4 -(4-iodobenzoyl)cytidine of the structure:
  • the active compound is ⁇ -D-2',3'-didehydro-2',3'-dideoxy- 5-fluoro-N 4 -(4-fluorobenzoyl)cytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(4-chlorobenzoyl)-2',3'- didehydro-2',3'-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-N 4 -(4- bromobenzoy ⁇ )-2 ' ,3 ' -didehydro-2 ' ,3 '-dideoxy-5 -fluorocytidine of the structure:
  • the active compound is ⁇ -D-N 4 -p-anisoyl-2',3'- didehydro-2',3'-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-2 ',3'- didehydro-2 ' ,3 ' -dideoxy-5 -fluoro-N 4 -(3 -nitrobenzoy l)cytidine of the structure:
  • the active compound is ⁇ -D-2',3'-didehydro-2',3'- dideoxy-5-fluoro-N 4 -j9-toluoylcytidine of the structure:
  • the active compound is ⁇ -D-2',3 '-didehydro-
  • the active compound is ⁇ -D-N 4 -(4-t-butylbenzoyl)- 2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-N 4 - cyclopentanecarbonyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine of the structure:
  • the active compound is ⁇ -D-N 4 - (cyclohexanecarbonyl)-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine of the structure:
  • the compounds of the present invention have asymmetric centers and occur as racemates, racemic mixtures, individual diastereomers or enantiomers, with all isomeric forms being included in the present invention. Some compounds may exhibit polymorphism.
  • the present invention encompasses racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein.
  • the optically active forms can be prepared by, for example, resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase or by enzymatic resolution.
  • Examples of methods to obtain optically active materials include at least the following. i) physical separation of crystals: a technique whereby macroscopic crystals of the individual enantiomers are manually separated. This technique can be used if crystals of the separate enantiomers exist, i.e., the material is a conglomerate, and the crystals are visually distinct; ii) simultaneous crystallization: a technique whereby the individual enantiomers are separately crystallized from a solution of the racemate, possible only if the latter is a conglomerate in the solid state; iii) enzymatic resolutions: a technique whereby partial or complete separation of a racemate by virtue of differing rates of reaction for the enantiomers with an enzyme; iv) enzymatic asymmetric synthesis: a synthetic technique whereby at least one step of the synthesis uses an enzymatic reaction to obtain an enantiomerically pure or enriched synthetic precursor of the desired enantiomer; v) chemical asymmetric synthesis:
  • first- and second-order asymmetric transformations a technique whereby diastereomers from the racemate equilibrate to yield a preponderance in solution of the diastereomer from the desired enantiomer or where preferential crystallization of the diastereomer from the desired enantiomer perturbs the equilibrium such that eventually in principle all the material is converted to the crystalline diastereomer from the desired enantiomer.
  • kinetic resolutions this technique refers to the achievement of partial or complete resolution of a racemate (or of a further resolution of a partially resolved compound) by virtue of unequal reaction rates of the enantiomers with a chiral, non-racemic reagent or catalyst under kinetic conditions; ix) enantiospecific synthesis from non-racemic precursors: a synthetic technique whereby the desired enantiomer is obtained from non- chiral starting materials and where the stereochemical integrity is not or is only minimally compromised over the course of the synthesis; x) chiral liquid chromatography: a technique whereby the enantiomers of a racemate are separated in a liquid mobile phase by virtue of their differing interactions with a stationary phase (including but not limited to via chiral HPLC).
  • the stationary phase can be made of chiral material or the mobile phase can contain an additional chiral material to provoke the differing interactions;
  • chiral gas chromatography a technique whereby the racemate is volatilized and enantiomers are separated by virtue of their differing interactions in the gaseous mobile phase with a column containing a fixed non-racemic chiral adsorbent phase;
  • extraction with chiral solvents a technique whereby the enantiomers are separated by virtue of preferential dissolution of one enantiomer into a particular chiral solvent;
  • xiii) transport across chiral membranes a technique whereby a racemate is placed in contact with a thin membrane barrier.
  • the barrier typically separates two miscible fluids, one containing the racemate, and a driving force such as concentration or pressure differential causes preferential transport across the membrane barrier. Separation occurs as a result of the non-racemic chiral nature of the membrane that allows only one enantiomer of the racemate to pass through.
  • Chiral chromatography including but not limited to simulated moving bed chromatography, is used in one embodiment.
  • a wide variety of chiral stationary phases are commercially available.
  • the term “substantially free of or “substantially in the absence of refers to a nucleoside composition that includes at least 95% to 98 % by weight, and even more preferably 99% to 100% by weight, of the designated enantiomer of that nucleoside.
  • the compounds are substantially free of enantiomers.
  • isolated refers to a nucleoside composition that includes at least 85 or 90% by weight, preferably 95% to 98 % by weight, and even more preferably 99% to 100% by weight, of the nucleoside, the remainder comprising other chemical species or enantiomers.
  • alkyl refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbon. The term includes both substituted and unsubstituted alkyl groups.
  • the alkyl group may be optionally substituted with any moiety that does not otherwise interfere with the reaction or that provides an improvement in the process, including but not limited to but limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfmyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, either unprotected, or protected as necessary, as known to those skilled
  • C(alkyl range) independently includes each member of that class as if specifically and separately set out.
  • C ⁇ -2 independently represents each species that falls within the scope.
  • Alkyl groups include, but are not limited to the radicals of methane, ethane, propane, cyclopropane, 2-methylpropane (isobutane), «-butane, 2,2- dimethylpropane (neopentane), cytobutane, 1,1 dimethylcyclopropane, 2-methylbutane, trans- 1,2-dimethylcyclopropane, ethylcyclopropane, n-pentane, methylcyclobutane, cis- 1,2-dimethylcyclopropane, spiropentane, cyclopentane, 2,2-dimethylbutane, 1,1,2- trimethylcyclopropane, 2,3-dimethylbutane, 2-methylpentane,
  • alkenyl refers to an unsaturated, hydrocarbon radical, linear or branched, in so much as it contains one or more double bonds.
  • the alkenyl group disclosed herein can be optionally substituted with any moiety that does not adversely affect the reaction process, including but not limited to but not limited to alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxi
  • Non-limiting examples of alkenyl groups include methylene, ethylene, methylethylene, isopropylidene, 1,2-ethane-diyl, 1,1-ethane-diyl, 1,3- propane-diyl, 1,2-propane-diyl, 1,3-butane-diyl, and 1,4-butane-diyl.
  • alkynyl refers to an unsaturated, acyclic hydrocarbon radical, linear or branched, in so much as it contains one or more triple bonds.
  • the alkynyl group may be optionally substituted with any moiety that does not adversely affect the reaction process, including but not limited to but not limited to hydroxyl, halo (F, CI, Br, I), perfluoro alkyl including but not limited to trifluoromethyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, acyl, amido, carboxamido, carboxylate, thiol, alkylthio, azido, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene et al, Protective Groups in Organic Synthesis. John Wiley & Sons, Second
  • alkynyl groups include ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl, pentyn-2-yl, 4-methoxypentyn-2-yl, 3-methylburyn-l-yl, hexyn-1-yl, hexyn- 2-yl, and hexyn-3-yl, 3,3-dimethylbutyn-l-yl radicals.
  • alkylamino or "arylamino” refers to an amino group that has one or two alkyl or aryl substituents, respectively.
  • aryl alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused.
  • Non-limiting examples of aryl include phenyl, biphenyl, or naphthyl, or the following aromatic group that remains after the removal of a hydrogen from the aromatic ring: benzene, toluene, ethylbenzene, 1,4-xylene, 1,3-xylene, 1,2- xylene, isopropylbenzene (cumene), ra-propylbenzene, l-ethyl-3-methylbenzene (m- ethyltoluene), l-ethyl-4-methylbenzene (p-ethyltoluene), 1,3,5-trimethylbenzene (mesitylene), l-ethyl-2-methylbenzene (o-ethyltoluene), tert-butylbenzene, 1,2,4- trimethylbenzene (pseudodocumene), isobutylbenzene, ⁇ 'ec-butyl
  • 1,2,3,4-tetrahydronaphthalene 6,7-dimethyl- 1,2,3,4-tetrahydronaphthalene, 5,7-dimethyl- 1,2,3,4-tetrahydrona ⁇ hthalene, 2-ethylnaphthalene, 1-7-dimethylnaphthalene, 1,6- dimethylnaphthalene, 1,3-dimethylnaphthalene, n-octylbenzene, 1-allylnaphthalene, 1- isopropylnaphthalene, 1,4-dimethylnaphthalene, 1,1-diphenylethane, 2- isopropylnaphthalene, 2-propylnaphthalene, 1-propylnaphthalene, 1,3,7- trimethylnaphthalene, l-isopropyl-7-methylnaphthalene, n-nonylbenzene, 2- butylnaphthalene, 2-tert-butylnaphthalen
  • 1,4-dimethylphenanthrene bibenzyl, methylenefluorene, 3,5-dimethylphenanthrene, 1,3- dimethylazulene, 7-methyl-3,4-benzphenanthrene, pentamethylbenzene, 1,2,4- trimethylnaphthalene, 3,3-dimethylstilbene, 1,4,5,7-tetramethylnaphthalene, 1,2,4,8- tetramethylnaphthalene, 2,9-dimethylphenanthrene, 1,5 -dimethylphenanthrene, 2- benzylnaphthalene, 1-benzylnaphthalene, 1-benzylnaphthalene, 1,2-dimethylazulene, 9- propylphenanthrene, l,7-dimethyl-4-isopropylnaphthalene, 3 -methylphenanthrene, 3,4- dimethylphenanthrene, 1-ethylphenanthrene, ,sym-diphenylacetylene, 9-e
  • aryl includes both substituted and unsubstituted moieties.
  • the aryl group may be optionally substituted with any moiety that does not adversely affect the process, including but not limited to but not limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, 5 alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, or any other viable functional
  • Non-limiting examples of substituted aryl include heteroarylamino, N-aryl-N-alkylamino, N-heteroarylamino-N-alkylamino, heteroaralkoxy, arylamino, aralkylamino, arylthio, monoarylamidosulfonyl, 5 arylsulfonamido, diarylamidosulfonyl, monoaryl amidosulfonyl, arylsulfinyl, arylsulfonyl, heteroarylthio, heteroarylsulfinyl, heteroarylsulfonyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, hydroxyaralkyl, hydoxyheteroaralkyl, haloalkoxyalkyl
  • halo includes chloro, bromo, iodo and fluoro.
  • acyl refers to a carboxylic acid ester in which the non-carbonyl moiety 5 of the ester group is selected from straight, branched, or cyclic alkyl or lower alkyl, alkoxyalkyl including but not limited to methoxymethyl, aralkyl including but not limited to benzyl, aryloxyalkyl such as phenoxymethyl, aryl including but not limited to phenyl optionally substituted with halogen (F, CI, Br, I), alkyl (including but not limited to C ⁇ , C 2 , C 3 , and C ) or alkoxy (including but not limited to C ⁇ , C 2 , C 3 , and C 4 ), sulfonate esters 0 such as alkyl or aralkyl sulphonyl including but not limited to methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl,
  • alkoxy and alkoxyalkyl embrace linear or branched oxy-containing radicals having alkyl moieties, such as methoxy radical.
  • alkoxyalkyl also embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals.
  • the "alkoxy” radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide "haloalkoxy" radicals.
  • radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, difluoromethoxy, trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, and fluoropropoxy.
  • alkylamino denotes “monoalkylamino” and “dialkylamino” containing one or two alkyl radicals, respectively, attached to an amino radical.
  • arylamino denotes “monoarylamino” and “diarylamino” containing one or two aryl radicals, respectively, attached to an amino radical.
  • aralkylamino embraces aralkyl radicals attached to an amino radical.
  • aralkylamino denotes
  • aralkylamino and “diaralkylamino” containing one or two aralkyl radicals, respectively, attached to an amino radical.
  • aralkylamino further denotes “monoaralkyl monoalkylamino” containing one aralkyl radical and one alkyl radical attached to an amino radical.
  • heteroatom refers to oxygen, sulfur, nitrogen and phosphorus.
  • heteroaryl or “heteroaromatic,” as used herein, refer to an aromatic that includes at least one sulfur, oxygen, nitrogen or phosphorus in the aromatic ring.
  • heterocyclic refers to a nonaromatic cyclic group wherein there is at least one heteroatom, such as oxygen, sulfur, nitrogen, or phosphorus in the ring.
  • heteroaryl and heterocyclic groups include furyl, furanyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4- thiadiazolyl, isooxazolyl, pyrrolyl, quinazolinyl, cinnolinyl, phthalazinyl, xanthinyl, hypoxanthinyl, thiophene, furan, pyrrole, isopyrrole, pyrazole, imidazo
  • the heteroaromatic group can be optionally substituted as described above for aryl.
  • the heterocyclic or heteroaromatic group can be optionally substituted with one or more substituent selected from halogen (F, CI, Br, I), haloalkyl, alkyl, alkoxy, hydroxy, carboxyl derivatives, amido, amino, alkylamino, dialkylamino.
  • the heteroaromatic can be partially or totally hydrogenated as desired.
  • dihydropyridine can be used in place of pyridine. Functional oxygen and nitrogen groups on the heterocyclic or heteroaryl group can be protected as necessary or desired.
  • Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl or substituted trityl, alkyl groups, acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenelsulfonyl.
  • the heterocyclic or heteroaromatic group can be substituted with any moiety that does not adversely affect the reaction, including but not limited to but not limited to those described above for aryl.
  • the term "host,” as used herein, refers to a unicellular or multicellular organism in which the virus can replicate, including but not limited to cell lines and animals, and preferably a human. Alternatively, the host can be carrying a part of the viral genome, whose replication or function can be altered by the compounds of the present invention.
  • the term host specifically refers to infected cells, cells transfected with all or part of the viral genome and animals, in particular, primates (including but not limited to chimpanzees) and humans. In most animal applications of the present invention, the host is a human patient. Veterinary applications, in certain indications, however, are clearly anticipated by the present invention (such as chimpanzees).
  • pharmaceutically acceptable salt or prodrug is used throughout the specification to describe any pharmaceutically acceptable form (such as an ester, phosphate ester, salt of an ester or a related group) of a nucleoside compound which, upon administration to a patient, provides the nucleoside compound.
  • Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium and magnesium, among numerous other acids well known in the pharmaceutical art.
  • Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present invention.
  • prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound.
  • Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound.
  • the compounds of this invention possess antiviral activity against
  • Flaviviridae or are metabolized to a compound that exhibits such activity.
  • Prodrugs also include natural or unnatural amino acid esters of the disclosed nucleosides (see, e.g., European Patent Specification No. 99493, the text of which is inco ⁇ orated by reference, which describes amino acid esters of acyclovir, specifically the glycine and alanine esters which show improved water-solubility compared with acyclovir itself, and US Pat. No. 4,957,924 (Beauchamp), which discloses the valine ester of acyclovir, characterized by side-chain branching adjacent to the ⁇ -carbon atom, which showed improved bioavailability after oral administration compared with the alanine and glycine esters).
  • a process for preparing such amino acid esters is disclosed in US Pat. No.
  • Suitable inorganic salts may also be formed, including but not limited to, sulfate, nitrate, bicarbonate and carbonate salts.
  • nucleosides described herein can be administered as a nucleotide prodrug to increase the activity, bioavailability, stability or otherwise alter the properties of the nucleoside.
  • a number of nucleotide prodrug ligands are known.
  • alkylation, acylation or other lipophilic modification of the mono, di or triphosphate of the nucleoside will increase the stability of the nucleotide.
  • substituent groups that can replace one or more hydrogens on the phosphate moiety are alkyl, aryl, steroids, carbohydrates, including but not limited to sugars, 1,2-diacylglycerol and alcohols. Many are described in R. Jones & N. Bischofberger, Antiviral Research, 27 (1995) 1-17. Any of these can be used in combination with the disclosed nucleosides to achieve' a desired effect.
  • the active nucleoside can also be provided as a 5'-phosphoether lipid or a 5'-ether lipid, as disclosed in the following references, which are incorporated by reference: Kucera, L.S., N. Iyer, E. Leake, A. Raben, Modest E.K., D.L.W., and C. Piantadosi, "Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation," AIDS Res. Hum. Retroviruses, 1990, 6, 491-501; Piantadosi, C, J. Marasco C.J., S.L. Morris-Natschke, K.L. Meyer, F. Gumus, J.R. Surles,
  • the active compound or its prodrug or salt can be administered in combination or alternation with another antiviral agent, such as another active anti-HIV or anti-HBV agent, including but not limited to those of the formulae above, others listed below or known in the art.
  • another antiviral agent such as another active anti-HIV or anti-HBV agent, including but not limited to those of the formulae above, others listed below or known in the art.
  • effective dosages of two or more agents are administered together, whereas during alternation therapy, an effective dosage of each agent is administered serially.
  • the dosage will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.
  • antiviral agents that can be used in combination with the compounds disclosed herein include those in the tables below.
  • MCC 478 nucleoside analogue Eli Lilly valLdC (valtorcitabine) nucleoside analogue Idenix
  • NRTIs Nucleoside/Nucleotide Reverse Transcriptase Inhibitors
  • NRTIs Transcriptase Inhibitors
  • the compounds of the invention may be employed together with at least one other antiviral agent chosen from reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors and polymerase inhibitors.
  • compounds according to the present invention can be administered in combination or alternation with one or more anti-retrovirus, anti-HBV, anti-HCV or anti- herpetic agent or interferon, anti-cancer or antibacterial agents, including but not limited to other compounds of the present invention.
  • Certain compounds according to the present invention may be effective for enhancing the biological activity of certain agents according to the present invention by reducing the metabolism, catabolism or inactivation of other compounds and as such, are co-administered for this intended effect.
  • Host including but not limited to humans, infected with a human immunodeficiency virus, a hepatitis virus, or a gene fragment thereof, can be treated by administering to the patient an effective amount of the active compound or a pharmaceutically acceptable prodrug or salt thereof in the presence of a pharmaceutically acceptable carrier or diluent.
  • the active materials can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid or solid form.
  • a preferred dose of the compound for an HIV or HBV infection will be in the range from about 1 to 50 mg/kg, preferably 1 to 20 mg/kg, of body weight per day, more generally 0.1 to about 100 mg per kilogram body weight of the recipient per day.
  • the effective dosage range of the pharmaceutically acceptable salts and prodrugs can be calculated based on the weight of the parent nucleoside to be delivered. If the salt or prodrug exhibits activity in itself, the effective dosage can be estimated as above using the weight of the salt or prodrug, or by other means known to those skilled in the art.
  • the compound is conveniently administered in unit any suitable dosage form, including but not limited to but not limited to one containing 7 to 3000 mg, preferably 70 to 1400 mg of active ingredient per unit dosage form.
  • An oral dosage of 50-1000 mg is usually convenient.
  • the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.2 to 70 ⁇ M, preferably about 1.0 to 10 ⁇ M. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or administered as a bolus of the active ingredient.
  • the concentration of active compound in the drug composition will depend on abso ⁇ tion, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
  • the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
  • Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets.
  • the active compound can be incorporated with excipients and used in the form of tablets, troches or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • a sweetening agent such
  • the compound can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like.
  • a syrup may contain, in addition to the active compound(s), sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
  • the compound or a pharmaceutically acceptable prodrug or salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, anti- inflammatories or other antivirals, including but not limited to other nucleoside compounds.
  • Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates or phosphates, and agents for the adjustment of tonicity, such as sodium chloride or dextrose.
  • the parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).
  • PBS physiological saline or phosphate buffered saline
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including but not limited to implants and microencapsulated delivery systems.
  • a controlled release formulation including but not limited to implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid.
  • enterically coated compounds can be used to protect cleavage by stomach acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Suitable materials can also be obtained commercially.
  • Liposomal suspensions including but not limited to liposomes targeted to infected cells with monoclonal antibodies to viral antigens are also preferred as pharmaceutically acceptable carriers.
  • liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container.
  • An aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives is then introduced into the container.
  • the container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
  • a method for the facile preparation of N -acyl-substituted 2',3'-dideoxy-5- fluorocytidine and 2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine nucleosides is also provided.
  • the method includes condensation of a 5'-O-silyl protected 2',3'-dideoxy-5- fluorocytidine or a 5'-O-silyl protected 2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine, with either a carboxylic acid chloride, or carboxylic acid anhydride, or a carboxylic acid, followed by desilylation.
  • the other N 4 -acyl-substiruted cytosine nucleosides can be synthesized using the similar approaches.
  • N 4 -acyl-substituted 2',3'-dideoxy-5-fluorocytidine and 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine nucleosides disclosed herein can be prepared as described in detail below, or by other assays known to those skilled in the art.
  • Anti-HIV-1 activity of the compounds was determined in human peripheral blood mononuclear (PBM) cells as described previously (Schinazi R.F., McMillan A., Cannon D., Mathis R., Lloyd R.M. Jr., Peck A., Sommadossi J.-P., St. Clair M., Wilson J., Furman P.A., Painter G., Choi W.-B., Liotta D.C. Antimicrob. Agents Chemother. 1992, 36, 2423; Schinazi R.F., Sommadossi J.-P., Saalmann V., Cannon D., Xie M.-Y., Hart G., Smith G., Hahn E.
  • Stock solutions (20-40 mM) of the compounds were prepared in sterile DMSO and then diluted to the desired concentration in growth medium.
  • Cells were infected with the prototype HIV-I AI at a multiplicity of infection of 0.01.
  • Virus obtained from the cell supernatant was quantified on day 6 after infection by a reverse transcriptase assay using (rA) n *(dT)j 2 -i 8 as template- primer.
  • the DMSO present in the diluted solution ( ⁇ 0.1 %) had no effect on the virus yield.
  • AZT was included as positive control.
  • the antiviral EC 50 and EC 90 were obtained from the concentration-response curve using the median effective method described previously (Chou T.-C. & Talalay P. Adv. Enzyme Regul 1984, 22, 27-55; Belen'kii M.S. & Schinazi R.F . Antiviral Res. 1994, 25, 1-11).
  • the potency of the compounds was determined by measurement of viral RNA accumulation in HIV-1 RF infected MT-2 cells (Bacheler LT, Paul M, Otto MJ, Jadhav PK, Stone BA & Miller JA (1994) An assay for HIV RNIn infected cell lysates, and its use for rapid evaluation of antiviral efficacy.
  • the virus titer was established to determine the dilution producing 15 to 30 ng/RNA per well of HIV RNIn 3 days of infection.
  • HIV-1 RNA was quantified using biotinylated capture and alkaline phosphatase-derivatized reporter oligonucleotides as described previously (Charvet A-S, Camplo M, Faury P, Graciet JC,
  • the anti-HBV activity of the compounds was determined by treating the AD-38 cell line carrying wild type HBV under the control of tetracycline (Ladner S.K careful Otto M.J., Barker C.S., Zaifert K., Wang G.H., Guo J.T., Seeger C. & King R.W. Antimicrob. Agents Chemother. 1997, 41, 1715-1720). Removal of tetracycline from the medium [Tet (-)] results in the production of HBV. The levels of HBV in the culture supernatant fluids from cells treated with the compounds were compared with that of the untreated controls.
  • the toxicity of the compounds was assessed in Vero, human PBM, CEM (human lymphoblastoid), MT-2, and HepG2 cells, as described previously (Schinazi R.F., Sommadossi J.-P., Saalmann V., Cannon D.L., Xie M.-Y., Hart G.C., Smith G.A. & Hahn
  • Cycloheximide was included as positive cytotoxic control, and untreated cells exposed to solvent were included as negative controls.
  • the cytotoxicity IC 50 was obtained from the concentration-response curve using the median effective method described previously (Chou T.-C. & Talalay P. Adv. Enzyme Regul. 1984, 22, 27-55; Belen'kii M.S. & Schinazi R.F. Antiviral Res. 1994,

Abstract

The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animals hosts, comprising the administration of N4-acyl-2',3'-dideoxy-5-flluorocytidine or N4-acyl-2',3'-didehydro-2',3' dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof.

Description

N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VTRAL
INFECTIONS
The present application claims priority to U.S.S.N. 60/341,555 filed on December 14, 2001.
FIELD OF THE INVENTION
The present invention is directed to compounds, methods and compositions for the treatment or prevention of viral infections using nucleoside analogues. More specifically, the invention describes N4-acyl-substituted cytosine nucleoside analogues, pharmaceutically acceptable salts, prodrugs, or other derivatives thereof, and the use thereof in the treatment of a viral infection, and in particular a human immunodeficiency virus (HIV) or hepatitis B virus (HBV) infection.
BACKGROUND OF THE INVENTION
In 1981, acquired immune deficiency syndrome (AIDS) was identified as a disease that severely compromises the human immune system, and that without exception leads to death. In 1983, the etiological cause of AIDS was determined to be what is now known as human immunodeficiency virus (HIV).
Another virus that causes a serious human health problem is the hepatitis B virus
(HBV). HBV is second only to tobacco as a cause of human cancer. The mechanism by which HBV induces cancer is unknown. It is postulated that it may directly trigger tumor development, or indirectly trigger tumor development through chronic inflammation, cirrhosis, and cell regeneration associated with the infection.
After a 2- to 6-month incubation period, during which the host is typically unaware of the infection, HBV infection can lead to acute hepatitis and liver damage, resulting in abdominal pain, jaundice and elevated blood levels of certain enzymes. HBV can cause fulminant hepatitis, a rapidly progressive, often fatal form of the disease in which large sections of the liver are destroyed. Patients typically recover from the acute phase of HBV infection. In some patients, however, high levels of viral antigen persist in the blood for an extended, or indefinite, period, causing a chronic infection. Chronic infections can lead to chronic persistent hepatitis. Patients infected with chronic persistent HBV are most common in developing countries. By mid-1991, there were approximately 225 million chronic carriers of HBV in Asia alone, and worldwide, almost 300 million carriers. Chronic persistent hepatitis can cause fatigue, cirrhosis of the liver, and hepatocellular carcinoma, a primary liver cancer.
In Western, industrialized countries, the high-risk group for HBV infection includes those in contact with HBV carriers or their blood samples. The epidemiology of
HBV is very similar to that of HIV/AIDS, which is a reason why HBV infection is common among patients infected with HIV or suffering from AIDS. However, HBV is more contagious than HIV.
In 1985, it was reported that the synthetic nucleoside 3'-azido-3'-deoxythymidine (AZT) inhibited the replication of HIV. Since then, several other synthetic nucleosides, including but not limited to 2',3'-dideoxyinosine (ddl), 2',3'-dideoxycytidine (ddC), 2',3'~ dideoxy-2',3'-didehydrothymidine (d4T), (-)-2',3'-dideoxy-3'-thiacytidine (3TC), and (-)- carbocyclic 2',3'-didehydro-2',3'-dideoxyguanosine (carbovir) and its prodrug abacavir, have proven effective against HIV. After phosphorylation to the 5'-triphosphate by cellular kinases, these synthetic nucleosides are incorporated into a growing strand of viral
DNA, causing chain termination, because they lack a 3 '-hydroxyl group. Some nucleosides also inhibit the viral enzyme reverse transcriptase.
3TC (lamivudine) and interferon are currently the only FDA-approved drugs for the treatment of HBV infection. Viral resistance develops within 6 months of 3TC treatment in about 14% of patients.
Cis-2-hydroxymethyl-5-(5-fluorocytosin-l-yl)-l,3-oxathiolane (FTC) is currently in clinical trials for the treatment of HIV and separately for HBV by Triangle Pharmaceuticals, Inc. See Schinazi et al. (1992) Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-l-[2- (hydroxymethyl)-l,3-oxathiolane-5-yl]cytosine. Antimicrob. Agents Chemother. 36,
2423-2431; US Pat. Nos. 5,210,085; 5,914,331; 5,814,639; WO 91/11186; and WO 92/14743. The success of 2',3'-dideoxy- and 2',3'-didehydro-2,'3'-dideoxy-nucleosides (referred to as a "ddN" or "d2N" nucleoside and a "d4N" nucleoside, respectively) in inhibiting the replication of HIV in vivo or in vitro has led a number of researchers to design and test a variety of modified d2- and d4-nucleosides. One modification has been the replacement of the 5-hydrogen on cytosine nucleosides with fluorine, resulting in several 5-fluorocytosine nucleosides with antiviral activity, including but not limited to β- D- and β-L-2',3'-dideoxy-5-fluorocytine (β-D-D2FC and β-L-D2FC) (US Pat. Nos. 4,788,181 and 6,156,737). β-D-2',3'-Dideoxy-2',3'-didehydro-5-fluorocytidine (d4FC) and its use to treat hepatitis B was first described in Example 2 of European Pat. Application No. 0 409 227
A2 (Ajinomoto Co., Inc.). Netherlands Pat. No. 8901258 (Stichting Rega V.Z.W.) discloses generally 5-halogeno-2',3'-dideoxy-2',3'-didehydrocytidine derivatives for use in treating HIV and HBV. β-D- and β-L-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine were further described in US Pat. Nos. 5,703,058; 5.905,070; 6,232,300; and 5,561,120. US Pat. No. 5,703,058 claims a method for the treatment of HIV and/or HBV infection that includes administering an effective amount of β-L-d4FC in combination or alternation with cis-2-hydroxymethyl-5-(5-fluorocytosin- 1 -yl)- 1 ,3-oxathiolane, cis-2-hydroxymethyl- 5-(cytosin- 1 -yl)- 1 ,3-oxathiolane, 9-[4-(hydroxymethyl)-2-cyclopenten- 1 -yl)-guanine
(carbovir), 9-[(2-hydroxyethoxy)methyl]-guanine (acyclovir), interferon, 3'-deoxy-3'- azido-thymidine (AZT), 2',3'-dideoxyinosine (ddl), 2',3'-dideoxycytidine (ddC), (-)-2'- fluoro-5-methyl-β-L-ara-uridine (L-FMAU) or 2',3'-didehydro-2',3'-dideoxythymidine (d4T). US Pat. No. 5,905,070 claims a method for the treatment of HIV and HBV infection that includes administering an effective amount of β-D-d4FC in combination or alternation with cis-2-hydroxymethyl-5-(5-fluorocytosin-l-yl)-l,3-oxathiolane, cis-2- hydroxymethyl-5-(cytosin- 1 -yl)- 1 ,3-oxathiolane, 9-[4-(hydroxy-methyl)-2-cyclopenten- 1 - yl)-guanine (carbovir), 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir), interferon, 3'- deoxy-3 '-azido-thymidine (AZT), 2',3'-dideoxyinosine (ddl), 2',3'-dideoxycytidine (ddC), (-)-2'-fluoro-5-methyl-β-L-ara-uridine (L-FMAU) or 2',3'-didehydro-2',3'- dideoxythymidine (d4T). US Pat. No. 6,232,300 claims a method to treat HIV with β-D- d4FC.
Modification of the amino group of antiviral cytosine nucleosides has not been fully explored. Only a few N4-substituted cytosine 2',3'-dideoxy nucleosides and N4- substituted cytosine 2',3'-didehydro-2',3'-dideoxy nucleosides have been reported. These include N4-benzoyl-2',3'-didehydro-2,'3-dideoxycytidine (Kawaguchi et al, Studies on 2',3'-dideoxy-2',3'-didehydropyrimidine nucleosides. II. N4-benzoyl-2',3'-dideoxy-2',3'- didehydrocytidine as a prodrug of 2',3'-dideoxy-2',3'-didehydrocytidine (DDCN), Chem. Pharm. Bull. (1989), 37(9), 2547-9), N4-benzoyl-2',3'-dideoxycytidine (Gulbis et al. (1993) Structure of a dideoxynucleoside active against the HIV (AIDS) virus. Acta Cryst.
C49, 1095-1097), N4-acetyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine, and N4- isopropyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine (Shi et al. (1999)) Synthesis and biological evaluation of 2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine (d4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase. J. Med. Chem. 42, 859-867). Of the sugar-modified cytosine nucleosides, some N4-acyl and imine-substituted 2',3'-dideoxy-3'-C- hydroxymethylcytidine analogues have been synthesized (Mauldin et al. (1998) Synthesis and antiviral activity of prodrugs of the nucleoside l-[2',3'-dideoxy-3'-C- (hydroxymethyl)-β-D-erythropentofuranosyl] cytosine. Bioorg. Med. Chem. 6, 577-585), and some N4-acetyl- and phosphonoacetyl-2',3'-dideoxy-3'-thiacytidine nucleosides have been prepared (Charvet et al. (1993) Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2',3'-dideoxy-3'-thiacytidine conjugates. J. Med. Chem. 37, 2216-2223).
Therefore, it is an object of the present invention to provide a method and composition for the treatment or prevention of HIV infection in human patients.
It is another object of the present invention to provide a method and composition for the treatment or prevention of HBV infection in human patients or other host animals.
It is still another object of the present invention to provide a method and composition for the treatment or prevention of HIV and HBV infection in human patients or other host animals.
SUMMARY OF THE INVENTION
It has been found that certain N4-acyl-cytosine nucleosides, and in particular, N4- acyl-2',3'-dideoxy-5-fluorocytidine and N4-acyl-2',3'-didehydro-2',3'-dideoxy-5-fluoro- cytidine, show improved inhibitory activity against HIV and HBV. Therefore, a method for the treatment or prevention of HIV and/or HBV infection in a host, and in particular, a human, is provided that includes administering an effective amount of a N4-acyl-cytosine nucleoside.
In one embodiment of the invention, the active compound is of formula (I) or (II):
Figure imgf000006_0001
or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O, S, NR5, CH2, CHF or CF2; ii) Y is CH2, CHF or CF2; iii) R1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to , C2, C3, C4, C5, and C6), haloalkyl (including but not limited to , C2, C3, C ,O5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), haloalkenyl (including but not limited to C2, C3, C , C5, and C6), alkynyl (including but not limited to C2, C3, C , C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), cycloalkyl (including but not limited to
C3, C , C5, C6, C7, and C$), CN, CF3, N3, NO , aryl (including but not limited to C6, C7, C8, Cg, and o), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, Cio, Cπ, and C12) and acyl (including but not limited to C2, C3, C4, C5, and C6); iv) R2 is chosen from alkyl (including but not limited to , C2, C3, C , C5, C6, C7, C8, C9, C]Q, Cπ, Cι , Cι3, Cι4, C15, Cι6, C\η, C18, C19, C2o, C21, and C22), alkenyl (including but not limited to C2, C3, C4, C5, C6, C7, C8, C9, o, Cπ, C12, C13, Cι , C15, C16, C]7, Ci8, C19, C2o, C2ι, and C22), alkynyl (including but not limited to C2, C3, C , C5, C6, C7, C8, C9, Qo, Cπ, Cj2, Cι3, Cι4, C15, Cι6, C1 ,
Ci8, C 9, C20, C21, and C22), cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), aminoalkyl (including but not limited to Ci, C2, C , C , C5, and C6), hydroxyalkyl (including but not limited to C\, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to Cj, C , C3, C4, C5, and C6), thioalkyl (including but not limited to C\, C , C3, C , C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), heteroaryl (including but not limited to C4, C5, C6, C , C8, C9, C10, Cπ, and 2), and CόHiR6 where R6 is chosen from halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to Ci, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to , C2, C3, C4, C5, and C6), aminoalkyl (including but not limited to , C2, C3, C , C5, and
C6), alkoxy (including but not limited to , C , C3, C , C5, and C6), thioalkyl (including but not limited to , C , C3, C , C5, and C6), alkenyl (including but not limited to C2, C3, C , C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), and aryl (including but not limited to C6, C7, C8, C9, and C10); v) R3 and R3 are chosen independently from H, halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to Ci, C2, C3, C , C5, and C6), alkenyl (including but not limited to C2, C3, C , C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6); vi) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to C\, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol; and vii) R5 is H, acyl, alkyl, alkenyl, alkynyl, or cycloalkyl.
In one embodiment of the present invention, if the active compound is of formula (II), and X is O, S, CH2, CHF or CF2, R1 is F, and R3 and R3' are H or F, then R2 cannot be an alkyl, alkoxyalkyl (such as methoxymethyl), aralkyl (such as benzyl or substituted benzyl), aryloxyalkyl (such as phenoxymethyl) or aryl (including but not limited to a phenyl optionally substituted with halogen (F, CI, Br, I), alkyl (including but not limited to Ct, C2, C3, and C4) or alkoxy (including but not limited to , C2, C3, and C )).
The compound of the present invention can be in the form of the isolated β-L- or β-D- configuration, or a mixture thereof, including but not limited to a racemic mixture. In one embodiment, Y is CH2 and both R3 and R3 groups are hydrogen, forming a d2 nucleoside (i.e., a 2',3'-dideoxy nucleoside).
In one embodiment, the active compound is β-D-N4-p-iodobenzoyl-2',3'-dideoxy- 5-fluorocytidine. Other specific examples of active compounds include β-D-N4-p-fluoro- benzoyl-2',3'-dideoxy-5-fluorocytidine, β-D-N -p-chlorobenzoyl-2',3'-dideoxy-5-fluoro- cytidine, β-D-N4-p-bromobenzoyl-2',3'-dideoxy-5-fluorocytidine, β-D-N4-p-ethyl- benzoyl-2 ' ,3 ' -dideoxy-5 -fluorocytidine, and β-D-N4-p-t-butylbenzoyl-2 ' ,3 '-dideoxy-5 - fluoro-cytidine.
In another embodiment, the active compound is β-D-Λ^-p-bromobenzoyl^'^'- didehydro-2',3'-dideoxy-5-fluorocytidine. Other specific examples of active compounds include β-D-N4-p-fluorobenzoyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine, β-D-N4- ρ-chlorobenzoyl-2',3 '-didehydro-2'3 '-dideoxy-5 -fluorocytidine, β-D-Ν4-p-iodobenzoyl- 2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine, β-D-N4-p-ethylbenzoyl-2',3'-didehydro- 2',3'-dideoxy-5-fluorocytidine, and β-D-N4-p-t-butylbenzoyl-2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine. In addition, the 2',3'-dideoxy-N4-acyl-cytosinenucleosides and 2',3'-didehydro- 2',3'-dideoxy-N4-acyl-cytosinenucleosides are inhibitors of HBV. Therefore, these compounds can also be used to treat patients that are co-infected with both HIV and HBV.
The present invention provides a compound, method and composition for treating an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
The present invention provides a compound, method and composition for preventing an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application. The present invention provides a compound, method and composition for treating an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
The present invention provides a compound, method and composition for preventing an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
In another aspect, there is provided a pharmaceutical formulation comprising a compound of the invention in combination with a pharmaceutically acceptable carrier or excipient for the treatment of a host infected with HIV or HBV.
In still another aspect, there is provided a compound, method and composition for treating or preventing an HIV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
In still another aspect, there is provided a method and composition for treating or preventing an HBV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent. BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is a non-limiting example of the synthesis of active compounds of the present invention, and in particular, the synthesis of β-D-N4-acyl-2',3'-dideoxy-5- fluorocytidine and β-D-N4-acyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine nucleosides.
Figure 2 is a graphic representation of the anti-HBV activity of selected N4-acyl- substituted β-D-2 ',3 '-dideoxy- and β-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine analogues.
DETAILED DESCRIPTION OF THE INVENTION
It has been found that N4-acyl-cytosine nucleosides, and in particular, N4-acyl-
2 ' ,3 ' -dideoxy-5 -fluorocytidine and N4-acyl-2 ',3 ' -didehydro-2 ',3 ' -dideoxy-5 - fluorocytidine, show improved inhibitory activity against HIV and HBV. Therefore, a method for the treatment or prevention of a host, and in particular, a human, infected with HIV and/or HBV, is provided that includes administering an effective amount of an N4- acyl-cytosine nucleosides.
The present invention also provides a method and composition for treating an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
The present invention provides a method and composition for preventing an HIV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application.
The present invention provides a method and composition for treating an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application. The present invention provides a method and composition for preventing an HBV infection in a host comprising administering a therapeutically effective amount of at least one compound as described in the present application. In another aspect, there is provided a pharmaceutical formulation comprising a compound of the invention in combination with a pharmaceutically acceptable carrier or excipient.
In still another aspect, there is provided a method and composition for treating or preventing an HIV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
In still another aspect, there is provided a method and composition for treating or preventing an HBV infection in a host comprising administering to the subject a combination comprising at least one compound of the invention and at least one further therapeutic agent.
I. Active Compound
In one embodiment of the invention, the active compound is of formula (I) or (II):
Figure imgf000011_0001
or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O, S, NR5, CH2, CHF or CF2; ii) Y is CH2, CHF or CF2; iii) R1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to Q, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to , C2, C3, C , C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), haloalkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl
(including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), CN, CF3, N3, NO2, aryl (including but not limited to C6, C , C8, C9, and C10), heteroaryl (including but not limited to C4, C5, C6, C7, Cs, C9, C10, Cπ, and C12) and acyl (including but not limited to C , C3, C4, C5, and C6); iv) R2 is chosen from alkyl (including but not limited to C\, C2, C3, C4, C5, C6, C7, C8, C9, Cio, Cπ, Cι2, C13, Cι4, 5, Cι6, C17, Cι8, C19, C20, C21, and C22), alkenyl (including but not limited to C2, C3, C4, C5, C6, C7, C8, C9, Clo, Cn, C12, C13, Cι4, C15, Ci6, C17, C18, C19, C20, C21, and C22), alkynyl (including but not limited to C2, C3, C4, C5, C6, C7, C8, C9, Cio, Cπ, Cι , C13, Cι , C15, Cι6, Cn, Cis, C19, C20, C21, and C22), cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), aminoalkyl (including but not limited to , C2, C3, C4, C5, and C6), hydroxyalkyl (including but not limited to Cls C2, C3, C , C5, and C6), haloalkyl (including but not limited to Q, C2, C3, C4, C5, and C6), thioalkyl
(including but not limited to Cj, C2, C3, C , C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and o), heteroaryl (including but not limited to C , C5, Cβ, Cη, C8, C9, C10 Cπ, and C12), and COHJR6 where R6 is chosen from halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to Ci, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to Cj, C2, C3, C4,
C5, and C6), aminoalkyl (including but not limited to C\, C2, C3, C4, C5, and C6), alkoxy (including but not limited to C\, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C\, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), and aryl (including but not limited to C6, C7, C8, C9, and
Cio); v) R3 and R3' are chosen independently from H, halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to Cls C2, C3, C , C5, and C6), alkenyl (including but not limited to C , C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6); vi) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to , C2, C3, C4, C5, and C6), alkenyl (including but not limited to C , C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C , Cs, C9, and Cio), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid
(including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol; and vii) R5 is H, acyl, alkyl, alkenyl, alkynyl, or cycloalkyl.
The compound of the present invention can be in the form of the β-L- or β-D- configuration, or a racemic mixture.
In one embodiment of the present invention, if the active compound is of formula (II), and X is O, S, CH , CHF or CF2, R1 is F, and R3 and R3' are H or F, then R2 cannot be an alkyl, alkoxyalkyl (such as methoxymethyl), aralkyl (such as benzyl or substituted benzyl), aryloxyalkyl (such as phenoxymethyl) or aryl (including but not limited to a phenyl optionally substituted with halogen (F, CI, Br, I), alkyl (including but not limited to Ci, C2, C3, and C ) or alkoxy (including but not limited to Ci, C2, C3, and C4)).
In another particular sub-embodiment of the present invention, the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) Y is CH2, CHF or CF2; iii) R1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to Ci, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to , C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C , C5, and
C6), haloalkenyl (including but not limited to C , C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, Cs, and C6), cycloalkyl (including but not limited to C3, C4, Cs, C6, C7, and Cs), CN, CF3, N3, NO , aryl (including but not limited to Cβ, C , C8, C9, and Cio), heteroaryl (including but not limited to C4, C5, C6, C7,
C8, C9, Cio, Cn, and Cι2) and acyl (including but not limited to C2, C3, C4, C5, and C6); iv) R2 is chosen from alkyl (including but not limited to Ci, C2, C3, C4, C5, Cβ, C7, C8, C9, Cio, Cπ, C12, Ci3, C14, C15, Ci6, C17, C18, C19, C2o, C21, and C22), alkenyl (including but not limited to C2, C3, C4, C5, C6, C7, C8, C9, Cio, Cn, Cι2, Cι3,
Cι4, C15, Cie, Cι7, Cis, C19, C20, C2ι, and C22), alkynyl (including but not limited to C2, C3, C4, C5, Cβ, C , C8, C9, Cio, Cπ, Cι2, C13, Cι4, C15, Ciβ, Cι , C]8, C19, C2o, C2ι, and C22), cycloalkyl (including but not limited to C3, C4, C5, Cβ, Cη, and C8), aminoalkyl (including but not limited to C\, C2, C3, C , C5, and C6), hydroxyalkyl (including but not limited to C\, C2, C3, C4, C5, and Cβ), haloalkyl (including but not limited to , C2, C3, C4, C5, and C6), thioalkyl (including but not limited to Ci, C2, C3, C , C5, and C6), aryl (including but not limited to C6, C , C8, C9, and C10), heteroaryl (including but not limited to C , C5, Cβ, C7, C8, C9, Cio, Cπ, and CJ2), and CβFLiR6 where R6 is chosen from halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to ,
C2, C3, C , C5, and Cβ), haloalkyl (including but not limited to Ci, C2, C3, C4, C5, and Ce), aminoalkyl (including but not limited to , C2, C3, C4, C5, and C6), alkoxy (including but not limited to d, C2, C3, C4, C5, and Cβ), thioalkyl (including but not limited to , C2, C3, C4, C5, and C6), alkenyl (including but not limited to C , C3, C4, C5, and C6), alkynyl (including but not limited to C2s
C3, C4, C5, and C6), and aryl (including but not limited to C6, C7, C8, C9, and Cio); v) R3 and R3 are chosen independently from H, halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C\, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C , C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6); and vi) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to , C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, Cs, and C6), aryl (including but not limited to C6, C7, C8, C9, and Cio), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid
(including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol .
In another particular sub-embodiment of the present invention, the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) Y is CH2, CHF or CF2; iii) R1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to Ci, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C , C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C , C5, and
C6), haloalkenyl (including but not limited to C2, C3, C4, C5, and Ce), alkynyl (including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), CN, CF3, N3, or NO2; iv) R2 is chosen from cycloalkyl (including but not limited to C3, C4, C5, C6, Cη, and C8), aminoalkyl (including but not limited to Ci, C2, C3, C4, C5, and Ce), haloalkyl (including but not limited to C\, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to Ci, C2, C3, C4, C5, and C6), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, Cio, Cn, and C12), and
Figure imgf000016_0001
where R6 is chosen from halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to , C2, C3, C4, C5, and Cβ), haloalkyl (including but not limited to , C2, C3, C4, C5, and C6), aminoalkyl (including but not limited to
Ci, C2, C3, C4, C5, and Cβ), alkoxy (including but not limited to Cj, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to C\, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C , C5, and Cβ), alkynyl (including but not limited to C2, C3, C4, C5, and Cβ), and aryl (including but not limited to
Figure imgf000016_0002
v) R3 and R3 are chosen independently from H, halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to , C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C , C5, and C6); and vi) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to Ci, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C , C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and Ce), aryl (including but not limited to C6, C7, C8, C9, and o), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl , group,,, is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid
(including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
In another particular sub-embodiment of the present invention, the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) Y is CH2, CHF or CF2; iii) R1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to , C2, C3, C4, C5, and C6), haloalkyl (including but not limited to , C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and Cβ), haloalkenyl (including but not limited to C2, C3, C4, Cs, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C , C5, and C6), CN, CF3, N3, or NO2; iv) R2 is chosen from cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and Cs), aminoalkyl (including but not limited to Ci, C2, C3, C4, C5, and Cβ), haloalkyl (including but not limited to , C , C3, C4, C5, and C6), thioalkyl (including but not limited to Cls C2, C3, C , C5, and C6), heteroaryl (including but not limited to C4, C5, Ce, C7, C8, C9, Cio, Cπ, and C12); v) R3 and R3 are chosen independently from H, halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to Ci, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C , C5, and Ce), and alkynyl (including but not limited to C2, C3, C4, Cs, and Cβ); and vi) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to Ci, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C , C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8,
C9, and C10), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
In another particular sub-embodiment of the present invention, the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) Y is CH2, CHF or CF2; iii) R1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to Cj, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to Cj, C2, C3, C4, C5, and Cβ), alkenyl (including but not limited to C2, C3, C4, C5, and Cβ), haloalkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl
(including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), CN, CF3, N3, or NO2; iv) R2 is CeHtR6 where R6 is chosen from CN, CF3, N3, NO2, haloalkyl (including but not limited to Ci, C2, C3, C4, C5, and C6), aminoalkyl (including but not limited to , C2, C3, C , C5, and C6), thioalkyl (including but not limited to Ci,
C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and Cβ), alkynyl (including but not limited to C , C3, C4, C5, and C6), and aryl (including but not limited to C6, C7, Cs, C9, and Cio); v) R3 and R3 are chosen independently from H, halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C1? C2, C3, C , C5, and Cβ), alkenyl
(including but not limited to C2, C3, C , C5, and C6), and alkynyl (including but not limited to C2, C3, C , C5, and C6); and vi) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to , C2, C3, C4, C5, and C6), alkenyl
(including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C , C5, and C6), aryl (including but not limited to C6, C , C8, C9, and Cio), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol. In another particular sub-embodiment of the present invention, the active compound is of formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) Y is CH2, CHF or CF2; iii) R1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to C\, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to , C2, C3, C4, C5, and Cβ), alkenyl (including but not limited to C2, C3, C , C5, and Cβ), haloalkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and Cβ), haloalkynyl (including but not limited to C2, C3, C , C5, and C6), CN, CF3, N3, or NO2; iv) R2 is C6H4R6 where R6 is chosen from halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to Ci, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to Cl5 C2, C3, C4, C5, and C6), aminoalkyl (including but not limited to Ci, C2, C3, C , C5, and C6), alkoxy (including but not limited to Ci, C2, C3, C4, C5, and C6), thioalkyl (including but not limited to , C2, C3, C4, C5, and Cβ), alkenyl (including but not limited to C2, C3, C , C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), and aryl (including but not limited to C6, C , C8, C9, and C10); v) R3 and R3' are chosen independently from H, halogen (F, CI, Br, I), CN, CF3,
N3, NO2, alkyl (including but not limited to , C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and Cβ); and vi) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to C C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C , C5, and C6), alkynyl (including but not limited to C2, C3, C , C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and C10), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol; and.
In a particular sub-embodiment of the present invention, the active compound is of formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) R1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to C\, C2, C3, C , C5, and C6), haloalkyl (including but not limited to Ci,
C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C , C5, and Cβ), haloalkenyl (including but not limited to C , C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and Cβ), haloalkynyl (including but not limited to C2, C3, C , C5, and C6), cycloalkyl (including but not limited to < C3, C4, C5, Cβ, Cη, and C8), CN, CF3, N3, NO2, aryl (including but not limited to
Cβ, Cη, C8, C9, and Cio), heteroaryl (including but not limited to C4, C5, C6, C7, Cs, C9, Cio, Cπ, and Q2) and acyl (including but not limited to C , C3, C4, C5, and C6); iii) R2 is chosen from cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), aminoalkyl (including but not limited to Ci, C2, C3, C4, C5, and Cβ), haloalkyl (including but not limited to Ci, C2, C3, C , C5, and C6), thioalkyl
(including but not limited to Cls C2, C3, C4, C5, and C6), heteroaryl (including but not limited to C , C5, C6, C7, C8, C9, Cio, Cn, and Cι2), and C6H4R6 where
R6 is chosen from halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to C , C2, C3, C , C5, and Cβ), haloalkyl (including but not limited to , C2, C3, C4, C5, and C6), aminoalkyl (including but not limited to d, C2, C3, C4, C5, and C6), alkoxy (including but not limited to , C2, C3, C4,
C5, and Cβ), thioalkyl (including but not limited to C\, C2, C3, C , C5, and Ce), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and C6), and aryl (including but not limited to
C6, C7, C8, C9, and Cio); iv) R3 and R3' are chosen independently from H, halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to , C , C3, C4, C5, and Cβ), alkenyl (including but not limited to C2, C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6); and v) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to Ci, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C4, C5, and Ce), aryl (including but not limited to C6, C7, C8, C9, and o), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid
(including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
In a particular sub-embodiment of the present invention, the active compound is of formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) R1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to Ci, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C\, C2, C3, C , C5, and Cβ), alkenyl (including but not limited to C2, C3, C , C5, and Cβ), haloalkenyl (including but not limited to C2, C3, C , C5, and C6), alkynyl (including but not limited to C2, C , C , C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), CN, CF3, N3, and NO2; iii) R2 is chosen from cycloalkyl (including but not limited to C3, C4, C5, C6, C7, and C8), aminoalkyl (including but not limited to Cl5 C2, C3, C , C5, and C6), haloalkyl (including but not limited to , C2, C3, C4, C5, and C6), thioalkyl (including but not limited to Ci, C2, C3, C4, C5, and C6), heteroaryl (including but not limited to C , C5, C6, C7, C8, C9, Cio, Cn, and C12); iv) R3 and R3 are chosen independently from H, halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to Cl5 C2, C3, C4, C5, and Cβ), alkenyl (including but not limited to C2, C3, C4, C5, and C6), and alkynyl (including but not limited to C2, C3, C4, C5, and C6); and v) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to , C2, C3, C , C5, and Cβ), alkenyl (including but not limited to C2, C3, C4, C5, and Cβ), alkynyl (including but not limited to C2, C3, C4, C5, and C6), aryl (including but not limited to C6, C7, C8, C9, and Cio), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid
(including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
In a particular sub-embodiment of the present invention, the active compound is of formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) R1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to , C2, C3, C4, C5, and C6), haloalkyl (including but not limited to C\, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and Cβ), haloalkenyl (including but not limited to C2, C3, C4, C5, and Cβ), alkynyl (including but not limited to C2, C3, C4, C5, and C6), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), cycloalkyl (including but not limited to C3, C , C5, C6, C7, and C8), CN, CF3, N3, NO , aryl (including but not limited to Cβ, Cη, Cs, C9, and Cio), heteroaryl (including but not limited to C4, C5, Ce, Cη, C8, C9, Cio, Cn, and 2) and acyl (including but not limited to C2, C3, C4, C5, and C6); iii) R2 is CeFLiR6 where R6 is chosen from halogen ((F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to Ci, C2, C3, C4, C5, and C6), haloalkyl (including but not limited to , C2, C3, C4, C5, and C6), aminoalkyl (including but not limited to , C2, C3, C4, C5, and Cβ), alkoxy (including but not limited to C1} C2, C3, C , C5, and Cβ), thioalkyl (including but not limited to , C2, C3, C , C5, and C6), alkenyl (including but not limited to C , C3, C4, C5, and C6), alkynyl (including but not limited to C2, C3, C , C5, and C6), and aryl (including but not limited to Cβ, Cη, C8, C9, and Cio); iv) R3 and R3 are chosen independently from H, halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to , C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and Cβ), and alkynyl (including but not limited to C , C3, C4, Cs, and C6); and v) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), carbonyl substituted with alkyl (including but not limited to , C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and Cβ), alkynyl (including but not limited to C2, C3, C , C5, and Cβ), aryl (including but not limited to C6, C7, C8,
C9, and Cio), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group is optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid (including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
In a particular sub-embodiment of the present invention, the active compound is* of - formula (II) or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O; ii) R1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl (including but not limited to , C2, C3, C , C5, and C6), haloalkyl (including but not limited to , C2, C3, C4, C5, and Ce), alkenyl (including but not limited to C2, C3, C , C5, and Cβ), haloalkenyl (including but not limited to C2, C3, C4, C5, and C6), alkynyl
(including but not limited to C2, C3, C4, C5, and Ce), haloalkynyl (including but not limited to C2, C3, C4, C5, and C6), cycloalkyl (including but not limited to C3, C4, C5, Cβ, Cη, and C8), CN, CF3, N3, NO2, aryl (including but not limited to C6, Cη, C8, C9, and Cio), heteroaryl (including but not limited to C4, C5, C6, C7, C8, C9, do, Cπ, and Cι2) and acyl (including but not limited to C2, C3, C , C5, and C6); iii) R2 is CeH tR6 where R6 is chosen from CN, CF3, N3, NO2, haloalkyl (including but not limited to , C , C3, C4, C5, and C6), aminoalkyl (including but not limited to , C2, C3, C4, C5, and C6), thioalkyl (including but not limited to , C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C , C5, and Cβ), alkynyl (including but not limited to C2, C3, C , C5, and C6), and aryl (including but not limited to C6, C7, C8, C9, and do); iv) R3 and R3 are chosen independently from H, halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl (including but not limited to Cj, C2, C3, C4, C5, and C6), alkenyl (including but not limited to C2, C3, C4, C5, and Cβ), and alkynyl (including but not limited to C2, C3, C4, C5, and C6); and v) R4 is H, phosphate (including but not limited to monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug), , carbonyl substituted with alkyl (including but not limited to Q, C2, C3, C , C5, and Cβ), alkenyl (including but not limited to C2, C3, C4, C5, and Cβ), alkynyl (including but not limited to C2, C3, C4, C5, and Cβ), aryl (including but not limited to C6, C7, C8, C9, and Cio), or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3 are H or phosphate, sulfonate ester (including but not limited to alkyl or arylalkyl sulfonyl including but not limited to methanesulfonyl), benzyl (wherein the phenyl group- ds. .optionally substituted with one or more substituents as described in the definition or aryl given above), a lipid
(including but not limited to a phospholipid), an amino acid, a peptide, or cholesterol.
In one embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the ortho position.
In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I) in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) ' R2 is a phenyl moiety optionally substituted with Br in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with I in the ortho position. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with F in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CI in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with NO2 in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
) X is O; Y is CH2; i) R1 is fluorine or hydrogen; ii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and
V) R2 is a phenyl moiety optionally substituted with methyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with ethyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R is a phenyl moiety optionally substituted with n-propyl in the ortho position. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with iso-propyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-butyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with sec-butyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with tert-butyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-pentyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with isopentyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3' are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with neopentyl in the ortho position. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with cyclopentyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-hexyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with a cyclohexyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CN in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CF3 in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with N3 in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with haloalkyl in the ortho position. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with aminoalkyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R and R are independently hydrogen or fluorine; R is hydrogen; and iv) R is a phenyl moiety optionally substituted with alkoxy in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with thioalkyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkenyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkynyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3' are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with aryl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with benzyl in the ortho position. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with thiophenyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine^ R4 is hydrogen; and iv) R is a phenyl moiety optionally substituted with furanyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with naphthyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with benzoyl in the ortho position.
In one embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I), CN, CF3,
N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the meta position.
In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I) in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3' are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with Br in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with I in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with F in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CI in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with NO2 in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with methyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with ethyl in the meta position. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-propyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula , its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with iso-propyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-butyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with sec-butyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with tert-butyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-pentyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with isopentyl in the meta position. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with neopentyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with cyclopentyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3' are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-hexyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with a cyclohexyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CN in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CF3 in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with N3 in the meta position. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with haloalkyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with aminoalkyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is.hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkoxy in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with thioalkyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkenyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkynyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically,.acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with aryl in the meta position. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with benzyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with thiophenyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with furanyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with naphthyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with benzoyl in the meta position.
In one embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the para position.
In another embodiment of the present invention, the active compound is of formula
(I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I) in the para position. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with Br in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3' are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with I in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and .. iv) R2 is a phenyl moiety optionally substituted with F in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CI in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with NO2 in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically. acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with methyl in the para position. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with ethyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-propyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii). R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen;..and*> iv) R2 is a phenyl moiety optionally substituted with iso-propyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorinέ; R4 is hydrogen; and
- I iv) R is a phenyl moiety optionally substituted with n-butyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and , iv) R2 is a phenyl moiety optionally substituted with sec-butyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with tert-butyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-pentyl in the para position. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with isopentyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with neopentyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) ,'J R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and, ,•- iv) R2 is a phenyl moiety optionally substituted with cyclopentyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine1, R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-hexyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and , iv) R2 is a phenyl moiety optionally substituted with a cyclohexyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y js CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CN in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable, salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CF3 in the para position. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with N3 in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with haloalkyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii): .; R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with aminoalkyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are Independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkoxy in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and ι iv) R2 is a phenyl .moiety optionally substituted with thioalkyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkenyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable, salts or prodrugs thereof, wherein: i) X is O; Y is GH2; i) R1 is fluorine or hydrogen; ii) R3 and R3' are independently hydrogen or fluorine; R4 is hydrogen; and v) R2 is a phenyl moiety optionally substituted with alkynyl in the para position. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with aryl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with benzyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii). -. :R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with thiophenyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with furanyl in the para position.
I
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and ι iv) R2 is a phenyl moiety optionally substituted with naphthyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; . iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with benzoyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3-dihalo. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; , iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4-dihalo.
n yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
X is O; Y is CH2; ii) R .1 i •s fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,5-dihalo.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
) X is O; Y is CH2; i) R1 is fluorine or hydrogen; ii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and v) R2 is a phenyl moiety optionally substituted with 2,6-dihalo.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorinej R4 is hydrogen; and iv) R is a phenyl moiety optionally substituted with 3,4-dihalo.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and , iv) R2 is a phenyl moiety optionally substituted with 3,5-dihalo.
1
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y ψ CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,4-trihalo.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,5-trihalo. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4,5-trihalo.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4,6-trihalo.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3-and.R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,5,6-trihalo.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R is a phenyl moiety optionally substituted with 3,4,5-trihalo.
In yet another1 embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and, iv) R2 is a phenyl moiety optionally substituted with 2,3,4,5-tetrahalo.
In yet another embodiment of the present invention, the active compound is of
I' formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,4,5,6-pentahalo.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3' are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3-dialkyl. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4- dialkyl.
n yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,5- dialkyl.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,6- dialkyl.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine} R4 is hydrogen; and iv) R is a phenyl moiety optionally substituted with 3,4- dialkyl.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and , iv) R2 is a phenyl moiety optionally substituted with 3,5- dialkyl.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and t iv) R2 is a phenyl moiety optionally substituted with 2,3,4-trialkyl.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,5- trialkyl. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4,5- trialkyl.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4,6- trialkyl.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3. are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,5,6- trialkyl.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R are independently hydrogen or fluorine^ R is hydrogen; and
I
- I iv) R is a phenyl moiety optionally substituted with 3,4,5- trialkyl.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
) X is O; Y is CH2; i) R1 is fluorine or hydrogen; ii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and , v) R2 is a phenyl moiety optionally substituted with 2,3,4,5-tetraalkyl.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,4,5,6-pentaalkyl.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3-di-NO2. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4- di-NO2.
n yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) Rl is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,5- di-NO2.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,6- di-NO2.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine;1 R4 is hydrogen; and iv) R 2 is a ph ' enyl moiety optionally substituted with 3,4- di-NO2.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and , iv) R2 is a phenyl moiety optionally substituted with 3,5- di-NO .
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,4- tri-NO2.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,5- tri-NO2. In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4,5- tri-NO .
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4,6- tri-NO2.
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,5,6- tri-NO .
In yet another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorinej R4 is hydrogen; and
I iv) R 2 is a p 'henyl moiety optionally substituted with 3,4,5- tri-NO .
In one embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and , iv) R2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the ortho position.
In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein:
i) X is O; ii) R1 is fluorine or hydrogen; iii) R and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I) in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with Br in the ortho position. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with I in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; i) R1 is fluorine or hydrogen; ii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and v) R2 is a phenyl moiety optionally substituted with F in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CI in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine1; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with NO2 in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and , iv) R2 is a phenyl moiety optionally substituted with alkyl in the ortho position.
I I
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; , ii) R1 is fluorine or hydrogen; iii) R3 and R3' are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with methyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with ethyl in the ortho position. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-propyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with iso-propyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-butyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3' are independently hydrogen or fluorine;! R4 is hydrogen; and
I I iv) R is a phenyl moiety optionally substituted with sec-butyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and , iv) R2 is a phenyl moiety optionally substituted with tert-butyl in the ortho position.
I
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and , iv) R2 is a phenyl moiety optionally substituted with n-pentyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3' are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with isopentyl in the ortho position. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with neopentyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with cyclopentyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-hexyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine} R4 is hydrogen; and
2 I iv) R is a phenyl moiety optionally substituted with a cyclohexyl in the ortho position.
5 In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and
10 iv) R2 is a phenyl moiety optionally substituted with CN in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O;
15 ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CF3 in the ortho position.
1. In yet another embodiment of the present invention, the active compound is of
20 formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with N3 in the ortho position.
25 In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with haloalkyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with aminoalkyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkoxy in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3' are independently hydrogen or fluorine; 'R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with thioalkyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and , iv) R2 is a phenyl, moiety optionally substituted with alkenyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkynyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with aryl in the ortho position. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with benzyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with thiophenyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with furanyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with naphthyl in the ortho position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with benzoyl in the ortho position.
In one embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the meta position.
In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iϋ) R3 and R3' are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I) in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with Br in the meta position. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with I in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with F in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CI in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with NO2 in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; , iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkyl in the meta position,
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3' are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with methyl in the meta position. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with ethyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-propyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with iso-propyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ϋ) R1 is fluorine or hydrogen; iii) R3 and R3' are independently hydrogen or fluorine); R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-butyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine r hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and, iv) R2 is a phenyl moiety optionally substituted with sec-butyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; r ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with tert-butyl in the meta position.
In yet another embodiment of the present invention, the active compound is of , . , formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: . i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-pentyl in the meta position. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with isopentyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with neopentyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with cyclopentyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-hexyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with a cyclohexyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CN in the meta position.
In yet another embodiment of the present invention, the active compound is of ■ formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:.. '->ι _ i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CF3 in the meta position. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with N3 in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with haloalkyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently, hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with aminoalkyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkoxy in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with thioalkyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkenyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: ... ,. «.. . i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkynyl in the meta position. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with aryl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with benzyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with thiophenyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with furanyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with naphthyl in the meta position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with benzoyl in the meta position.
In one embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, or aryl in the para position. In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with halogen (F, CI, Br, I) in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with Br in the para position. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with I in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with F in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CI in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with NO2 in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) , X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with methyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with ethyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-propyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with iso-propyl in the para position. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-butyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with sec-butyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with tert-butyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-pentyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with isopentyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
:) X is O; i) R1 is fluorine or hydrogen; ii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and v) R2 is a phenyl moiety optionally substituted with neopentyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with cyclopentyl in the para position. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with n-hexyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with a cyclohexyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CN in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with CF3 in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with N3 in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with haloalkyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with aminoalkyl in the para position. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkoxy in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with thioalkyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 andR3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkenyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with alkynyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with aryl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with benzyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with thiophenyl in the para position. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with furanyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with naphthyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with benzoyl in the para position.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3-dihalo.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4-dihalo.
n yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,5-dihalo.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,6-dihalo. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 3,4-dihalo.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 3,5-dihalo.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,4-trihalo.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,5-trihalo.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4,5-trihalo.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4,6-trihalo.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,5,6-trihalo. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 3,4,5-trihalo.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,4,5-tetrahalo.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
) X is O; i) R1 is fluorine or hydrogen; ii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and v) R2 is a phenyl moiety optionally substituted with 2,3,4,5,6-pentahalo.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3-dialkyl.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4- dialkyl.
n yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,5- dialkyl.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,6- dialkyl. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 3,4- dialkyl.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen;
■a γ iii) R and R are independently hydrogen or fluorine; R is hydrogen; and iv) R is a phenyl moiety optionally substituted with 3,5- dialkyl.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,4-trialkyl.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,5- trialkyl.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4,5- trialkyl.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; ϋi) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4,6- trialkyl.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,5,6- trialkyl. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) . X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 3,4,5- trialkyl.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,4,5-tetraalkyl.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,4,5,6-pentaalkyl.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein:
i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3-di-NO2.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4- di-NO2.
n yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,5- di-NO2.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,6- di-NO2. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 3,4- di-NO2.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 3,5- di-NO2.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,4- tri-NO2.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,3,5- tri-NO2.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R and R are independently hydrogen or fluorine; R is hydrogen; and d iv) R2 is a phenyl moiety optionally substituted with 2,4,5- tri-NO2.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,4,6- tri-NO2.
In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 2,5,6- tri-NO2. In yet another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salts or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a phenyl moiety optionally substituted with 3,4,5- tri-NO2.
In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a thienyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 2- position.
In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a thienyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 3- position or the 4-position.
In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a benzothiophenyl optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl on the benzene ring.
In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a benzothiophenyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl on the thienyl ring.
In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a cyclohexyl optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 2 or 3- position. In another embodiment of the present invention, the active compound is of formula (I), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; Y is CH2; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a cyclohexyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 4- position.
In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a thienyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 2 or 3 position.
In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R and R are independently hydrogen or fluorine; R is hydrogen; and iv) R2 is a thienyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 4- position. In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a benzothiophenyl optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl on the benzene ring.
In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a benzothiophenyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl on the thienyl ring.
In another embodiment of the present invention, the active compound is of formula
(II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a cyclohexyl optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 2 or 3 position.
Ill In another embodiment of the present invention, the active compound is of formula (II), its pharmaceutically acceptable salt or prodrugs thereof, wherein: i) X is O; ii) R1 is fluorine or hydrogen; iii) R3 and R3 are independently hydrogen or fluorine; R4 is hydrogen; and iv) R2 is a cyclohexyl moiety optionally substituted with alkyl, halo, alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, or heteroaryl in the 4 position.
In one preferred embodiment, the active compound is β-D-2',3'-dideoxy-5-fluoro- N4-(4-iodobenzoyl)cytidine of the structure:
Figure imgf000113_0001
or a pharmaceutically acceptable salt or prodrug thereof. In another preferred embodiment, the active compound is β-D-2',3'-dideoxy-5- fluoro-N τ4 -(4-fluorobenzoyl)cytidine of the structure:
Figure imgf000113_0002
or a pharmaceutically acceptable salt or prodrug thereof. In still another preferred embodiment, the active compound is β-D-N4-(4- chlorobenzoyl)-2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000114_0001
or a pharmaceutically acceptable salt or prodrug thereof.
In one preferred embodiment, the active compound is β-D-N4-(4-bromobenzoyl)- 2 ',3 '-dideoxy-5 -fluorocytidine of the structure:
Figure imgf000114_0002
or a pharmaceutically acceptable salt or prodrug thereof.
In another preferred embodiment, the active compound is β-D-2',3 '-dideoxy-5- fluoro-N4-(3-fluorobenzoyl)cytidine of the structure:
Figure imgf000114_0003
or a pharmaceutically acceptable salt or prodrug thereof. In still another preferred embodiment, the active compound is β-D-N4-(3- chlorobenzoyl)-2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000115_0001
or a pharmaceutically acceptable salt or prodrug thereof.
In one preferred embodiment, the active compound is β-D-N4-(3-bromobenzoyl)- 2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000115_0002
or a pharmaceutically acceptable salt or prodrug thereof.
In another preferred embodiment, the active compound is β-D-2',3'-dideoxy-5- fluoro-N4-(4-nitrobenzoyl)cytidine of the structure:
Figure imgf000115_0003
or a pharmaceutically acceptable salt or prodrug thereof. In still another preferred embodiment, the active compound is β-D-2',3 '-dideoxy- 5-fluoro-N4- »-toluoylcytidine of the structure:
Figure imgf000116_0001
or a pharmaceutically acceptable salt or prodrug thereof. In one preferred embodiment, the active compound is β-D-2',3 '-dideoxy-5-fluoro-
N4-(ff2-toluoyl)cytidine of the structure:
Figure imgf000116_0002
or a pharmaceutically acceptable salt or prodrug thereof.
In another preferred embodiment, the active compound is β-D-2',3'-dideoxy-N4- (4-ethylbenzoyl)-5-fluorocytidine of the structure:
Figure imgf000116_0003
or a pharmaceutically acceptable salt or prodrug thereof. In still another preferred embodiment, the active compound is β-D-2',3 '-dideoxy- 5-fluoro-N4-(4-propylbenzoyl)cytidine of the structure:
Figure imgf000117_0001
or a pharmaceutically acceptable salt or prodrug thereof.
In one preferred embodiment, the active compound is β-D-N4-(4-tert- butylbenzoyl)-2', 3 '-dideoxy-5 -fluorocytidine of the structure:
Figure imgf000117_0002
or a pharmaceutically acceptable salt or prodrug thereof.
In still another preferred embodiment, the active compound is β-D-2',3'-dideoxy- 5-fluoro-N -(2-thiophenecarbonyl)cytidine of the structure:
Figure imgf000117_0003
or a pharmaceutically acceptable salt or prodrug thereof.
In one preferred embodiment, the active compound is β-D-N4-(benzo-[b]-thiophene-2- carbonyl)-2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000118_0001
or a pharmaceutically acceptable salt or prodrug thereof.
In another preferred embodiment, the active compound is β-D-N4-(cyclohexane-carbonyl)-
2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000118_0002
or a acceptable salt or prodrug thereof.
In still another preferred embodiment, the active compound is β-D-2',3'-didehydro-2',3'- dideoxy-5-fluoro-N4-(4-iodobenzoyl)cytidine of the structure:
Figure imgf000118_0003
or a pharmaceutically acceptable salt or prodrug thereof.
In one preferred embodiment, the active compound is β-D-2',3'-didehydro-2',3'-dideoxy- 5-fluoro-N4-(4-fluorobenzoyl)cytidine of the structure:
Figure imgf000118_0004
or a pharmaceutically acceptable salt or prodrug thereof. In another preferred embodiment, the active compound is β-D-N4-(4-chlorobenzoyl)-2',3'- didehydro-2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000119_0001
or a pharmaceutically acceptable salt or prodrug thereof.
In still another preferred embodiment, the active compound is β-D-N4-(4- bromobenzoyι)-2 ' ,3 ' -didehydro-2 ' ,3 '-dideoxy-5 -fluorocytidine of the structure:
Figure imgf000119_0002
or a pharmaceutically acceptable salt or prodrug thereof. In one preferred embodiment, the active compound is β-D-N4-p-anisoyl-2',3'- didehydro-2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000119_0003
or a pharmaceutically acceptable salt or prodrug thereof. In still another preferred embodiment, the active compound is β-D-2 ',3'- didehydro-2 ' ,3 ' -dideoxy-5 -fluoro-N4-(3 -nitrobenzoy l)cytidine of the structure:
Figure imgf000120_0001
or a pharmaceutically acceptable salt or prodrug thereof.
In one preferred embodiment, the active compound is β-D-2',3'-didehydro-2',3'- dideoxy-5-fluoro-N4-j9-toluoylcytidine of the structure:
Figure imgf000120_0002
or a pharmaceutically acceptable salt or prodrug thereof. In another preferred embodiment, the active compound is β-D-2',3 '-didehydro-
2',3'-dideoxy-5-fluoro-N4-ffz-toluoylcytidine of the structure:
Figure imgf000120_0003
or a pharmaceutically acceptable salt or prodrug thereof. In one preferred embodiment, the active compound is β-D-N4-(4-t-butylbenzoyl)- 2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000121_0001
or a pharmaceutically acceptable salt or prodrug thereof.
In still another preferred embodiment, the active compound is β-D-N4- cyclopentanecarbonyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000121_0002
or a pharmaceutically acceptable salt or prodrug thereof.
In one preferred embodiment, the active compound is β-D-N4- (cyclohexanecarbonyl)-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000121_0003
or a pharmaceutically acceptable salt or prodrug thereof. II. Stereoisomerism and Polymorphism
The compounds of the present invention have asymmetric centers and occur as racemates, racemic mixtures, individual diastereomers or enantiomers, with all isomeric forms being included in the present invention. Some compounds may exhibit polymorphism. The present invention encompasses racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein. The optically active forms can be prepared by, for example, resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase or by enzymatic resolution.
Examples of methods to obtain optically active materials include at least the following. i) physical separation of crystals: a technique whereby macroscopic crystals of the individual enantiomers are manually separated. This technique can be used if crystals of the separate enantiomers exist, i.e., the material is a conglomerate, and the crystals are visually distinct; ii) simultaneous crystallization: a technique whereby the individual enantiomers are separately crystallized from a solution of the racemate, possible only if the latter is a conglomerate in the solid state; iii) enzymatic resolutions: a technique whereby partial or complete separation of a racemate by virtue of differing rates of reaction for the enantiomers with an enzyme; iv) enzymatic asymmetric synthesis: a synthetic technique whereby at least one step of the synthesis uses an enzymatic reaction to obtain an enantiomerically pure or enriched synthetic precursor of the desired enantiomer; v) chemical asymmetric synthesis: a synthetic technique whereby the desired enantiomer is synthesized from an achiral precursor under conditions that produce asymmetry (i.e., chirality) in the product, which may be achieved using chiral catalysts or chiral auxiliaries; vi) diastereomer separations: a technique whereby a racemic compound is reacted with an enantiomerically pure reagent (the chiral auxiliary) that converts the individual enantiomers to diastereomers.
The resulting diastereomers are then separated by chromatography or crystallization by virtue of their now more distinct structural differences and the chiral auxiliary later removed to obtain the desired enantiomer; vii) first- and second-order asymmetric transformations: a technique whereby diastereomers from the racemate equilibrate to yield a preponderance in solution of the diastereomer from the desired enantiomer or where preferential crystallization of the diastereomer from the desired enantiomer perturbs the equilibrium such that eventually in principle all the material is converted to the crystalline diastereomer from the desired enantiomer. The desired enantiomer is then released from the diastereomer; viii) kinetic resolutions: this technique refers to the achievement of partial or complete resolution of a racemate (or of a further resolution of a partially resolved compound) by virtue of unequal reaction rates of the enantiomers with a chiral, non-racemic reagent or catalyst under kinetic conditions; ix) enantiospecific synthesis from non-racemic precursors: a synthetic technique whereby the desired enantiomer is obtained from non- chiral starting materials and where the stereochemical integrity is not or is only minimally compromised over the course of the synthesis; x) chiral liquid chromatography: a technique whereby the enantiomers of a racemate are separated in a liquid mobile phase by virtue of their differing interactions with a stationary phase (including but not limited to via chiral HPLC). The stationary phase can be made of chiral material or the mobile phase can contain an additional chiral material to provoke the differing interactions; xi) chiral gas chromatography: a technique whereby the racemate is volatilized and enantiomers are separated by virtue of their differing interactions in the gaseous mobile phase with a column containing a fixed non-racemic chiral adsorbent phase; xii) extraction with chiral solvents: a technique whereby the enantiomers are separated by virtue of preferential dissolution of one enantiomer into a particular chiral solvent; xiii) transport across chiral membranes: a technique whereby a racemate is placed in contact with a thin membrane barrier. The barrier typically separates two miscible fluids, one containing the racemate, and a driving force such as concentration or pressure differential causes preferential transport across the membrane barrier. Separation occurs as a result of the non-racemic chiral nature of the membrane that allows only one enantiomer of the racemate to pass through.
Chiral chromatography, including but not limited to simulated moving bed chromatography, is used in one embodiment. A wide variety of chiral stationary phases are commercially available.
III. Definitions
The term "independently" is used herein to indicate that the variable, which is independently applied, varies independently from application to application. Thus, in a compound such as R"XYR", wherein R" is "independently carbon or nitrogen," both R" can be carbon, both R" can be nitrogen, or one R" can be carbon and the other R" nitrogen.
As used herein, the term "substantially free of or "substantially in the absence of refers to a nucleoside composition that includes at least 95% to 98 % by weight, and even more preferably 99% to 100% by weight, of the designated enantiomer of that nucleoside. In a preferred embodiment, in the methods and compounds of this invention, the compounds are substantially free of enantiomers.
Similarly, the term "isolated" refers to a nucleoside composition that includes at least 85 or 90% by weight, preferably 95% to 98 % by weight, and even more preferably 99% to 100% by weight, of the nucleoside, the remainder comprising other chemical species or enantiomers.
The term "alkyl," as used herein, unless otherwise specified, refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbon. The term includes both substituted and unsubstituted alkyl groups. The alkyl group may be optionally substituted with any moiety that does not otherwise interfere with the reaction or that provides an improvement in the process, including but not limited to but limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, aryl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfmyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene et al, Protective Groups in Organic Synthesis. John Wiley & Sons, Second Edition, 1991, hereby incorporated by reference. Specifically included are CF3 and CH2CF3
In the text, whenever the term C(alkyl range) is used, the term independently includes each member of that class as if specifically and separately set out. As a nonlimiting example, the term "Cι-2 " independently represents each species that falls within the scope. Alkyl groups include, but are not limited to the radicals of methane, ethane, propane, cyclopropane, 2-methylpropane (isobutane), «-butane, 2,2- dimethylpropane (neopentane), cytobutane, 1,1 dimethylcyclopropane, 2-methylbutane, trans- 1,2-dimethylcyclopropane, ethylcyclopropane, n-pentane, methylcyclobutane, cis- 1,2-dimethylcyclopropane, spiropentane, cyclopentane, 2,2-dimethylbutane, 1,1,2- trimethylcyclopropane, 2,3-dimethylbutane, 2-methylpentane, 3-methylpentane, 1,2,3- trimethylcyclopropane, rø-hexane, ethylcyclobutane,, methylcyclopentane,
2,2dimethylpentane, 2,4-dimethylpentane, cyclohexane, 2,2,3-trimethylbutane, 3,3- dimethylpentane, 1,1-dimethylcyclopentane, 2,3-dimethylpentane, 2-methylhexane, trans- 1,3-dimethylcyclopentane, cw-l,3-dimethylcyclopentane, 3-methylhexane, trans-1,1- dimethylcyclopentane, 3-ethylpentane, quadricyclane (quadricyclo [2,2,1,0Z6,03,5] heptane), n-heptane, 2,2,4-trimethylpentane, cw-l,2-dimethylcyclopentane, methylcyclohexane, ethylcyclopentane, 1,1,3-trimethylcyclopentane, 2,2-dimethylhexane, 5 2,5-dimethylhexane, l,tra«5-2,cz5-4trimethylcyclopentane, 2,4-dimethylhexane, 2,2,3- trimethylpentane, l,trarø-2,cw-3-trimethylcyclopentane, 3,3-dimethylhexane, 2,3,4- trimethylpentane, 1,1,2-trimethylcycloρentane, 2,3,3-trimethylpentane, 2,3- dimethylhexane, 3-ethyl-2-methylpentane, l,cw-2,trara-4-trimethylcyclopentane, l,cis- 2,trøra,-3trimethylcyclopentane, 2-methylheptane, 4-methylheptane, 3,4-dimethylhexane,
10 l,c/s-2,cw-4trimethylcyclopentane, 3-ethyl-3-methylpentane, 3-ethylhexane, 3- methylheptane, cylotheptane (suberane), trarø-l,4-dimethylcyclohexane, 1,1- dimethylcyclohexane, c 5-l,3-dimethylcychohexane, trarø-1 -ethyl-3 -methylcyclopentane, trans- 1 -ethyl-2-methylcyclopentane, cis- 1 -ethyl-3 -methylcyclopentane, 1 -ethyl- 1 - methylcyclopentane, 2,2,4,4-tetramethylpentane, 1 ,cz£-2-c s-3-trimethylcyclopentane,
15 trø«s-l,2-dimethylcyclohexane, 2,2,5-trimethylhexane, trαrø-l,3-dimethylcyclohexane, n- octane, isopropylcyclopentane, 2,2,4-trimethylhexane, c/5-l-ethyl-2-methylcyclopentane, c/5-l,2-dimethylcyclohexane, 2,4,4-trimethylhexane, H-propylcyclopentane, 2,3,5- trimethylhexane, ethylcyclohexane, 2,2-dimethylheptane, 2,2,3,4-tetramethylpentane, 2,4- dimethylheptane, methylcycloheptane, 2,2,3-trimethylhexane, 4-ethyl-2-methylhexane, 3-
20 ethyl-2.2-dimethylpentane, 4,4-dimethylheptane, 2,6-dimethylheptane, 2,5- dimethylheptane, 3,5-dimethylheptane, bicyclo[4.2.0]octane, c/5-bicyclo[3.3.0]octane, 2,4- dimethyl-3-ethylpentane, 1,1,3-trimethylcyclohexane, 3,3-dimethylheptane, 2,2,5,5- tetramethylhexane, 2,3,3-trimethylhexane, 3-ethyl-2-methylhexane, trans-1,3,5- trimethylcyclohexane, 2,3,4-trimethylhexane, cw-l,3,5-trimethylcyclohexane, trarø-1,2,4-
,25, . trimethylcyclohexane, 2,2,3,3-tetramethylpentane, 4-ethyl-3-methylhexane, 3,3,4- trimethylhexane, 2,3-dimethylheptane, 3,4-dimethylheptane, 3 -ethyl-3 -methylhexane, 4- ethylheptane, 2,3,3,4-tetramethylpentane, 2,3-dimethyl-3-ethylpentane, trans-1,2,3- trimethylcyclohexane, 1-isopropyl-e-methylcyclopentane (pulegan), 4-methyloctane, 1- isopropyl-2-methylcyclopentane, 3-ethylheptane, 2-methyloctane, cis-1,2,3-
30 trimethylcyclohexane, 3-methyloctane, 2,4,6-trimethylheptane, cis-1,2,4- trimethylcyclohexane, 3,3-diethylpentane, 2,2-dimethyl-4-ethylhexane, 2,2,4- trimethylheptane, 2,2,4,5-tetramethylhexane, 2,2,5-trimethylheptane, 2,2,6- trimethylheptane, 2,2,3,5-tetramethylhexane, nopinane (7,7- dimethylbicyclo[3.1.1]heptane), trarø-1-ethyl-r-methylcyclohexane, cycloctane, l-ethyl-2- methylcyclohexane, «-nonane, l,3,3-trimethylbicyclo[2.2.1]heptane(fenchane), trans-l- ethyl-4-methylcyclohexane, cis-l , 1 ,3,5-tetramethylcyclohexane, cis- 1 -ethyl-4- methylcyclohexane, 2,5,5-trimethylheptane, 2,4,4-trimethylheptane, 2,3,3,5- tetramethylhexane, 2,2,4,4-tetramethylhexane, isopropylcyclohexane, 1,1,2,2- tetramethylcyclohexane, 2,2,3,4-tetramethylhexane, 2,2-dimethyloctane, 3-ethyl-2,2,4- trimethylpentane, 3,3,5-trimethylheptane, 2,3,5-trimethylheptane, 2,4-dimethyloctane, d,l- cw-l-ethyl-3-methylcyclohexane, ,7-2,5-dimethyloctane, 1,1,3,5- tetramethylcyclohexane, H-butylcyclopentane, n-propylcyclohexane, 2,3,5- trimethylheptane, 2,5-dimethyl-3-ethylhexane, 2,4,5-trimethylheptane, 2,4-dimethyl-3- isopropylpentane, 2,2,3-trimethylheptane, 2,4-dimethyl-4-ethylhexane, 2,2-dimethyl-3- ethylhexane, 2,2,3,4,4-pentamethylpentane, 1,1,3,4-tetramethylcyclohexane, 5-ethyl-2- methylheptane, 2,7-dimethyloctane, 3,6-dimethyloctane, 3,5-dimethyloctane, 4- isopropylheptane, 2,3,3-trimethylheptane, 4-ethyl-2-methylheptane, 2,6-dimethyloctane, 2,2,3 ,3 -tetramethylhexane, trans- 1 -isopropyl-4-methylcyclohexane(p-menthane), 4,4- dimethyloctane, 2,3,4,5-tetramethylhexane, 5-ethyl-e-methylheptane, 3,3-dimethyloctne,
4,5-dimethyloctane, 3,4-diethylhexane, 4-propylheptane, 1,1,4-trimethylcycloheptane (eucarvane), trα«s-l,2,3,5~tetramethylcyclohexane, 2,3,4,4-tetramethylhexane, 2,3,4- trimethylheptane, 3-isopropyl-2-methylhexane, 2,2,7-trimethylbicyclo[2.2.1]heptane( - frenchane), 3-methylheptane, 2,4-dimethyl-3-ethylhexane, 3,4,4-trimethylheptane, 3,3,4- trimethylheptane, 3,4,5-trimethylheptane, 2,3-dimemthyl-4-ethylhexane, 1-methyl-e- propylcyclohexane, 2,3-dimethyloctane, ύ -pinane, 2,3,3,4-tetramethylhexane, 3,3- dimethyl-4-ethylhexane, 5-methylnonane, 4-methylnonane, 3-ethyl-2-methylheptane, 3,4- dimethyloctane, c-α-pinane, d, 7-1 -isopropyl-3-methylcyclohexane( d, /-wz-menthane), 2,2,3,3,4-pentamethylpentane, trans- 1 ,2,4,5-tetramethylcyclohexane, 3,3-diethylhexane, 2-methylnonane, -lrisopr©pyl-3-methylcyclohexane ( -m-menthane), 3-ethyl-4- methylheptane, 4-ethyl-3-methylheptane, 4-ethyl-4-methylheptane, 7- ?-pinane, 3- methylnonane, 3-ethyloctane, 4-ethyloctane, 3-ethyl-2,2,3-trimethylpentane, l-l- isopropyl-3 -methylcyclohexane (i-rø-menthane)c/s-l-isopropyl-4-methylcyclohexane (cw- 7-menthane), cw-l,2,3,5-tetramethylcyclohexane, 2,3-dimethyl-3-ethylhexane, 1- isopropyl-4-methylcyclohexane ( -menthane), 3,4-dimethyl-3-ethylhexane, 3,3,4,4- tetramethylhexane, cyclononane, l-isopropyl-2-methylcyclohexane (ø-menthane), cis- 1,2,4,5-tetramethylcyclohexane, 1 -methyl- 1-propylcyclohexane, «-decane, l-methyl-4- propylcyclohexane, l-methyl-2-propylcyclohexane, w-pentrylcyclopentane, n- butylcyclohexane, trørø-decahydronaphthalene (trarø-decalin), isoamylcyclohexane, cis- decahydronaphthalene (cw-decalin), «-undecane («-hendecane), cyclodecane, n- pentylcyclohexane, n-hexylcyclopentane, 9-methyl-trarø-decahydronaphthalene, 1,10- dimethyl-trøns-decahydronaphthalene, 9-methyl-c/5-decahydronaphthalene, n-dodecane, 1,10-dimethyl-c/s-decahydronaphthalene, n-hexycyclohexane, n-heptylcyclopentane, 9- ethyl-trøns-decahydronaphthalene, 9-ethyl-cw-decahydronaphthalene, l-methyl-tran.s- decahydronaphthalene, n-tridecane, bicyclohexyl, n-octylcyclopentane, n- heptylcyclohexane, n-tetradecane, n-nonylcyclopentane, n-octylcyclohexane, n- pentadecane, «-decyclopentane, n-nonylcyclohexane, n-undecylcyclopentane (n- hendecylcyclopentane), n-decylcyclohexane, 2-methylheptadecane, n- dodecylcyclopentane, n-undecylcyclohexane («-hendecylcyclohexane), n- tridecylcyclopentane, «-dodecylcyclohexane, n-tetradecylcyclopentane, pentadecyclcyclopentane, «-hexadecane (cetane), tridecylcyclohexane, hexadeclcyclopentane, «-heptadecane, tetradecylcyclohexane, heptadecylcyclopentane, n- octadecane, pentadecylcyclohexane, octadecylcyclopentane, n-nonadecane, hexadecylcyclohexane, nonadecylcyclopentane, n-eicosane, heptadecylcyclohexane, eicosylcyclopentane, n-heneicosane, octadecylcyclohexane, heneicosylcyclopentane, n- docosane, docosylcyclopentane, nonadecylcyclohexane, w-tricosane, eicosylcyclohexane, tricosylcyclopentane, n-tetracosane, tetracosylcyclopentane, heneicosylcyclohexane, n- pentacosane, pentacosylcyclopentane, docosylcyclohexane, hexacosylcyclopentane, notricyclene (tricyclo[2.2.1.026]heptane), n-hexacosane, cyclohexadecane, tricosylcyclohexane, heptacosylcyclopentane, n-heptacosane, tetracosylcyclohexane, cyclopentadecane, octacosylcyclopentane, «-octacosane, pentacosylcyclohexane, nonacosylcyclopentane, n-nonacosane, hexacosylcyclohexane, triacontylcyclopentane, d,i-isobomane(2,2,3-trimethylbicyclo[2.2.2]heptane), n-triacontane, heptacosylcyclohexane, hentriacontylcyclopentane, n-hentriacontane, octacosylcyclohexane, dotriacontylcyclopentane, «-dotriacontane (bicetyl), noncosylcyclohexane, tritriacontylcyclopentane, tritriacontane, triacontylcyclohexane, tetratriacontylcyclopentane, tetratriacontane, 28-methylnonacosane, hentriacontylcyclohexane, pentatriacontylcyclopentane, pentatriacontane, dotriacontylcyclohexane, hexatriacontylcyclopentane, hexatriacontane, tritriacontylcyclohexane, heptatriacontane, tetratriacontylcyclohexane, octatriacontane, pentatriacontylcyclohexane, nonatriacontane, hexatriacontylcyclohexane, tetracontane, norbornane (bicyclo[2.2.1]heptane], 2,2,3,3-tetramethylbutane, bornane (camphane), and adamantane. It is understood to those of ordinary skill in the art that the relevant alkyl radical is named by replacing the suffix "-ane" with the suffix "-yl".
The term "alkenyl" refers to an unsaturated, hydrocarbon radical, linear or branched, in so much as it contains one or more double bonds. The alkenyl group disclosed herein can be optionally substituted with any moiety that does not adversely affect the reaction process, including but not limited to but not limited to alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene et al, Protective Groups in Organic Synthesis. John Wiley & Sons, Second Edition, 1991, hereby incorporated by reference. Non-limiting examples of alkenyl groups include methylene, ethylene, methylethylene, isopropylidene, 1,2-ethane-diyl, 1,1-ethane-diyl, 1,3- propane-diyl, 1,2-propane-diyl, 1,3-butane-diyl, and 1,4-butane-diyl.
The term "alkynyl" refers to an unsaturated, acyclic hydrocarbon radical, linear or branched, in so much as it contains one or more triple bonds. The alkynyl group may be optionally substituted with any moiety that does not adversely affect the reaction process, including but not limited to but not limited to hydroxyl, halo (F, CI, Br, I), perfluoro alkyl including but not limited to trifluoromethyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, acyl, amido, carboxamido, carboxylate, thiol, alkylthio, azido, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene et al, Protective Groups in Organic Synthesis. John Wiley & Sons, Second
Edition, 1991, hereby incorporated by reference. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, hydroxypropynyl, butyn-1-yl, butyn-2-yl, pentyn-1-yl, pentyn-2-yl, 4-methoxypentyn-2-yl, 3-methylburyn-l-yl, hexyn-1-yl, hexyn- 2-yl, and hexyn-3-yl, 3,3-dimethylbutyn-l-yl radicals. The term "alkylamino" or "arylamino" refers to an amino group that has one or two alkyl or aryl substituents, respectively. The term "protected" as used herein and unless otherwise defined refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis. The term "aryl", alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. Non-limiting examples of aryl include phenyl, biphenyl, or naphthyl, or the following aromatic group that remains after the removal of a hydrogen from the aromatic ring: benzene, toluene, ethylbenzene, 1,4-xylene, 1,3-xylene, 1,2- xylene, isopropylbenzene (cumene), ra-propylbenzene, l-ethyl-3-methylbenzene (m- ethyltoluene), l-ethyl-4-methylbenzene (p-ethyltoluene), 1,3,5-trimethylbenzene (mesitylene), l-ethyl-2-methylbenzene (o-ethyltoluene), tert-butylbenzene, 1,2,4- trimethylbenzene (pseudodocumene), isobutylbenzene, Λ'ec-butylbenzene, 3-isopropyl- methylbenzene (3-isopropyltoluene; rø-cymene), 1,2,3-trimethylbenzene (hemimellitene), trørø-propenylbenzene, indane, 4-isopropyl-l-methylbenzene (4-isopropyltoluene; 4- cymene), 2-isopropyl-methylbenzene (2-isopropyltoluene; 2-cymene), 1,3-diethbenzene, 1 methyl-3-proplybenzene (λw-propyltoluene), indene, «-butylbenzene, l-methyl-4- propylbenzene (p-propyltoluene), 1,2-diethylbenzene, 1,4-diethylbenzene, l,3-dimethyl-5- ethylbenzene, l-methyl-2-propylbenzene (o-propyltoluene), 2,2-dimethyl-l- phenylpropane (neopentylbenzene), l,4-dimethyl-2-ethylbenzene, 2-methylindane, 3- methyl-2-phenylbutane, 1-methylindane, l,3-dimethyl-4-ethylbenzene, 3-tert-butyl- menthylbenzene, (3-tert-butyltoluene), l,2-dimethyl-4-ethylbenzene, l,3-dimethyl-2- ethylbenzene, 3-phenylpentane, 1 -ethyl-3 -isopropylbenzene, 2-methyl-2-phenylbutane, 4- tert-butyll-methylbenzene (4-tert-butyltoluene), l-ethyl-2-isopropylbenzene, 2- phenylpentane, l,2-dimethyl-3-ethybenzene, 3 -sec-butyl- 1-methylbenzene, (3-sec- butylotoluene), 3 -isobutyl- 1-methylbenzene, (3-isobutyltoluene), -2-methyl-l- phenylbutane, l,3-dimethyl-5-isopropyl-benzene, 2-phenyl-c/s-2-butene, 4-isobutyl- methylblenzene (p-isobutyltoluene), 2-sec-butyl- 1-methylbenzene (2-5ec-butyltoluene), 2- isobutyl-1-methylblenzene (o-isobutyltoluene), l,4-dimethyl-2-isopropyl-benzene, 1- ethyl-4-isopropylbenzene, cζ7-2-methyl-l-phenylbutane, 1,2,3,5-tetramethylbenzene
(isodurene), 3 -methyl- 1-phenylbutane (isopentylbenzene), l,3-dimethyl-2- isopropylbenzene, l,3-dimethyl-4-isopropylbenzene), 3-methylindene, 4-5ec-butyl-l- methylbenzene (p-5ec-butyltoluene), 2-tert-butyl- 1-methylbenzene (2-tert-butyltoluene), 3,5-diethyl-l-methylbenzene (3,5-diethyltoluene), 2-butyl- 1-methylbenzene (2 butyltoluene), 1 -ethyl-3 -propylbenzene, l,2-dimethyl-4-isopropylbenzene, l,2-dimethyl-3- isopropylbenzene, l-ethyl-2-propylbenzene, 1,3-di-isopropyllbenzene, l,2-diethyl-4- methylbenzene, 1,2-di-isopropylbenzene, l,4-dimethyl-2-proplybenzene, 1,2,3,4- tetramethylbenzene (prehnitene), l-ethyl-4-propylbenzene, 3-butyl-l-methlybenzene (m- butyltoluene), 2,4-diethyl- 1-methylbenzene (2,,4-diethyltoluene), «-pentylbenzene, 3- methyl-3-phenylpentane, l,3-dimethyl-5-tert-butylbenzene, l,3-dimethyl-4- propylbenzene, l,2-diethyl-3-methylbenzene, 4-butyl- 1-methylbenzene, 4-butyl-l- methylbenzene, 1,2,3,4-tetrahydronaphthalene, l,3-diethyl-2-propylbenzene, 2,6-diethyl- 1-methylbenzene, l,2-dimethyl-4-propylbenzene, l,3-dimethyl-5-propylbenzene, 2- methyl-3-phenylpentane, 4-terz-butyl-l,3-dimethylbenzene, 1,4-di-isopropylbenzene, 1,2- dimethyl-3 -propylbenzene, l-ter/-butyl-4-ethylbenzene, cζi-S-phenylhexane, 2-ethyly- 1,3,5-trimethyl-benzene, 3 -ethyly-4-isopropyl- 1-methylbenzene, 5-ethyl- 1,2,4- trimethylbenzene, 6-ethyl-l-2,4-trimethylbenzene, 2-phenylhexane, 2-methyl-l- phenylpentane, 4-isopropyl-l -propylbenzene, 1,3-dipropylbenzene, 5-ethyl-l,2,3- trimethylbenzene, 1,2,4-triethylbenzene, 1,3,5-triethylbenzene, 2-methyl-l,2,3,4- tetrahydronaphthalene, l-methyl-l,2,3,4-tetrahydronaphthalene, 4-ethyl-l,2,3- trimethylbenzene, 1,4-dipropylbenzene, 3 -methyl-1 -phenylpentane, 2-propyl-l,3,5- trimethylbenzene, 1 , 1 -dimethyl- 1 ,2,3,4-tetrahydronaphthalene, 3-tert-butyl- 1 - isopropylbenzene, l-methyl-3-pentylbenzene, 4-tert-butyl-l -isopropylbenzene, 2-methyl-
2-phenylhexane, 2,4-di-isopropyl- 1-methylbenzene, 3-methyl-3-phenylhexane, n- hexylbenzene, 3-phenylheptane, 2,6-di-isopropyl- 1-methylbenzene, 5 -propyl- 1,2,4- trimethylbenzene, 6-methyl- 1 ,2,3,4-tetrahydronaphthalene, 2,2-dimethyl- 1 ,2,3,4- tetrahydronaphthalene, 2-phenylheptane, 5-methyl- 1,2,3,4-tetrahydronaphthalene, 2-ethyl- 1,2,3,4-tetrahydronaphthalene, cyclohexylbenzene, 1 -ethyl- 1,2,3,4-tetrahydronaphthalene,
2,5-dimethyl-l,2,3,4-tetrahydronaphthalene, 2,8-dimethyl-l,2,3,4-tetrahydronaphthalene, 2,7-dimethyl-l,2,3,4-tetrahydronaphthalene, 2,6-dimethyl-l,2,3,4-tetrahydronaphthalene, 1,4-di-Jec-butylbenzene, 1,5-dimethyl- 1,2,3,4-tetrahydronaphthalene, 3-ethyl-3- phenylhexane, 6-ethyl-l,2,3,4-tetrahydronaphthalene, 2-methyl-l -phenyl- 1 -butene, 5- ethyl-l,2,3,4-tetrahydronaphthalene, H-heptylbenzene, 1-methylnaphthalene, 5,6-dimethyl-
1,2,3,4-tetrahydronaphthalene, 6,7-dimethyl- 1,2,3,4-tetrahydronaphthalene, 5,7-dimethyl- 1,2,3,4-tetrahydronaρhthalene, 2-ethylnaphthalene, 1-7-dimethylnaphthalene, 1,6- dimethylnaphthalene, 1,3-dimethylnaphthalene, n-octylbenzene, 1-allylnaphthalene, 1- isopropylnaphthalene, 1,4-dimethylnaphthalene, 1,1-diphenylethane, 2- isopropylnaphthalene, 2-propylnaphthalene, 1-propylnaphthalene, 1,3,7- trimethylnaphthalene, l-isopropyl-7-methylnaphthalene, n-nonylbenzene, 2- butylnaphthalene, 2-tert-butylnaphthalene, 1-tert-butylnaphthalene, 1-butylnaphthalene, 4,5-benzindane, n-decylbenzene, 1-pentylnaphthalene, 2-pentylnaphthalene, n- undecylbenzene, 1-hexylnaphthalene, 2-hexylnaphthalene, n-dodecylbenzene, 1- heptylnaphthalene, 2-heptylnaphthalene, tridecylbenzene, 1-octylnaphthalene, 2- octylnaphthalene, 1-nonylnaphthalene, 2-nonylnaphthalene, 1-decylnaphthalene, 1,2,6- trimethylnaphthalene, diphenylmethane, 1,2,3-trimethylnaphthalene, 1,6,7- trimethylnaphthalene, 2-isopropylazulene, l,4-dimethyl-7-isopropylazulene, 2,6- dimethylphenanthrene, 1,2,5-trimethylnaphthalene, 1-propylphenanthrene, 5- isopropylazulene, 5-isopropylazulene, 2-propylphenanthrene, 2-methylnaphthalene, 1- ethyl-5-methylnaphthalene, 9-isopropylnaphthalene, 6-isopropylazulene, 2-ethyl-6- methylnaphthalene, 2-isopropylphenanthrene, 6-isopropyl-l -methylphenanthrene, 2- ethylazulene, 2,5,-dimethylphenanthrene, 1,3,5-trimethylnaphthalene, 3-ethyl-6- methylphenanthrene, 2-methylazulene, 1,3,8-trimethylnaphthalene, 4-methylphenanthrene,
1,4-dimethylphenanthrene, bibenzyl, methylenefluorene, 3,5-dimethylphenanthrene, 1,3- dimethylazulene, 7-methyl-3,4-benzphenanthrene, pentamethylbenzene, 1,2,4- trimethylnaphthalene, 3,3-dimethylstilbene, 1,4,5,7-tetramethylnaphthalene, 1,2,4,8- tetramethylnaphthalene, 2,9-dimethylphenanthrene, 1,5 -dimethylphenanthrene, 2- benzylnaphthalene, 1-benzylnaphthalene, 1-benzylnaphthalene, 1,2-dimethylazulene, 9- propylphenanthrene, l,7-dimethyl-4-isopropylnaphthalene, 3 -methylphenanthrene, 3,4- dimethylphenanthrene, 1-ethylphenanthrene, ,sym-diphenylacetylene, 9-ethylphenanthrene, 1,4,5-trimethylnaphthalene, 4-methylfluorene, 1,4,6,7-tretramethylnaphthalene, 1,2,3- trimethylphenanthrene, 1,8-dimethylnaphthalene, 8-methyl-3,4-benzphenanthrene, 2- ethylphenanthrene, 3,4-benzphenanthrene, 1,3,7-trimethylphenanthrene, 4-isopropyl-l- methylphenanthrene, 4,8-dimethylazulene, biphenyl, 2-methyl-3,4-benzphenanthrene, 3- methylpyrene, 1,4,7-trimethylphenanthrene, 1,4-dimethylanthracene, 4,9-dimethyl-l,2- benzanthracene, benzalfluorene, 1,3-dimethylphenanthrene, l-methyl-3,4- benzphenanthrene, 3-isopropyl-l -methylphenanthrene, 1,2-binaphthyl, 2,3- dimethylphenanthrene, l-ethyl-2-methylphenanthrene, 1,5-dimethylnaphthalene, 6- methyl-3,4-benzphenanthrene, naphthalene, 1,3,6,8-tetramethylnaphthalene, 1-ethyl- 7methylphenanthrene, 9-methylanthracene, l-isopropyl-7-methylphenanthrene, 6- methylazulene, 1,3-dimethylanthracene, 2,2-dimethylstilbene, 1-methylanthracene, 1,7- dimethylphenanthrene, 1,6-diphenylnaphthalene, 1,6-dimethylphenanthrene, 1,9- dimethylphenanthrene, 9-methylphenanthrene, 1,2,10-trimethylanthracene, 7-ethyl-l- methylphenanthrene, triphenylmethane, 5-isopropylnaphthanthracene, 3,9-dimethyl-l,2- benzanthracene, 5,6-benzindane, 12-isopropylnaphthanthracene, acenaphthene, 2,7- dimethylnaphthalene, 7-isopropyl-l-methylfluorene, azulene, retene, phenanthrene, 2,7- dimethfylphenanthrene, 2,3,6-trimethfylnaphthalene, 2-phenylnaphthalene, 1,2,3,4- tetrahydroanthracene, 2,3-dimethylnaphthalene, ethylidenefluorene,, 1,7-dimethylfuorene, 1,1-dinaphthylmethane, fluoranthrene, 2,6-dimethylnaphthalene, 2,4- dimethylphenanthrene, fluorene, 4,10-dimethyl-l,2-benzanthracene, 4h- cyclopenta(def)phenanthrene, 1,3,8-trimethylphenanthrene, 11-methylnaphthanthracene, 5-methylchrysene, 1,2,5,6-tetramethylnaphthalene, cyclohept(fg)acenaphthene, 1,2,7- trimethylphenanthrene, 1 , 10-dimethyl- 1 ,2-dibenzanthracene, 9, 10-dimethyl- 1,2- benzanthracene, benz(bc)aceanthrylene, 1 -methylphenanthrene, 1,6,7- trimethylphenanthrene, 1,1-diacenaphthene, trans-stilbene, 3,4-benzflurorene, 9- isopropylnaphthanthracene, 6-methylnaphthanthracene, 5,8-dimethyl-l,2-bezanthracene, 8-isopropylnaphthanthracene, 1,4,5,8-tetramethylnaphthalene, 12- methylnaphthanthracene, 2-methyl-l,2-benzpyrene, 1,5-dimethylanthracene, 7- methylnaphthanthracene, 3,6-dimethylphenanthrene, 5-methyl-3,4-benzphenanthrene, 1,4- dimethylchrysene, 1,2-dimethylphenanthrene, 8,10-dimethyl- 1,2-benzanthracene, 1,2,8- trimethylphenanthrene, 3 -methyl- 1,2-benzpyrene, 9-methyl-l,2-benzpyrene, 9- phenylfluorene, 2-methylnaphthanthracene, pyrene, 9-methylnaphthanthracene, 4- methylchrysene, traτ«-trørø-l,4-diphenyl-l,3-butadiene, cinnamalfluorene, 5- methylnaphthanthracene, 1,2-benzanthracene, 8-methylnaphthanthracene, 1,1-binaphthyl, di-1-naphthastibene, 6-methylchrysene, 3-methylnaphthanthracene, 2,6-dimethyl- 1,2- benzanthracene, cyclopentadienophenanthrene, 10,11-benzfluoranthene, hexamethylbenzene, 3-methylchrysene, cholanthrene, 6-methyl- 1,2-benzpyrene, 6,7- dimethyl- 1,2-benzanthracene, 1,2-benzpyrene, 5,10-dimethyl- 1,2-benzanthracene, 4,5- benzpyrene, 9,10-dimethylanthracene, 10-methylnaphthanthracene, 5,6-dimethyl-l,2- benzanthracene, 2,2-binaphthyl, 1,2-benfluorene, 1,8-dimethylphenanthrene, 8-methyl- 1,2-benzpyrene, bifluorenylidene, 1,2,7,8-dibenzanthracene, 4-methylnaphthanthracene, 1,2,3,4-dibenzanthracene, di-2-fluorenylmethane, 2,3-benzfluorene, 5-methyl-l,2- benzpyrene, anthracene, 11,12-benzfluoranthene, 4-methyl- 1,2-benzpyrene, 2,8- dimethylchrysene, 2-methylchrysene, 6,12-dimethylchrysene, 1,2-benzphenanthrene, di-2- naphthastilbene, 1-methylchrysene, 2,3,6,7-dibenzphenanthrene, 2,3,5,6- dibenzphenanthrene, 1,2,5,6-dibenzanthracene, perylene, picene, 1,2,3,4,5,6,7,8- tetrabenzanthracene, and coronene. The term aryl includes both substituted and unsubstituted moieties. The aryl group may be optionally substituted with any moiety that does not adversely affect the process, including but not limited to but not limited to halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, amido, carboxyl derivatives, 5 alkylamino, dialkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, thiol, imine, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, ester, carboxylic acid, amide, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrozine, carbamate, phosphonic acid, phosphonate, or any other viable functional group that does not inhibit the pharmacological activity of this compound, either unprotected, or 0 protected as necessary, as known to those skilled in the art, for example, as taught in
Greene et al., Protective Groups in Organic Synthesis, John Wiley & Sons, Second Edition, 1991, hereby incorporated by reference. Non-limiting examples of substituted aryl include heteroarylamino, N-aryl-N-alkylamino, N-heteroarylamino-N-alkylamino, heteroaralkoxy, arylamino, aralkylamino, arylthio, monoarylamidosulfonyl, 5 arylsulfonamido, diarylamidosulfonyl, monoaryl amidosulfonyl, arylsulfinyl, arylsulfonyl, heteroarylthio, heteroarylsulfinyl, heteroarylsulfonyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, hydroxyaralkyl, hydoxyheteroaralkyl, haloalkoxyalkyl, aryl, aralkyl, aryloxy, aralkoxy, aryloxyalkyl, saturated heterocyclyl, partially saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, and 0 heteroarylalkenyl, carboaralkoxy. The terms "alkaryl" or "alkylaryl" refer to an alkyl group with an aryl substituent. The terms "aralkyl" or "arylalkyl" refer to an aryl group with an alkyl substituent.
The term "halo," as used herein, includes chloro, bromo, iodo and fluoro.
! > The term "acyl" refers to a carboxylic acid ester in which the non-carbonyl moiety 5 of the ester group is selected from straight, branched, or cyclic alkyl or lower alkyl, alkoxyalkyl including but not limited to methoxymethyl, aralkyl including but not limited to benzyl, aryloxyalkyl such as phenoxymethyl, aryl including but not limited to phenyl optionally substituted with halogen (F, CI, Br, I), alkyl (including but not limited to C\, C2, C3, and C ) or alkoxy (including but not limited to C\, C2, C3, and C4), sulfonate esters 0 such as alkyl or aralkyl sulphonyl including but not limited to methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl (e.g., dimethyl-t-butylsilyl) or diphenylmethylsilyl. Aryl groups in the esters optimally comprise a phenyl group. The term "lower acyl" refers to an acyl group in which the non- carbonyl moiety is lower alkyl.
The terms "alkoxy" and "alkoxyalkyl" embrace linear or branched oxy-containing radicals having alkyl moieties, such as methoxy radical. The term "alkoxyalkyl" also embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The "alkoxy" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide "haloalkoxy" radicals. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, difluoromethoxy, trifluoroethoxy, fluoroethoxy, tetrafluoroethoxy, pentafluoroethoxy, and fluoropropoxy.
The term "alkylamino" denotes "monoalkylamino" and "dialkylamino" containing one or two alkyl radicals, respectively, attached to an amino radical. The terms arylamino denotes "monoarylamino" and "diarylamino" containing one or two aryl radicals, respectively, attached to an amino radical. The term "aralkylamino", embraces aralkyl radicals attached to an amino radical. The term aralkylamino denotes
"monoaralkylamino" and "diaralkylamino" containing one or two aralkyl radicals, respectively, attached to an amino radical. The term aralkylamino further denotes "monoaralkyl monoalkylamino" containing one aralkyl radical and one alkyl radical attached to an amino radical. The term "heteroatom," as used herein, refers to oxygen, sulfur, nitrogen and phosphorus.
The terms "heteroaryl" or "heteroaromatic," as used herein, refer to an aromatic that includes at least one sulfur, oxygen, nitrogen or phosphorus in the aromatic ring.
The term "heterocyclic" refers to a nonaromatic cyclic group wherein there is at least one heteroatom, such as oxygen, sulfur, nitrogen, or phosphorus in the ring.
Nonlimiting examples of heteroaryl and heterocyclic groups include furyl, furanyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4- thiadiazolyl, isooxazolyl, pyrrolyl, quinazolinyl, cinnolinyl, phthalazinyl, xanthinyl, hypoxanthinyl, thiophene, furan, pyrrole, isopyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, oxazole, isoxazole, thiazole, isothiazole, pyrimidine or pyridazine, and pteridinyl, aziridines, thiazole, isothiazole, 1,2,3-oxadiazole, thiazine, pyridine, pyrazine, piperazine, pyrrolidine, oxaziranes, phenazine, phenothiazine, morpholinyl, pyrazolyl, pyridazinyl, pyrazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, pteridinyl, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, adenine, N6-alkylpurines, N6-benzylpurine, N6-halopurine, N6- vinypurine, N6-acetylenic purine, N6-acyl purine,N6-hydroxyalkyl purine, N6-thioalkyl purine, thymine, cytosine, 6-azapyrimidine, 2-mercaptopyrmidine, uracil, N5- alkylpyrimidines, N5-benzylpyrimidines, N5-halopyrimidines, N5-vinylpyrimidine, N5- acetylenic pyrimidine, N5-acyl pyrimidine, N5-hydroxyalkyl purine, and N6-thioalkyl purine, and isoxazolyl. The heteroaromatic group can be optionally substituted as described above for aryl. The heterocyclic or heteroaromatic group can be optionally substituted with one or more substituent selected from halogen (F, CI, Br, I), haloalkyl, alkyl, alkoxy, hydroxy, carboxyl derivatives, amido, amino, alkylamino, dialkylamino. The heteroaromatic can be partially or totally hydrogenated as desired. As a nonlimiting example, dihydropyridine can be used in place of pyridine. Functional oxygen and nitrogen groups on the heterocyclic or heteroaryl group can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, and t-butyldiphenylsilyl, trityl or substituted trityl, alkyl groups, acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenelsulfonyl. The heterocyclic or heteroaromatic group can be substituted with any moiety that does not adversely affect the reaction, including but not limited to but not limited to those described above for aryl.
The term "host," as used herein, refers to a unicellular or multicellular organism in which the virus can replicate, including but not limited to cell lines and animals, and preferably a human. Alternatively, the host can be carrying a part of the viral genome, whose replication or function can be altered by the compounds of the present invention. The term host specifically refers to infected cells, cells transfected with all or part of the viral genome and animals, in particular, primates (including but not limited to chimpanzees) and humans. In most animal applications of the present invention, the host is a human patient. Veterinary applications, in certain indications, however, are clearly anticipated by the present invention (such as chimpanzees). The term "pharmaceutically acceptable salt or prodrug" is used throughout the specification to describe any pharmaceutically acceptable form (such as an ester, phosphate ester, salt of an ester or a related group) of a nucleoside compound which, upon administration to a patient, provides the nucleoside compound. Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium and magnesium, among numerous other acids well known in the pharmaceutical art. Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present invention. Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound. The compounds of this invention possess antiviral activity against
Flaviviridae, or are metabolized to a compound that exhibits such activity.
Prodrugs also include natural or unnatural amino acid esters of the disclosed nucleosides (see, e.g., European Patent Specification No. 99493, the text of which is incoφorated by reference, which describes amino acid esters of acyclovir, specifically the glycine and alanine esters which show improved water-solubility compared with acyclovir itself, and US Pat. No. 4,957,924 (Beauchamp), which discloses the valine ester of acyclovir, characterized by side-chain branching adjacent to the α-carbon atom, which showed improved bioavailability after oral administration compared with the alanine and glycine esters). A process for preparing such amino acid esters is disclosed in US Pat. No. 4,957,924 (Beauchamp), the text of which is incorporated by reference. As an alternative to the use of valine itself, a functional equivalent of the amino acid may be used (e.g., an acid halide such as the acid chloride, or an acid anhydride). In such a case, to avoid undesirable side-reactions, it may be is advantageous to use an amino-protected derivative. IV. Nucleotide Salt or Prodrug Formulations
In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compound as a pharmaceutically acceptable salt may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids, which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α-ketoglutarate and α-glycerophosphate. Suitable inorganic salts may also be formed, including but not limited to, sulfate, nitrate, bicarbonate and carbonate salts. Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid, affording a physiologically acceptable anion. Alkali metal (e.g., sodium, potassium or lithium) or alkaline earth metal (e.g., calcium) salts of carboxylic acids can also be made. Any of the nucleosides described herein can be administered as a nucleotide prodrug to increase the activity, bioavailability, stability or otherwise alter the properties of the nucleoside. A number of nucleotide prodrug ligands are known. In general, alkylation, acylation or other lipophilic modification of the mono, di or triphosphate of the nucleoside will increase the stability of the nucleotide. Examples of substituent groups that can replace one or more hydrogens on the phosphate moiety are alkyl, aryl, steroids, carbohydrates, including but not limited to sugars, 1,2-diacylglycerol and alcohols. Many are described in R. Jones & N. Bischofberger, Antiviral Research, 27 (1995) 1-17. Any of these can be used in combination with the disclosed nucleosides to achieve' a desired effect. The active nucleoside can also be provided as a 5'-phosphoether lipid or a 5'-ether lipid, as disclosed in the following references, which are incorporated by reference: Kucera, L.S., N. Iyer, E. Leake, A. Raben, Modest E.K., D.L.W., and C. Piantadosi, "Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation," AIDS Res. Hum. Retroviruses, 1990, 6, 491-501; Piantadosi, C, J. Marasco C.J., S.L. Morris-Natschke, K.L. Meyer, F. Gumus, J.R. Surles,
K.S. Ishaq, L.S. Kucera, N. Iyer, CA. Wallen, S. Piantadosi, and E.J. Modest, "Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV activity," J. Med. Chem., 1991, 34, 1408-1414; Hosteller, K.Y., D.D. Richman, D.A. Carson, L.M. Stuhmiller, G.M. T. van Wijk, and H. van den Bosch, "Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6C cells by 3'- deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3,-deoxythymidine,"
Antimicrob. Agents Chemother., 1992, 36, 2025-2029; Hostetier, K.Y., L.M. Stuhmiller, H.B. Lenting, H. van den Bosch, and D.D. Richman, "Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides." J. Biol. Chem., 1990, 265, 61127. Nonlimiting examples of US patents that disclose suitable lipophilic substituents that can be covalently incorporated into the nucleoside, preferably at the 5' -OH position of the nucleoside or lipophilic preparations, include US Pat. Nos. 5,149,794 (Yatvin et al.); 5,194,654 (Hostetier et al), 5,223,263 (Hostetier et al); 5,256,641 (Yatvin et al); 5,411,947 (Hostetier et al); 5,463,092 (Hostetier et al); 5,543,389 (Yatvin et al); 5,543,390 (Yatvin et al); 5,543,391 (Yatvin et al); and 5,554,728 (Basava et al), all of which are incorporated by reference. Foreign patent applications that disclose lipophilic substituents that can be attached to nucleosides of the present invention, or lipophilic preparations, include WO 89/02733, WO 90/00555, WO 91/16920, WO 91/18914, WO 93/00910, WO 94/26273, WO 96/15132, EP 0 350 287, EP 93917054.4, and WO 91/19721.
V. Combination or Alternation Therapy
In another embodiment for the treatment of HIV or HBV infection, the active compound or its prodrug or salt can be administered in combination or alternation with another antiviral agent, such as another active anti-HIV or anti-HBV agent, including but not limited to those of the formulae above, others listed below or known in the art. In general, in combination therapy, effective dosages of two or more agents are administered together, whereas during alternation therapy, an effective dosage of each agent is administered serially. The dosage will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.
Nonlimiting examples of antiviral agents that can be used in combination with the compounds disclosed herein include those in the tables below.
Hepatitis B Therapies
Drug Name Drug Class Company
Intron A (interferon alfa-2b) interferon Schering-Plough
Epivir-HBV (lamivudine; 3TC) nucleoside analogue GlaxoSmithKline
Hepsera (Adefovir Dipivoxi)" nucleotide analogue Gilead Sciences
Coviracil (emtricitabine; FTC) nucleoside analogue Triangle Pharmaceuticals
Entecavir nucleoside analogue Bristol-Myers Squibb
Clevudine (L-FMAU) nucleoside analogue Triangle Pharmaceuticals
ACH 126, 443 (L-Fd4C) nucleoside analogue Achillion Pharmaceuticals
AM 365 nucleoside analogue Amrad
Amdoxovir (formerly DAPD) nucleoside analogue Triangle Pharmaceuticals
LdT (telbivudine) nucleoside analogue Idenix
XTL 001 monoclonal antibody XTL Biopharm
Theradigm Immune stimulant Epimmune
Zadaxin (thymosin) Immune stimulant SciClone
EHT 899 viral protein Enzo Biochem
HBV DNA vaccine Immune stimulant PowderJect (UK)
MCC 478 nucleoside analogue Eli Lilly valLdC (valtorcitabine) nucleoside analogue Idenix
ICN 2001 nucleoside analogue ICN
Fluro L and D nucleosides nucleoside analogue Pharmasset
Racivir nucleoside analogue Pharmasset
Robustaflavone nucleoside analogue Advanced Life Sciences
Penciclovir
DXG
HDP-P-acyclovir
LM-019c
CS-109
PS-019
PS-018
ara-AMP prodrugs
HBV/MF59
Hammerhead ribozymes
Glycosidase Inhibitors
Pegylated Interferon
Human Monoclonal Antibodies
Famciclovir HIV Therapies: Protease Inhibitors (Pis)
Figure imgf000142_0001
HIV Therapies: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
Figure imgf000143_0001
HIV Therapies: Non-Nucleoside Reverse
Transcriptase Inhibitors (NNRTIs)
Figure imgf000144_0001
HIV Therapies: Other Classes of Drugs
Figure imgf000145_0001
Cellular Inhibitors
Figure imgf000145_0002
Entry Inhibitors (including Fusion Inhibitors)
Figure imgf000145_0003
HIV Therapies: Immune-Based Therapies
Figure imgf000146_0001
HIV Therapies: Treatments for Side Effects
Figure imgf000147_0001
Figure imgf000147_0002
In one embodiment, the compounds of the invention may be employed together with at least one other antiviral agent chosen from reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors and polymerase inhibitors. In addition, compounds according to the present invention can be administered in combination or alternation with one or more anti-retrovirus, anti-HBV, anti-HCV or anti- herpetic agent or interferon, anti-cancer or antibacterial agents, including but not limited to other compounds of the present invention. Certain compounds according to the present invention may be effective for enhancing the biological activity of certain agents according to the present invention by reducing the metabolism, catabolism or inactivation of other compounds and as such, are co-administered for this intended effect.
VI. Pharmaceutical Compositions
Host, including but not limited to humans, infected with a human immunodeficiency virus, a hepatitis virus, or a gene fragment thereof, can be treated by administering to the patient an effective amount of the active compound or a pharmaceutically acceptable prodrug or salt thereof in the presence of a pharmaceutically acceptable carrier or diluent. The active materials can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid or solid form. A preferred dose of the compound for an HIV or HBV infection will be in the range from about 1 to 50 mg/kg, preferably 1 to 20 mg/kg, of body weight per day, more generally 0.1 to about 100 mg per kilogram body weight of the recipient per day. The effective dosage range of the pharmaceutically acceptable salts and prodrugs can be calculated based on the weight of the parent nucleoside to be delivered. If the salt or prodrug exhibits activity in itself, the effective dosage can be estimated as above using the weight of the salt or prodrug, or by other means known to those skilled in the art.
The compound is conveniently administered in unit any suitable dosage form, including but not limited to but not limited to one containing 7 to 3000 mg, preferably 70 to 1400 mg of active ingredient per unit dosage form. An oral dosage of 50-1000 mg is usually convenient.
Ideally the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.2 to 70 μM, preferably about 1.0 to 10 μM. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or administered as a bolus of the active ingredient.
The concentration of active compound in the drug composition will depend on absoφtion, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
A preferred mode of administration of the active compound is oral. Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, unit dosage forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.
The compound can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compound(s), sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
The compound or a pharmaceutically acceptable prodrug or salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, anti- inflammatories or other antivirals, including but not limited to other nucleoside compounds. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates or phosphates, and agents for the adjustment of tonicity, such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).
In a preferred embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including but not limited to implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid. For example, enterically coated compounds can be used to protect cleavage by stomach acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Suitable materials can also be obtained commercially. Liposomal suspensions (including but not limited to liposomes targeted to infected cells with monoclonal antibodies to viral antigens) are also preferred as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in US Pat. No. 4,522,811 (incorporated by reference). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
VII. Processes for the Preparation of Active Compounds
A method for the facile preparation of N -acyl-substituted 2',3'-dideoxy-5- fluorocytidine and 2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine nucleosides is also provided. The method includes condensation of a 5'-O-silyl protected 2',3'-dideoxy-5- fluorocytidine or a 5'-O-silyl protected 2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine, with either a carboxylic acid chloride, or carboxylic acid anhydride, or a carboxylic acid, followed by desilylation. The other N4-acyl-substiruted cytosine nucleosides can be synthesized using the similar approaches.
The N4-acyl-substituted 2',3'-dideoxy-5-fluorocytidine and 2',3'-didehydro-2',3'- dideoxy-5-fluorocytidine nucleosides disclosed herein can be prepared as described in detail below, or by other assays known to those skilled in the art.
The present invention is further illustrated in the following examples. It will be understood by one of ordinary skill in the art that these examples are in no way limiting and that variations of detail can be made without departing from the spirit and scope of the present invention.
EXAMPLES
Anhydrous solvents were purchased from Aldrich Chemical Company, Inc. (Milwaukee). Melting points (mp) were determined on an Electrothermal digit melting point apparatus and are uncorrected. 1H and 13C NMR spectra were taken on a Varian Unity Plus 400 spectrometer at room temperature and reported in ppm downfield from internal tetramethylsilane. Deuterium exchange, decoupling experiments or 2D-COSY were performed to confirm proton assignments. Signal multiplicities are represented by s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quadruplet), br (broad), bs
(broad singlet), m (multiplet). All J-values are in Hz. Mass spectra were recorded on a JEOL JMS-SX/SX102A/Ε mass spectrometer. Elemental analyses were performed by Atlantic Microlab Inc. (Norcross, GA). Analytic TLC was performed on Whatman LK6F silica gel plates, and preparative TLC on Whatman PK5F silica gel plates. Column chromatography was carried out on Silica Gel (Fisher, S733-1) at atmospheric pressure.
Example 1
(S)-(+)-5-Oxo-2-tetrahydrofiιrancarboxylic acid (2)
To a mixture of L-glutamic acid (1, 25 g, 170 mmol) in water (67 mL) and cone. HCl (35 mL) at 0°C with stirring was added a solution of NaNO2 (17.5 g, 253.6 mmol) in water (37.5 mL) over a period of 4 h, and then the resulting clear solution was stirred at room temperature overnight. After removal of the solvent by evaporation in vacuo, the residue was treated with EtOAC (80 mL) and filtered. The filtrate was dried over Na2SO , and concentrated. The residue, after crystallization from EtOAc/benzene/hexane, afforded the title compound 2 as a white crystalline solid (13.12 g, 59%). M.P. 71-73°C; Η NMR (400 MHz, CD3OD) 4.20 (m, IH, CHO), 1.8-2.3 (m, 4H, CH2CH2).
Example 2
(S)-(+)-Dihydro-5-(hydroxymethyl)-2(3H)-furanone (3)
To a solution of 2 (10 g, 76.85 mmol) in anhydrous THF (200 mL) at 0°C was slowly added BH3-SMe2 (2 M solution in THF, 46.1 mL, 92.2 mmol) over a period of 10 min. The reaction solution was stirred at 0°C for 3 h under nitrogen, followed by the slow addition of anhydrous MeOH (20 mL). After removal of the solvent, the residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH (95:5) to give the title compound 3 as a colorless oil (8.41 g, 94%). 1H NMR (CDC13) £4.66-4.65 (m, IH, H-5), 3.95-3.91 (m, IH, CH2OH), 3.72-3.65 (m, IH, CH2OH), 2.65-2.57 (m, 2H, H- 3), 2.30-2.17 (m, 3H, H-4, OH).
Example 3
(S)-5-[(tert-Butyldiphenylsilyl)hydroxymethyl]-dihydro-2(3H)-furanone (4)
To a solution of 3 (7.0 g, 60 mmol) and imidazole (9.19 g, 135 mmol) in anhydrous DMF (70 mL) was added tert-butyldiphenylsilyl chloride (18.14 g, 66 mmol, 17.2 mL), and the solution was stirred at room temperature under a nitrogen atmosphere for 1 h. After removal of the solvent by evaporation, the residue was dissolved in CHC13, washed with water and brine, dried (Na2SO ), filtered, and concentrated. After crystallization from hexane, the oily residue gave the title compound 4 as a white crystalline solid (20.6 g, 97%). M.P. 76°C; 1H NMR (CDC13) £7.68-7.65 (m, 4H, arom.), 7.47-7.39 (m, 6H, arom.), 4.63-4.61 (m, IH, H-5), 3.90-3.87 (dd, J = 3 & 11 Hz, IH,
CH2OH), 3.70-3.67 (dd, J= 3 & 11 Hz, IH, CH2OH), 2.69-2.65 (m, IH, H-3), 2.56-2.52 (m, IH, H-3), 2.32-2.23 (m, 2H, H-4), 1.06 (s, 9H, t-Bu).
Example 4
(5S,3R)-5-[(tert-Butyldiphenylsilyl)hydroxymethyl]-dihydro-3-(phenylselenenyl)-2(3H)- furanone (5)
To a solution of 4 (5 g, 14.1 mmol) in anhydrous THF (50 mL) at -78°C was added lithium bis(trimethylsilyl)amide (1 M solution in THF, 15.8 mL, 15.8 mmol) over a period of 10 min. After stirring at -78°C for 1 h, Me3SiCl (1.918 g, 17.65 mmol) was added dropwise, and the reaction mixture was allowed to warm to room temperature. After being stirred at room temperature for 30 min, the mixture was cooled to -78°C, and a solution of PhSeBr (5 g, 21.19 mmol) in anhydrous THF (25 mL) was added rapidly. The mixture was diluted with ether (50 mL), washed with water until the color of organic layer changed from dark brown to light yellow, dried (Na2SO4), filtered, and evaporated. The resulting oily residue [containing 3R( , 5) and 3S(β) isomers; TLC: hexane/EtOAc, 10:1; Rf = 0.42 and 0.28, respectively] was purified by flash chromatography on silica gel eluting with hexane/EtOAc (99:1 to 95:5) to give the title compound 5 as a light yellow oil (4.22 g, 59%). !H NMR (CDC13) £7.69-7.60 (m, 6H, arom.), 7.46-7.30 (m, 9H, arom.), 4.37-4,34 (m, IH, H-5), 4.12-4.08 (m, IH, H-3), 3.86-3.82 (dd, J = 3 & 11 Hz, IH, CH2OH), 3.62-3.59 (dd, J= 3 & 11 Hz, IH, CH2OH), 2.73-2.67 (m, IH, H-4), 2.32-2.28 (m, IH, H-4), 1.02 (s, 9H, t-Bu).
Example 5
l-0-Acetyl-5-0-(tert-butyldiphenylsilyl)-2,3-dideoxy-2-(phenylselenenyl)-a/β-D-erythro- pentofuranose (6)
To a stirred solution of 5 (13.68 g, 26.88 mmol) in anhydrous toluene (120 mL) at -78°C was added diisobutylaluminum hydride (1 M solution in toluene, 43 mL, 43 mmol), and the solution was stirred at -78°C for 2 h under an argon atmosphere. The reaction was quenched by addition of anhydrous MeOH (10 mL), and the mixture was allowed to warm to room temperature. After stirring at room temperature for 30 min, EtOAc (50 mL) and water (50 mL) were added. The resulting white precipitate was filtered, and the aqueous layer was extracted with EtOAc. The combined organic phase was washed with water and brine, dried (Na2SO4), filtered, and evaporated. The resulting oily residue was dissolved in anhydrous CH2C12 (60 mL), and cooled to 0°C. 4-Dimethylaminopyridine (DMAP, 5 mg) and pyridine (15 mL) were added, followed by Ac2O (8.22 g, 80.64 mmol). The mixture was stirred at 0°C for 30 min, then at room temperature overnight. Evaporation of the solvent in vacuo afforded the title compound 6 as a clear yellow oil (13.45 g, 90%).
This crude product was used directly without further purification. Η NMR (CDC13) £ 7.69-7.55 (m, 6H, arom.), 7.44-7.25 (m, 9H, arom.), 6.47-6.46 (d, H-1), 6.28 (s, H-1), 4.47.4,34 (m, IH, H-4), 3.82-3.54 (m, 3H, H-5, H-2), 2.50-1.99 (m, 2H, H-3), 2.12, 1.86 (2s, 3H, CH3CO), 1.05, 1.96 (2s, 9H, t-Bu). Example 6
β-D-5 '-0-(tert-Butyldiphenylsilyl)-2 ',3 '-dideoxy-5-fluoro-2 '-(phenylselenenyl)-cytidine (7)
A suspension of 5-fluorocytosine (1.61 g, 12.5 mmol) and (NH4)2SO (165 mg, 1.25 mmol) in hexamethyldisilazane (20 mL) was heated at reflux for 2 h under an argon atmosphere, and then evaporated to dryness in vacuo. To the residue was added a solution of 6 (5.53 g, 10.0 mmol) in anhydrous 1,2-dichloroethane (25 mL), and the mixture was cooled to 5°C. TMSOTf (2.0 mL, 11 mmol) was added, and the resulting solution was stirred at 5°C for 15 min under an argon atmosphere, then at room temperature for another 30 min. The solution was poured into a mixture of EtOAc and saturated aqueous NaHCO3 with stirring. The organic layer was separated, washed with saturated NaHCO3 solution, water, and brine, dried (Na2SO4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH (99:1 to 96:4) to give 7 (5.36 g, 86%) as a white solid. M.P. 163-164°C; 1H NMR (CDC13) £7.95 (d, J= 6.4 Hz, IH, H-6), 7.67-7.62 (m, 6H, arom.), 7.47-7.25 (m, 9H, arom.), 6.90 (bs, IH, NH), 6.15- 6.14 (m, IH, H-1'), 5.40 (bs, IH, NH), 4.32-4.30 (m, IH, H-4'), 4.12-4.08 (m, IH, H-
5 'a), 3.84-3.83 (m, IH, H-2'), 3.65 (dd, J= 2.4 & 11.2 Hz, IH, H-5'b), 2.45-2.42, 2.01- 1.98 (2m, 2H, H-3'), 1.08 (s, 9H, t-Bu); 13C NMR (CDC13) £ 157.0, 156.8, 153.3, 137.3, 135.6, 135.5, 135.4, 134.9, 132.6, 132.3, 130.1, 130.0, 129.2, 128.3, 127.9, 127.4, 125.5, 125.2, 91.0, 80.2, 64.8, 45.4, 32.3, 26.9, 19.2.
Example 7
β-D-5 '-0-(tert-Butyldiphenylsilyl)-2 ',3 '-dideoxy-5-fluorocytidine (8)
A suspension of 7 (4.976 g, 8 mmol), Et3B (1 M solution in hexane, 8.8 mL, 8.8 mmol), and «-Bu3SnH (3.23 mL, 12 mmol) in anhydrous benzene (40 mL) was stirred at room temperature under an argon atmosphere for 5 h. After evaporation of the solvent, the residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH
(99:1 to 96:4) to give the title compound 8 as a pale yellow foam (3.45 g, 92%). H NMR (CDC13) £8.14 (d, J = 6.4 Hz, IH, H-6), 7.71-7.66 (m, 4H, arom.), 7.49-7.38 (m, 6H, arom.), 6.04 (m, IH, H-1'), 4.17-4.12 (m, IH, H-4'), 4.12-4.08 (m, IH, H-5'a), 3.73-3.69 (m, IH, H-5'b), 2.54-2.44, 2.18-2.09 (2m, 2H, H-2'), 2.05-1.95, 1.89-1.82 (2m, 2H, H-3'), 1.10 (s, 9H, t-Bu).
Example 8
β-D-5 '-0-(tert-Butyldiphenylsilyl)-2 ',3 '-didehydro-2 ',3 '-dideoxy-5-fluorocytidine (9)
To a solution of 7 (15.47 g, 24.87 mmol) in CH2C12 (150 mL) containing 5 drops of pyridine at 0°C was added a solution of H2O2 (15.5 mL of 30% solution) dropwise over a period of 15 min. After stirring at 0°C for 20 min, and at room temperature for 30 min, the reaction solution was diluted with CHC13 (200 mL), washed with H2O, saturated
NaHCO3 solution, and H2O, dried (Na2SO4), filtered, and concentrated. The residue, after purification by chromatography over silica gel eluted with CH2Cl2/MeOH (96:4), gave 9 as a pale yellow foam (9.907 g, 86%). M.P. 150-152°C; 1H NMR (CDC13) £7.88 (d, J = 6.4 Hz, IH, H-6), 7.66-7.65 (m, 4H, arom.), 7.47-7.37 (m, 6H, arom.), 7.00-6.99 (m, IH, H-1'), 6.50 (bs, IH, NH), 6.12 (d, J= 6.0 Hz, IH, H-3'), 5.98 (d, J= 4.8 Hz, IH, H-2'),
5.35 (bs, IH, NH), 4.89 (bs, IH, H-4'), 4.00 (dd, J= 3.2 & 11.6 Hz, IH, H-5'a), 3.81 (dd, J = 3.6 & 12.4 Hz, IH, H-5'b), 1.06 (s, 9H, t-Bu). 13C NMR (CDCI3) £ 157.3, 157.1, 153.6, 137.5, 135.6, 135,4, 135.1, 133.3, 132.8, 132.6, 130.1, 130.0, 127.9, 127.8, 127.4, 126.1, 125.8, 91.3, 87.3, 65.1, 26.9, 19.2.
Example 9
β-D-2 ',3 '-Dideoxy-5-fluoro-} -(4-iodobenzoyl)cytidine (10)
To a solution of 8 (131 mg, 0.28 mmol) and DMAP (5 mg) in anhydrous CH2C12 (2 mL) and Et3N (0.5 mL) at 0°C was added 4-iodobenzoyl chloride (85 mg, 0.31 mmol). The reaction mixture was stirred at 0°C for 30 min, then at room temperature for another 3 h. After removal of the solvent by evaporation, the residue was mixed with THF (3 mL), and TBAF (1 M solution in THF, 0.28 mL, 0.28 mmol) was added. After stirring for 2 h at room temperature, the solvent was evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH Cl2 MeOH (96:4) to give, after recrystallization from CH2Cl2/hexane, the title compound 10 as a yellow powder (48 mg, 37%). 1H NMR (DMSO- ) £8.9 (bs, IH, NH), 7.90-7.73 (m, 5H, H-6, arom.), 5.91 (bs, IH, H-1'), 5.10 (m, IH, OH), 4.14 (m, IH, H-4'), 3.80, 3.57 (2m, 2H, H-5'), 2.35, 2.08 (2m, 2H, H-2'), 1.86 (m, 2H, H-3').
By following the same procedures as above but using the corresponding carboxylic acid chloride starting materials, the following compounds are also prepared: β-D-2 3 '-Dideoxy-5-fluoro-N4-(4-fluorobenzoyl)cytidine (11)
1H NMR (DMSO- δ) £8.9 (bs, IH, NH), 8.05, 7.34 (2m, 5H, H-6, arom.), 5.90 (d, IH, H-1'), 5.25 (m, IH, OH), 4.11 (m, IH, H-4'), 3.79, 3.58 (2m, 2H, H-5'), 2.35, 2.08 (2m, 2H, H-2'), 1.85 (m, 2H, H-3').
β-D-N4 -(4-chlororobenzoyl)-2 ',3 '-dideoxy-5 -fluorocytidine (12)
1H NMR (DMSO- e) £8.9 (bs, IH, NH), 7.99, 7.60 (2m, 5H, H-6, arom.), 5.90 (bs, IH, H-1'), 5.38 (m, IH, OH), 4.14 (m, IH, H-4'), 3.82, 3.58 (2m, 2H, H-5'), 2.35, 2.08 (2m, 2H, H-2'), 1.84 (m, 2H, H-3').
β-D-N4 -(4-bromobenzoyl)-2 ',3 '-dideoxy-5-fluorocytidine (13)
!H NMR (DMSO- 6) £8.9 (bs, IH, NH), 7.93, 7.72 (2m, 5H, H-6, arom.), 5.91 (d, IH, H-1'), 5.25 (m, IH, OH), 4.11 (m, IH, H-4'), 3.79, 3.58 (2m, 2H, H-5'), 2.35, 2.07 (2m, 2H, H-2'), 1.85 (m, 2H, H-3'). β-D-2 ',3 '-DideoxyS-fluoro-Nf-β-fluorobenzoytycytidine (14)
!H NMR (CDC13) £8.37 (d, IH, H-6), 8.09-7.24 (m, 4H, arom.), 6.08 (m, IH, H- 1'), 4.27 (m, IH, H-4'), 4.13, 3.82 (2d, 2H, H-5'), 2.48, 2.20 (2m, 2H, H-2'), 2.02 (m, 2H, H-3').
β-D-N4 -(3-Chlorobenzoyl)-2 ',3 '-dideoxy-5-fluorocytidine (15)
Η NMR (DMSO- 6) £8.8 (bs, IH, NH), 8.01-7.53 (m, 5H, H-6, arom.), 5.91 (d, IH, H-1'), 5.34 (t, IH, OH), 4.12 (m, IH, H-4'), 3.81, 3.58 (2d, 2H, H-5'), 2.40, 2.10 (2m, 2H, H-2'), 1.85 (m, 2H, H-3').
β-D-N4 -(3-Bromobenzoyl)-2 ',3 '-dideoxy-5 -fluorocytidine (16)
1H NMR (DMSO- e) £8.75 (bs, IH, NH), 8.14-7.45 (m, 5H, H-6, arom.), 5.90 (d, IH, H-1'), 5.29 (bs, IH, OH), 4.11 (m, IH, H-4'), 3.80, 3.58 (2m, 2H, H-5'), 2.40, 2.08 (2m, 2H, H-2'), 1.85 (m, 2H, H-3').
β-D-N4 -p-Anisoyl-2 ',3 '-dideoxy- 5 -fluorocytidine (17)
'HNMR (OMSO-de) £8.1 (bs, IH, NH), 7.97, 7.04 (2m, 5H, H-6, arom.), 5.95 (m, IH, H-1'), 4.50 (m, IH, OH), 4.40 (m, IH, H-4'), 3.82 (s, 3H, CH3), 3.80 (m, 2H, H-5'), 2.35, 2.05 (2m, 2H, H-2'), 1.90 (m, 2H, H-3').
β-D-2 ',3 '-DideoxyS-fluoro-rf-ft-nitrobenzoytycytidine (18)
'HNMR (DMSO- 6) £8.9 (bs, IH, NH), 8.32, 8.23 (2m, 5H, H-6, arom.), 5.92 (d, IH, H-1'), 5.30 (bs, IH, OH), 4.11 (m, IH, H-4'), 3.79, 3.59 (2m, 2H, H-5'), 2.35, 2.10 (2m, 2H, H-2'), 1.86 (m, 2H, H-3'). β-D-2 ',3 '-DideoxyS-fluoro-rf-β-nitrobenzoytycytidine (19)
1H NMR (DMSO-d6) £8.76 (d, IH, H-6), 8.7 (bs, IH, NH), 8.40, 7.80 (2m, 4H, arom.), 5.95 (d, IH, H-1'), 5.30 (m, IH, OH), 4.08 (m, IH, H-4'), 3.79, 3.58 (2m, 2H, H- 5'), 2.35, 2.08 (2m, 2H, H-2'), 1.85 (m, 2H, H-3').
β-D-2 ',3 '-DideoxyS-fluoro-Nf-β-nitrobenzoytycytidine (20)
!H NMR (CDC13) £8.49 (d, IH, H-6), 7.96-7.50 (m, 4H, arom.), 6.02 (d, IH, H- 1'), 4.22 (m, IH, H-4'), 4.11, 3.81 (2d, 2H, H-5'), 2.45, 2.15 (2m, 2H, H-2'), 1.98 (m, 2H, H-3').
β-D-N4 -Benzoyl-2 ',3 '-dιdeoxy-5-fluorocytidine (21)
1H NMR (DMSO-de) £8.2 (bs, IH, NH), 7.98, 7.52 (2m, 5H, H-6, arom.), 5.95 (d, IH, H-1'), 5.74 (bs, IH, OH), 4.57, 4.40 (2m, 3H, H-4', H-5'), 2.35, 2.08 (2m, 2H, H-2'), 1.90 (m, 2H, H-3').
β-D-2',3 ' -Dideoxy-5 -fluoro-N -^-toluoylcytidine (22)
Η NMR (CDC13) £8.31 (d, IH, H-6), 8.15, 7.24 (2m, 4H, arom.), 6.08 (m, IH, H- 1'), 4.25 (m, IH, H-4'), 4.10, 3.82 (2m, 2H, H-5'), 2.42 (s, 3H, CH3), 2.47, 2.15 (2m, 2H, H-2'), 2.00 (m, 2H, H-3').
β-D-2 ',3 '-DideoxyS-fluoro-N^-m-toluoylcytidine (23)
1H MR (CDC13) £8.31 (d, IH, H-6), 8.07, 7.36 (2m, 4H, arom.), 6.09 (m, IH, H- 1'), 4.25 (m, IH, H-4'), 4.11, 3.83 (2m, 2H, H-5'), 2.45, 2.18 (2m, 2H, H-2'), 2.42 (s, 3H, CH3), 2.00 (m, 2H, H-3'). β-D-2 ',3 '-Dideoxy-5-fluoro-N4-o-toluoylcytidine (24)
1H NMR (DMSO- e) £8.8 (bs, IH, NH), 7.55-7.26 (m, 6H, H-6, arom.), 5.88 (d, IH, H-1'), 5.30 (t, IH, OH), 4.12 (m, IH, H-4'), 3.82, 3.58 (2m, 2H, H-5'), 2.41 (s, 3H, CH3), 2.32, 2.07 (2m, 2H, H-2'), 1.83 (m, 2H, H-3').
β-D-2 ',3 '-Dideoxy-N4-(4-ethylbenzoyl)-5-fluorocytidine (25)
1H NMR (CDC13) £8.24 (d, IH, H-6), 8.18, 7.29 (2m, 4H, arom.), 6.10 (d, IH, H- 1'), 4.24 (m, IH, H-4'), 4.10, 3.80 (2m, 2H, H-5'), 2.72 (q, 2H, CH2), 2.50, 2.20 (2m, 2H,
H-2'), 2.00 (m, 2H, H-3'), 1.26 (t, 3H, CH3).
β-D-2 ',3 '-Dideoxy-5-fluoro-N4-(4-n-propylbenzoyl)cytidine (26)
1H NMR (CDC13) £8.30 (d, IH, H-6), 8.17, 7.25 (2m, 4H, arom.), 6.09 (m, IH, H- 1'), 4.24 (m, IH, H-4'), 4.11, 3.80 (2m, 2H, H-5'), 2.65 (t, 2H, CH2), 2.45, 2.18 (2m, 2H, H-2'), 2.02 (m, 2H, H-3'), 1.66 (m, 2H, CH2), 0.94 (t, 3H, CH3).
β-D-~N4-(4~n-Butylbenzoyl)-2 ',3 '-dideoxy-5-fluorocytidine (27)
1H NMR (CDCI3) £8.34 (d, IH, H-6), 8.17, 7.25 (2m, 4H, arom.), 6.10 (m, IH, H- 1'), 4.25 (m, IH, H-4'), 4.13, 3.82 (2m, 2H, H-5'), 2.68 (t, 2H, CH2), 2.50, 2.20 (2m, 2H, H-2'), 2.02 (m, 2H, H-3'), 1.66 (m, 2H, CH2), 1.37 (m, 2H, CH2), 0.93 (t, 3H, CH3).
β-D-~N4-(4-tert-Butylbenzoyl)-2 ',3 '-dideoxy-5-fluorocytidine (28)
1HNMR (CDC13) £8.31 (d, IH, H-6), 8.17, 7.48 (2m, 4H, arom.), 6.08 (m, IH, H- 1'), 4.25 (m, IH, H-4'), 4.10, 3.80 (2m, 2H, H-5'), 2.47, 2.15 (2m, 2H, H-2'), 2.00 (m, 2H, H-3'), 1.35 (s, 9H, t-Bu). β-D-2 ',3 '-Dideoxy-5~fluoro-N4-(2-furoyl)cytidine (29)
Η NMR (CDC13) £8.37 (d, IH, H-6), 7.62, 7.38, 6.52 (3m, 3H, furoyl), 6.07 (m, IH, H-1'), 4.25 (m, IH, H-4'), 4.11, 3.80 (2m, 2H, H-5'), 2.47, 2.17 (2m, 2H, H-2'), 2.01 (m, 2H, H-3').
β-D-2 ',3 '-Dideoxy-5-fluoro-N' i-(2-thiophenecarbonyl)cytidine (30)
Η NMR (CDCI3) £8.32 (d, IH, H-6), 7.96 (d, IH, thiophenyl), 7.60 (d, IH, thiophenyl), 7.13 (t, IH, thiophenyl), 6.08 (m, IH, H-1'), 4.25 (m, IH, H-4'), 4.13, 3.82 (2m, 2H, H-5'), 2.47, 2.17 (2m, 2H, H-2'), 2.02 (m, 2H, H-3').
β-D-2 ',3 '-Dideoxy-5-fluoro-N4-(nicotinoyl)cytidine (31)
Η NMR (CDC13) £9.11 (s, IH, nicotinoyl), 8.53 (d, IH, H-6), 8.75, 8.54, 7.40 (3m, 3H, nicotinoyl), 6.10 (m, IH, H-1'), 4.27 (m, IH, H-4'), 4.16, 3.83 (2m, 2H, H-5'), 2.48, 2.20 (2m, 2H, H-2'), 2.03 (m, 2H, H-3').
β-D-2 ',3 '-Dideoxy-5-fluoro-N4-(benzo[b]thiophene-2-carbonyl)cytidine (32)
Η NMR (DMSO-de) £8.7 (bs, IH, NH), 8.00, 7.45 (2m, 6H, H-6, arom.), 5.91 (d, IH, H-1'), 5.32 (m, IH, OH), 4.11 (m, IH, H-4'), 3.80, 3.58 (2m, 2H, H-5'), 2.44, 2.08 (2m, 2H, H-2'), 1.86 (m, 2H, H-3').
β-D-Η -(Cyclohexanecarbonyl)-2',3 '-dideoxy-5-fluorocytidine (33)
Η NMR (CDC13) £8.45 (d, IH, H-6), 6.04 (d, IH, H-1'), 4.25 (m, IH, H-4'), 4.12, 3.8.1 (2m, 2H, H-5'), 2.50-1.20 (m, 15H, H-2', H-3', c-hexyl). Example 10
β-D-N4 -Butyryl-2 ',3 '-dideoxy- 5 -fluorocytidine (34)
To a solution of 8 (131 mg, 0.28 mmol) and DMAP (5 mg) in anhydrous CH2C12 (2 mL) and Et3N (0.5 mL) at 0°C was added butyric anhydride (52 mg, 0.33 mmol). The reaction mixture was stirred at 0°C for 30 min, then at room temperature for another 2 h.
After removal of the solvent by evaporation, the residue was mixed with THF (3 mL), and TBAF (1 M solution in THF, 0.30 mL, 0.30 mmol) was added. After stirring for 2 h at room temperature, the solvent was evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH (96:4) to give, after recrystallization from CH2Cl2/hexane, the title compound 34 as a white solid (31 mg,
35%). 1H NMR (DMSO-d6) £ 8.21 (d, IH, H-6), 5.92 (t, IH, H-1'), 4.26 (m, IH, H-4'), 4.22 (m, 2H, H-5'), 2.30 (t, 2H, CH2), 2.38, 2.04 (2m, 2H, H-2'), 1.90 (m, 2H, H-3'), 1.58 (m, 2H, CH2), 0.85 (t, 3H, CH3).
Example 11
β-D-2 ', 3 '-Didehydro-2 ', 3 '-dideoxy-5-fluoro-N4-(4-fluorobenzoyl)cytidine (35)
To a solution of 9 (140 mg, 0.3 mmol) and DMAP (5 mg) in anhydrous CH2C12 (2 mL) and Et3N (0.5 mL) at 0°C was added 4-fluorobenzoyl chloride (52 mg, 0.33 mmol). The reaction mixture was stirred at 0°C for 30 min, then at room temperature for another 2 h. After removal of the solvent by evaporation, the residue was mixed with THF (3 mL), and TBAF (1 M solution in THF, 0.30 mL, 0.30 mmol) was added. After stirring for 2 h at room temperature, the solvent was evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH (96:4) to give, after recrystallization from CH2Cl2/hexane, the title compound 35 as a pale yellow solid (33 mg, 32%). XB NMR (DMSO-d6) £8.07, 7.35 (2m, 5H, H-6, arom.), 6.84 (bs, IH, H-1'), 6.42 (m, IH, H-2'), 5.98 (m, IH, H-3'), 5.22 (m, IH, OH), 4.88 (m, IH, H-4'), 3.66 (m,
2H, H-5'). By following the same procedures as above but using the corresponding carboxylic acid chloride starting materials, the following compounds are also prepared:
β-D-N4 -(4-Chlorobenzoyl)-2 ',3 '-didehydro-2 ',3 '-dideoxy-5-fluorocytidine (36)
1H NMR (DMSO-de) £8.00, 7.59 (2m, 5H, H-6, arom.), 6.84 (bs, IH, H-1'), 6.42 (m, IH, H-2'), 5.97 (m, IH, H-3'), 5.22 (m, IH, OH), 4.88 (m, IH, H-4'), 3.66 (m, 2H, H-
5').
β-D-N4 -(4-Bromobenzoyl)-2 ',3 '-didehydro-2 ',3 '-dideoxy-5-fluorocytidine (37)
lB NMR (DMSO-de) £7.86, 7.72 (2m, 5H, H-6, arom.), 6.85 (bs, IH, H-1'), 6.42
(m, IH, H-2'), 5.97 (m, IH, H-3'), 4.88 (m, IH, H-4'), 3.90-3.65 (m, 2H, H-5').
β-D-2 ',3 '-Didehydro-2 ',3'-dideoxy-5-fluoro-N4-(4-iodobenzoyl)cytidine (38)
XB NMR (DMSO-de) £7.90-7.60 (2m, 5H, H-6, arom.), 6.83 (bs, IH, H-1'), 6.42 (m, IH, H-2'), 5.97 (m, IH, H-3'), 5.22 (m, IH, OH), 4.88 (m, IH, H-4'), 3.66 (m, 2H, H-
5').
β-D-2 ',3 '-Didehydro-2 ',3 '-dideoxy-5-fluoro-N4-(3-fluorobenzoyl)cytidine (39)
lB NMR (DMSO-de) £7.85-7.39 (m, 5H, H-6, arom.), 6.84 (bs, IH, H-1'), 6.42 (m, IH, H-2'), 5.98 (m, IH, H-3'), 5.22 (m, IH, OH), 4.88 (m, IH, H^4'), 3.66 (m, 2H, H-
5')-
β-D-N4 -(3-Chlorobenzoyl)-2 ',3 '-didehydro-2 ',3 '-dideoxy-5 -fluorocytidine (40)
1H NMR (DMSO-d6) £8.00-7.40 (2m, 5H, H-6, arom.), 6.84 (bs, IH, H-1'), 6.42 (m, IH, H-2'), 5.97 (m, IH, H-3'), 5.22 (m, IH, OH), 4.88 (m, IH, H-4'), 3.66 (m, 2H, H-
5')- β-D-N4 -(3-Bromobenzoyl)-2 ',3 '-didehydro-2 ',3 '-dideoxy-5 -fluorocytidine (41)
B NMR (DMSO-de) £8.16-7.34 (m, 5H, H-6, arom.), 6.84 (bs, IH, H-1'), 6.46 (m, IH, H-2'), 5.98 (m, IH, H-3'), 5.23 (t, IH, OH), 4.88 (bs, IH, H-4'), 3.68 (m, 2H, H- 5').
β-D-N4 -p-Anisoyl-2 ',3 '-didehydro-2 ' ,3'-dideoxy-5-fluorocytidine (42)
B NMR (CDC13 + DMSO-d6) £7.72 (d, 2H, arom.), 7.12 (d, J = 7.2 Hz, IH, H-6), 6.93 (m, IH, H-1'), 6.48 (d, 2H, arom.), 6.45 (m, IH, H-2'), 5.87 (m, IH, H-3'), 5.78 (m, IH, H-4'), 4.03 (s, 3H, OCH3), 3.40 (m, 2H, H-5').
β-D-N4 -m-Anisoyl-2 ',3 '-didehydro-2 ',3 '-dideoxy-5 -fluorocytidine (43)
1HNMR (CDC13) £7.35-6.60 (m, 5H, H-6, H-1', arom.), 6.60 (m, IH, arom.), 6.58 (m, IH, H-2'), 5.82 (m, IH, H-3'), 5.74 (m, IH, H-4'), 3.99 (s, 3H, OCH3), 3.36 (m, 2H, H-5').
β-D-N4 -o-Anisoyl-2 ',3 '-didehydro-2 ',3 '-dideoxy-5-fluorocytidine (44)
XB NMR (DMSO-dg) £10.75(bs, IH, NH), 8.55 (d, IH, H-6), 7.77-7.08 (m, 4H, arom.), 6.84 (bs, IH, H-1'), 6.40 (m, IH, H-2'), 5.99 (m, IH, H-3'), 5.19 (t, IH, OH), 4.89 (m, IH, H-4'), 3.91 (s, 3H, OCH3), 3.66 (m, 2H, H-5').
β-D-2 3 '-Didehydro-2 ',3 '-dideoxy-5-fluoro-N4-(4-nitrobenzoyl)cytidine (45)
XB NMR (DMSO-de) £8.34-8.20 (m, 5H, H-6, arom.), 6.83 (bs, IH, H-1'), 6.42 (m, IH, H-2'), 5.95 (m, IH, H-3'), 5.18 (m, IH, OH), 4.87 (bs, IH, H-4'), 3.66 (m, 2H, H- 5')- β-D-2 ',3 '-Didehydro-2 ',3 '-dideoxy-5-fluoro-N4-(3-nitrobenzoyl)cytidine (46)
XB NMR (DMSO-de) £8.74-7.38 (m, 5H, H-6, arom.), 6.83 (bs, IH, H-1'), 6.42 (m, IH, H-2'), 5.97 (m, IH, H-3'), 5.18 (m, IH, OH), 4.87 (bs, IH, H-4'), 3.66 (m, 2H, H- 5').
β-D-2 ',3 '-Didehydro-2 ',3 ' -dideoxy-5 -fluoro-N4 -(2-nitrobenzoyl)cytidine (47)
B NMR (DMSO-de) £8.14-7.71 (m, 5H, H-6, arom.), 6.83 (bs, IH, H-1'), 6.42 (m, IH, H-2'), 5.95 (m, IH, H-3'), 5.18 (m, IH, OH), 4.87 (bs, IH, H-4'), 3.66 (m, 2H, H- 5').
β-D-2 ',3 '-Didehydro-2 ',3 '-dideoxy-5 fluoro-N4 -p-toluoylcytidine (48)
XB NMR (DMSO-de) £7.87-7.31 (2m, 5H, H-6, arom.), 6.83 (m, IH, H-1'), 6.40 (m, IH, H-2'), 5.95 (m, IH, Hr3'), 5.18 (m, IH, OH), 4.85 (m, IH, H-4'), 3.66 (m, 2H, H- 5'), 2.37 (s, 3H, CH3).
β-D-2 ',3' -Didehydro-2 ',3 '-dideoxy-5 -fluoro-N i -m-toluoylcytidine (49)
XB NMR (DMSO-de) £7.78, 7.42 (2m, 5H, H-6, arom.), 6.83 (bs, IH, H-1'), 6.41 (m, IH, H-2'), 5.97 (m, IH, H-3'), 5.17 (bs, IH, OH), 4.87 (m, IH, H-4'), 3.66 (m, 2H, H- 5'), 2.36 (s, 3H, CH3). , β-D-2 ',3 '-Didehydro-2 ',3 '-dideoxy- 5 -fluoro-N4 -o-toluoylcytidine (50)
Η NMR (DMSO-d6) £7.60-7.40 (m, 5H, H-6, arom.), 6.83 (bs, IH, H-1'), 6.40 (m, IH, H-2'), 5.99 (m, IH, H-3'), 5.17 (bs, IH, OH), 4.88 (m, IH, H-4'), 3.66 (m, 2H, H- 5'), 2.42 (s, 3H, CH3). β-D-2 ',3 '-Didehydro-2 ',3 '-dideoxy-Nf-(4-ethyllbenzoyl)-5-fluorocytidine (51)
XB NMR (CDC13) £8.19 (m, 2H, arom.), 8.09 (d, IH, H-6), 7.28 (m, 2H, arom.), 7.03 (m, IH, H-1'), 6.39 (m, IH, H-2'), 5.91 (m, IH, H-3'), 5.20 (m, IH, OH), 4.97 (m, IH, H-4'), 4.02-3.85 (m, 2H, H-5'), 2.71 (q, 2H, CH2), 1.26 (t, 3H, CH3).
β-D-N4 -(4-n-Butylbenzoyl)-2 ',3 '-didehydro-2 ',3 '-dideoxy-5 -fluoro-4 cytidine (52)
XB NMR (CDCI3) £8.19 (m, 2H, arom.), 8.12 (d, IH, H-6), 7.26 (m, 2H, arom.), 7.04 (m, IH, H-1'), 6.37 (m, IH, H-2'), 5.92 (m, IH, H-3'), 4.99 (m, IH, H-4'), 4.03-3.87 (m, 2H, H-5'), 2.68 (t, 2H, CH2), 1.66 (m, 2H, CH2), 1.36 (m, 2H, CH2), 0.93 (t, 3H, CH3).
β-D-N4 -(4-tert-Butylbenzoyl)-2 ',3 '-didehydro-2 ',3 '-dideoxy-5-fluorocytidine (53)
XB NMR (CDC13) £8.19 (m, 2H, arom.), 8.09 (d, IH, H-6), 7.48 (m, 2H, arom.), 7.04 (m, IH, H-1'), 6.36 (m, IH, H-2'), 5.91 (m, IH, H-3'), 5.22 (m, IH, OH), 4.98 (m, IH, H-4'), 4.02-3.86 (m, 2H, H-5'), 1.34 (s, 9H, t-Bu).
β-D-2 ',3 '-Didehydro-2 ',3 '-dideoxy-5-fluoro-N -(2-thiophenecarbonyl)cytidine (54)
XB NMR (DMSO-de) £8.30-7.20 (m, 4H, H-6, thiophene), 6.82 (m, IH, H-1'), 6.42 (m, IH, H-2'), 5.93 (m, IH, H-3'), 5.16 (m, IH, OH), 4.85 (m, IH, H-4'), 3.65 (m, 2H, H-5').
β-D-2 ',3 '-Didehydro-2 ',3 '-dideoxy-5-fluoro-N4-nιcotinoylcytidine (55)
XB NMR (DMSO-de) £9.11-7.53 (m, 5H, H-6, nicotinoyl), 6.83 (bs, IH, H-1'), 6.42 (d, IH, H-2'), 5.95 (m, IH, H-3'), 5.18 (m, IH, OH), 4.88 (m, IH, H-4'), 3.66 (m, 2H, H-5'). β-D-2 ',3 '-Didehydro-2 ',3 '-dideoxyS-fluoro-N^- enzofbJthiophene^-carbonytycytidine (56)
XB NMR (DMSO-de) £8.34-7.44 (m, 6H, H-6, arom.), 6.83 (bs, IH, H-1'), 6.41 (d, IH, H-2'), 5.94 (m, IH, H-3'), 5.18 (m, IH, OH), 4.85 (m, IH, H-4'), 3.66 (m, 2H, H-5').
β-D-N -(Cyclopentanecarbonyl)-2 ',3 '-didehydro-2 ',3 '-dideoxy-5 -fluorocytidine (57)
1H NMR (DMSO-de) £10.60 (bs, IH, NH), 8.48 (d, IH, H-6), 6.81 (bs, IH, H-1'), 6.38 (m, IH, H-2'), 5.97 (m, IH, H-3'), 5.16 (t, IH, OH), 4.88 (bs, IH, H-4'), 3.65 (m, 2H, H-5'), 3.06 (m, IH, CH), 1.85-1.51 (m, 8H, 4 CH2).
β-D-N4 -(Cyclohexanecarbonyl)-2 ',3 '-didehydro-2 3 ' -dideoxy- 5-fluorocytidine (58)
1H NMR (DMSO-d6) £10.50 (bs, IH, NH), 8.47 (d, IH, H-6), 6.81 (d, IH, H-1'), 6.38 (m, IH, H-2'), 5.97 (m, IH, H-3'), 5.16 (t, IH, OH), 4.88 (bs, IH, H-4'), 3.65 (m, 2H, H-5'), 2.60 (m, IH, CH), 1.81-1.17 (m, 10H, 5 CH2).
β-D-2 ',3 '-Didehydro-2 ',3 ' -dideoxy-5 -fluoro-W-heptanoylcytidine (59)
XB NMR (CDC13) £8.27 (d, IH, H-6), 7.00 (bs, IH, H-1'), 6.28 (m, IH, H-2'), 5.99 (m, IH, H-3'), 5.30 (bs, IH, OH), 5.01 (bs, IH, H-4'), 4.03-3.86 (m, 2H, H-5'), 1.68, 1.30 (2m, 10H, 5 CH2), 0.88 (t, 3H, CH3).
Example 12
β-D-N4 -Butyryl-2 ',3 '-didehydro-2 ',3 '-dideoxy-5-fluorocytidine (60)
To a solution of 9 (140 mg, 0.3 mmol) and DMAP (5 mg) in anhydrous CH2C12 (2 mL) and Et3N (0.5 mL) at 0°C was added butyric anhydride (52 mg, 0.33 mmol). The reaction mixture was stirred at 0°C for 30 min, then at room temperature for another 2 h. After removal of the solvent by evaporation, the residue was mixed with THF (3 mL), and TBAF (1 M solution in THF, 0.30 mL, 0.30 mmol) was added. After stirring for 2 h at room temperature, the solvent was evaporated, and the residue was purified by flash chromatography on silica gel eluting with CH2Cl2/MeOH (96:4) to give, after recrystallization from CH2Cl2/hexane, the title compound 60 as a white solid (31 mg, 35%). 1H NMR (DMSO-d6) £8.47 (d, IH, H-6), 6.82 (t, IH, H-1'), 6.39 (m, IH, H-2'), 5.98 (m, IH, H-3'), 5.20 (t, IH, OH), 4.89 (m, IH, H-4'), 3.66 (m, 2H, H-5'), 2.51 (t, 2H, CH2), 1.58 (m, 2H, CH2), 0.89 (t, 3H, CH3).
Example 13
Anti-HIV (in PBM cells) Assay
Anti-HIV-1 activity of the compounds was determined in human peripheral blood mononuclear (PBM) cells as described previously (Schinazi R.F., McMillan A., Cannon D., Mathis R., Lloyd R.M. Jr., Peck A., Sommadossi J.-P., St. Clair M., Wilson J., Furman P.A., Painter G., Choi W.-B., Liotta D.C. Antimicrob. Agents Chemother. 1992, 36, 2423; Schinazi R.F., Sommadossi J.-P., Saalmann V., Cannon D., Xie M.-Y., Hart G., Smith G., Hahn E. Antimicrob. Agents Chemother. 1990, 34, 1061). Stock solutions (20-40 mM) of the compounds were prepared in sterile DMSO and then diluted to the desired concentration in growth medium. Cells were infected with the prototype HIV-I AI at a multiplicity of infection of 0.01. Virus obtained from the cell supernatant was quantified on day 6 after infection by a reverse transcriptase assay using (rA)n*(dT)j2-i8 as template- primer. The DMSO present in the diluted solution (< 0.1 %) had no effect on the virus yield. AZT was included as positive control. The antiviral EC50 and EC90 were obtained from the concentration-response curve using the median effective method described previously (Chou T.-C. & Talalay P. Adv. Enzyme Regul 1984, 22, 27-55; Belen'kii M.S. & Schinazi R.F . Antiviral Res. 1994, 25, 1-11).
Anti-HIV (in MT-2 cells) Assay
In a second antiviral testing system, the potency of the compounds was determined by measurement of viral RNA accumulation in HIV-1RF infected MT-2 cells (Bacheler LT, Paul M, Otto MJ, Jadhav PK, Stone BA & Miller JA (1994) An assay for HIV RNIn infected cell lysates, and its use for rapid evaluation of antiviral efficacy. Antivir. Chem. Chemother. 5:111-121). The virus titer was established to determine the dilution producing 15 to 30 ng/RNA per well of HIV RNIn 3 days of infection. HIV-1 RNA was quantified using biotinylated capture and alkaline phosphatase-derivatized reporter oligonucleotides as described previously (Charvet A-S, Camplo M, Faury P, Graciet JC,
Mourier N, Chermann JC & Kraus JL (1994) Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate- and phosphonoacetate-2',3'-dideoxy-3'- thiacytidine conjugates. J. Med. Chem. 37:2216-2223). In a third system, the effect of analogs on the replication of HIV-INM-3 was determined via the Intercompany Consortium consensus p24 assay as previously described (Jadhav PK & MacKay MF
(1997) Cyclic urea amide: HIV-1 protease inhibitors with low nanomolar potency against both wild types and protease inhibitor resistant mutants of HIV. J. Med. Chem. 40:181- 190). Recombinant viruses were recovered by transfecting the appropriate NL4-3 plasmid by lipofection. Virus stocks recovered 7 to 10 days post-transfection were titered on MT-4 cells to determine if the dilution produced 1,000 to 3,000 ng p24 in 4 days. This dilution was then used in drug susceptibility assays, where drug was added 24 h post infection of cells, and p24 quantified by ELISA 3 days later.
Example 14
Anti-HBV assay
The anti-HBV activity of the compounds was determined by treating the AD-38 cell line carrying wild type HBV under the control of tetracycline (Ladner S.K„ Otto M.J., Barker C.S., Zaifert K., Wang G.H., Guo J.T., Seeger C. & King R.W. Antimicrob. Agents Chemother. 1997, 41, 1715-1720). Removal of tetracycline from the medium [Tet (-)] results in the production of HBV. The levels of HBV in the culture supernatant fluids from cells treated with the compounds were compared with that of the untreated controls.
Control cultures with tetracycline [Tet (+)] were also maintained to determine the basal levels of HBV expression. 3TC was included as positive control (see Tables 1, 2). Example 15
Cytotoxicity assay
The toxicity of the compounds was assessed in Vero, human PBM, CEM (human lymphoblastoid), MT-2, and HepG2 cells, as described previously (Schinazi R.F., Sommadossi J.-P., Saalmann V., Cannon D.L., Xie M.-Y., Hart G.C., Smith G.A. & Hahn
E.F. Antimicrob Agents Chemother. 1990, 34, 1061-1067). Cycloheximide was included as positive cytotoxic control, and untreated cells exposed to solvent were included as negative controls. The cytotoxicity IC50 was obtained from the concentration-response curve using the median effective method described previously (Chou T.-C. & Talalay P. Adv. Enzyme Regul. 1984, 22, 27-55; Belen'kii M.S. & Schinazi R.F. Antiviral Res. 1994,
25, 1-11) (see Tables 1, 2).
Table 1. Anti-HIV activity and cytotoxicity of N4-acyl-2', 3 '-dideoxy-5 -fluorocytidine
-4
O
Figure imgf000171_0001
Figure imgf000172_0001
Figure imgf000173_0001
Table 2. Anti-HIV activity and cytotoxicity of N τ4 -acyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine
-4 i
Figure imgf000174_0001
Figure imgf000175_0001
Figure imgf000176_0001
ND=not determined
-4

Claims

1. A compound of formula (I) or (II) :
Figure imgf000177_0001
or a pharmaceutically acceptable salt or prodrug thereof, wherein i) X is O, S, NR5, CH2, CHF or CF2; ii) Y is CH2, CHF or CF2; iii) R1 is chosen from hydrogen, halogen (F, CI, Br, I), alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, CN, CF3, N3, NO , aryl, heteroaryl and acyl; iv) R2 is chosen from alkenyl, alkynyl, cycloalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, thioalkyl, aryl, heteroaryl, and CδHtR where R is chosen from halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl, haloalkyl, aminoalkyl, alkoxy, thioalkyl, alkenyl, alkynyl, and aryl; v) R3 and R3 are chosen independently from H, halogen (F, CI, Br, I), CN, CF3, N3, NO2, alkyl, alkenyl, and alkynyl; vi) R4 is H, phosphate, carbonyl substituted with alkyl, alkenyl, alkynyl, aryl, or other pharmaceutically acceptable leaving group, which, when administered in vivo, is capable of providing a compound wherein R3 and R3 are H or phosphate, sulfonate ester, a lipid, an amino acid, a peptide, or cholesterol; and vii) R5 is H, acyl, alkyl, alkenyl, alkynyl, or cycloalkyl.
A pharmaceutical composition that includes an effective HIV or HBV treatment amount of a compound of claim 1 in a pharmaceutically acceptable carrier or diluent.
3. A method for the treatment of a host infected with HIV that includes administering an effective amount of a compound of claim 1 or 17 in a pharmaceutically acceptable carrier.
4. A method for the treatment of a host infected with HBV that includes administering an effective amount of a compound of claim 1 or 17 in a pharmaceutically acceptable carrier.
5. A method for the treatment of a host infected with HIV that includes administering an effective amount of a compound of claim 1 or 17 in a pharmaceutically acceptable carrier in combination with another anti-HIV agent.
6. A method for the treatment of a host infected with HBV that includes administering an effective amount of a compound of claim 1 or 17 in a pharmaceutically acceptable carrier in combination with another anti-HIV agent.
7. A compound of claim 1 or 17 for use in the treatment of host infected with HIV.
8. A compound of claim 1 or 17 for use in the treatment of a host infected with HBV infection.
9. The use of a compound of claim 1 or 17 in the manufacture of a medicament for the treatment of a host infected with HIV.
10. The use of a compound of claim 1 or 17 in the manufacture of a medicament for the treatment of a host infected with HBV.
11. The compound of claim 1, 7 or 8 selected from the group consisting of β-D-N4-p- iodobenzoyl-2' ,3 ' -dideoxy-5 -fluorocytidine, β-D-N4-p-fluoro-benzoyl-2 ' ,3 ' - dideoxy-5-fluorocytidine, β-D-N4-p-chlorobenzoyl-2',3'-dideoxy-5-fluoro- cytidine, β-D-N4-p-bromobenzoyl-2 ' ,3 ' -dideoxy-5 -fluorocytidine, β-D-N4-p- ethyl-benzoyl-2',3'-dideoxy-5-fluorocytidine, β-D-N4-p-t-butylbenzoyl-2',3'- dideoxy-5-fluoro-cytidine.
12. The compound of claim 1, 7 or 8 selected from the group consisting of β-D-N4-p-bromobenzoyl-2 ' ,3 ' -didehydro-2 ' ,3 ' -dideoxy-5 -fluorocytidine,
β-D-N -p-fluorobenzoyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine, β-D-Λ^-p-chlorobenzoyl^ ' ,3 ' -didehydro-2' 3 ' -dideoxy-5 -fluorocytidine,
β-D-Ν4-p-iodobenzoyl-2 ' ,3 ' -didehydro-2 ' ,3 ' -dideoxy-5 -fluorocytidine, β-D-N4-p-ethylbenzoyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine, and β-D-N4-p-t-butylbenzoyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine.
13. The method of claims 2 or 3 wherein the compound is selected from the group consisting of β-D-N4-p-iodobenzoyl-2', 3 '-dideoxy-5 -fluorocytidine, β-D-N -p- fluoro-benzoyl-2 ' ,3 ' -dideoxy-5 -fluorocytidine, β-D-N -p-chlorobenzoyl-2 ' ,3 ' - dideoxy-5 -fluoro-cytidine, β-D-N4-p-bromobenzoyl-2',3'-dideoxy-5- fluorocytidine, β-D-N4-p-ethyl-benzoyl-2',3'-dideoxy-5-fluorocytidine, . ,β-D-N4- p-t-butylbenzoyl-2' ,3 ' -dideoxy-5-fluoro-cytidine.
14. The method of claims 2 or 3 wherein the compound is selected from the group consisting of β-D-N^p-bromobenzoyW ' ,3 ' -didehydro-2 ' ,3 ' -dideoxy-5 -fluorocytidine, β-D-N4-p-fluorobenzoyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine,
β-D-N4-p-chlorobenzoyl-2 ' ,3 ' -didehydro-2 ' 3 ' -dideoxy-5-fluorocytidine, β-D-N4-p-iodobenzoyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine, β-D-N4-p-ethylbenzoyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine, and
β-D-N4-p-t-butylbenzoyl-2 ' ,3 ' -didehydro-2 ' ,3 ' -dideoxy-5 -fluorocytidine.
15. The use of claims 9 or 10 wherein the compound is selected from the group consisting of β-D-N4-p-iodobenzoyl-2',3'-dideoxy-5-fluorocytidine, β-D-N -p- fluoro-benzoyl-2',3'-dideoxy-5-fluorocytidine, β-D-N4-p-chlorobenzoyl-2',3'- dideoxy-5-fluoro-cytidine, β-D-N4-p-bromobenzoyl-2',3'-dideoxy-5- fluorocytidine, β-D-N4-p-ethyl-benzoyl-2',3 '-dideoxy-5-fluorocytidine, β-D-N4- p-t-butylbenzoyl-2',3'-dideoxy-5-fluoro-cytidine.
16. The use of claims 9 or 10 wherein the compound is selected from the group consisting of β-D-N4-p-bromobenzoyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine, β-D-N4-p-fluorobenzoyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine,
β-D-N4-p-chlorobenzoyl-2 ' ,3 ' -didehydro-2 ' 3 ' -dideoxy-5-fluorocytidine, β-D-Ν4-p-iodobenzoyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine,
β-D-N4-p-ethylbenzoyl-2 ' ,3 ' -didehydro-2 ' ,3 ' -dideoxy-5 -fluorocytidine, and β-D-N4-p-t-butylbenzoyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine.
17. A compound selected from the following, or its pharmaceutically acceptable salt or prodrug:
β-D-2',3 ' -dideoxy-5 -fluoro-N4-(4-iodobenzoyl)cytidine of the structure:
Figure imgf000181_0001
β-D-2',3 '-dideoxy-5-fluoro-N -(4-fluorobenzoyl)cytidine of the structure:
Figure imgf000181_0002
β-D-N4-(4-chlorobenzoyl)-2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000181_0003
β-D-N4-(4-bromobenzoyl)-2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000181_0004
β-D-2',3'-dideoxy-5-fluoro-N4-(3-fluorobenzoyl)cytidine of the structure:
Figure imgf000182_0001
β-D-N -(3-chlorobenzoyl)-2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000182_0002
or a pharmaceutically acceptable salt or prodrug thereof.
In one preferred embodiment, the active compound is β-D-N4-(3-bromobenzoyl)- 2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000182_0003
β-D-2',3 '-dideoxy-5-fluoro-N -(4-nitrobenzoyl)cytidine of the structure:
Figure imgf000182_0004
β-D-2',3 '-dideoxy-5-fluoro-N4-p-toluoylcytidine of the structure:
Figure imgf000183_0001
β-D-2',3 '-dideoxy-5-fluoro-N4-(m-toluoyl)cytidine of the structure:
Figure imgf000183_0002
β-D-2',3'-dideoxy-N4-(4-ethylbenzoyl)-5-fluorocytidine of the structure:
Figure imgf000183_0003
β-D-2',3 '-dideoxy-5-fluoro-N4-(4-propylbenzoyl)cytidine of the structure:
Figure imgf000183_0004
β-D-N4-(4-tert-butylbenzoyl)-2',3 '-dideoxy-5 -fluorocytidine of the structure:
Figure imgf000184_0001
β-D-2',3 '-dideoxy-5-fluoro-N -(2-thiophenecarbonyl)cytidine of the structure:
Figure imgf000184_0002
β-D-N4-(benzo-[b]-thiophene-2-carbonyl)-2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000184_0003
β-D-N4-(cyclohexane-carbonyl)-2',3 '-dideoxy-5-fluorocytidine of the structure:
Figure imgf000184_0004
β-D-2',3'-didehydro-2',3'-dideoxy-5-fluoro-N4-(4-iodobenzoyl)cytidine of the structure:
Figure imgf000185_0001
Figure imgf000185_0002
β-D-2',3'-didehydro-2',3'-dideoxy-5-fluoro-N -(4-fluorobenzoyl)cytidine of the structure:
Figure imgf000185_0003
- τ4 -(4-chlorobenzoyl)-2 ' ,3 ' -didehydro-2 ' ,3 ' -dideoxy-5 -fluorocytidine of the structure :
β-D-N4-(4-bromobenzoyl)-2',3 '-didehydro-2 ',3 '-dideoxy-5 -fluorocytidine of the structure:
Figure imgf000186_0001
β-D-N4-p-anisoyl-2',3 '-didehydro-2',3 '-dideoxy-5-fluorocytidine of the structure:
Figure imgf000186_0002
β-D-2',3 '-didehydro-2',3 ' -dideoxy-5 -fluoro-N4-(3-nitrobenzoyl)cytidine of the structure:
Figure imgf000186_0003
β-D-2',3' -didehydro-2 ' ,3 ' -dideoxy-5 -fluoro-N4-^-toluoylcytidine of the structure:
Figure imgf000187_0001
Figure imgf000187_0002
β-D-2 ' ,3 ' -didehydro-2 ' ,3 ' -dideoxy-5-fluoro-N4- -toluoylcytidine of the structure:
β-D-N4-(4-t-butylbenzoyl)-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000187_0003
or a pharmaceutically acceptable salt or prodrug thereof. β-D-N4-cyclopentanecarbonyl-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine of the structure:
Figure imgf000187_0004
or a pharmaceutically acceptable salt or prodrug thereof.
β-D-N4-(cyclohexanecarbonyl)-2',3 '-didehydro-2',3 '-dideoxy-5 -fluorocytidine of the structure:
Figure imgf000188_0001
PCT/US2002/040081 2001-12-14 2002-12-13 N4-acylcytosine nucleosides for treatment of viral iinfections WO2003063771A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2003563467A JP2005519916A (en) 2001-12-14 2002-12-13 N4-acylcytosine nucleosides for the treatment of viral infection
KR1020047009263A KR100978904B1 (en) 2001-12-14 2002-12-13 N4-Acylcytosine nucleosides for treatment of viral infections
MXPA04005779A MXPA04005779A (en) 2001-12-14 2002-12-13 N4.
AU2002365234A AU2002365234B2 (en) 2001-12-14 2002-12-13 N4-acylcytosine nucleosides for treatment of viral infections
CA2470255A CA2470255C (en) 2001-12-14 2002-12-13 N4-acylcytosine nucleosides for treatment of viral infections
EP02804833A EP1569652A4 (en) 2001-12-14 2002-12-13 N sp 4 /sp-acylcytosine nucleosides for treatment of viral iinfections
BR0214944-3A BR0214944A (en) 2001-12-14 2002-12-13 N4-Acylcytosine Nucleosides for the Treatment of Viral Infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34155501P 2001-12-14 2001-12-14
US60/341,555 2001-12-14

Publications (2)

Publication Number Publication Date
WO2003063771A2 true WO2003063771A2 (en) 2003-08-07
WO2003063771A3 WO2003063771A3 (en) 2005-07-07

Family

ID=23338072

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2002/040081 WO2003063771A2 (en) 2001-12-14 2002-12-13 N4-acylcytosine nucleosides for treatment of viral iinfections
PCT/US2002/040090 WO2003051306A2 (en) 2001-12-14 2002-12-16 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2002/040090 WO2003051306A2 (en) 2001-12-14 2002-12-16 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections

Country Status (10)

Country Link
US (6) US7105527B2 (en)
EP (1) EP1569652A4 (en)
JP (1) JP2005519916A (en)
KR (1) KR100978904B1 (en)
CN (1) CN100560073C (en)
AU (2) AU2002365234B2 (en)
BR (1) BR0214944A (en)
CA (1) CA2470255C (en)
MX (1) MXPA04005779A (en)
WO (2) WO2003063771A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914054B2 (en) 2000-05-23 2005-07-05 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus
US7094770B2 (en) 2000-04-13 2006-08-22 Pharmasset, Ltd. 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
US7105493B2 (en) 2000-05-26 2006-09-12 Idenix Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
US8093380B2 (en) 2002-08-01 2012-01-10 Pharmasset, Inc. Compounds with the bicyclo[4.2.1]nonane system for the treatment of Flaviviridae infections
US8658616B2 (en) 2006-11-24 2014-02-25 University College Cardiff Consultants Limited Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
US10525072B2 (en) 2002-11-15 2020-01-07 Idenix Pharmaceuticals Llc 2′-branched nucleosides and flaviviridae mutation

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790228B2 (en) * 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
CN100560073C (en) * 2001-12-14 2009-11-18 法玛塞特公司 The N that is used for the treatment of viral infection 4-acyl group cytidine
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AU2003248748A1 (en) * 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
EP2319853B1 (en) * 2002-12-12 2014-03-12 IDENIX Pharmaceuticals, Inc. Process for the production of 2'-branched nucleosides
CA2425031A1 (en) * 2003-04-01 2004-10-01 Smithkline Beecham Corporation Pharmaceutical compositions
SI2604620T1 (en) 2003-05-30 2016-10-28 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Modified fluorinated nucleoside analogues
US7741334B2 (en) * 2004-04-01 2010-06-22 Achillion Pharmaceuticals, Inc. Low dose therapy for treating viral infections
CN101023094B (en) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
EP1809301B1 (en) 2004-09-14 2019-11-06 Gilead Pharmasset LLC 2-fluoro-2-alkyl-substituted d-ribonolactone intermediates
EP2266579A1 (en) * 2004-10-19 2010-12-29 Achillion Pharmaceuticals, Inc. Pharmaceutical composition comprising elvucitavine
US7968703B2 (en) * 2005-03-07 2011-06-28 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
CA2634749C (en) * 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
SG172361A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside analogs
EP2376088B1 (en) 2008-12-23 2017-02-22 Gilead Pharmasset LLC 6-O-Substituted-2-amino-purine nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (en) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
PL3290428T3 (en) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
PL2552930T3 (en) 2010-03-31 2016-02-29 Gilead Pharmasset Llc Crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1-(2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
JP6069215B2 (en) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー Compound
PE20141056A1 (en) 2011-09-16 2014-09-05 Gilead Pharmasset Llc METHODS FOR THE TREATMENT OF HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN103242400B (en) * 2012-02-08 2016-06-08 河南师范大学 There is 5-substituted pyrimidines nucleoside-thiazolidhybrid hybrid and its preparation method of HIV (human immunodeficiency virus)-resistant activity
MD4595B1 (en) 2013-01-31 2018-10-31 Gilead Pharmasset Llc. Combination formulation of two antiviral compounds
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3265102A4 (en) 2015-03-06 2018-12-05 ATEA Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EA037868B1 (en) 2016-09-07 2021-05-28 Атеа Фармасьютикалс, Инк. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
WO2018144640A1 (en) 2017-02-01 2018-08-09 Atea Pharmaceuticals, Inc. Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043691A1 (en) * 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US13660A (en) * 1855-10-09 Improvements
US3309359A (en) * 1965-10-22 1967-03-14 Hoffmann La Roche N-mono-acyl-5-fluorocytosine derivatives and process
NL8202626A (en) 1982-06-29 1984-01-16 Stichting Rega V Z W DERIVATIVES OF 9- (2-HYDROXYETHOXYMETHYL) GUANINE.
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
ZA886890B (en) * 1987-10-09 1989-05-30 Hoffmann La Roche Novel dideoxycytidine derivatives
US6350753B1 (en) * 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
NL8901258A (en) 1989-05-19 1990-12-17 Stichting Rega V Z W New 5-halo-2'-3'-di:deoxy-cytidine derivs. - useful as anti-retro-viral agents, esp. for treating HIV infections
DD293498A5 (en) 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De METHOD FOR PRODUCING A MEDIUM FOR THE TREATMENT OR PROPHYLAXIS OF HEPATITE INFECTIONS IN HUMANS AND ANIMALS
JPH05310777A (en) 1992-05-14 1993-11-22 Yoshitomi Pharmaceut Ind Ltd 2'-deoxy-2'-methylidynecytidine compound
TW254946B (en) * 1992-12-18 1995-08-21 Hoffmann La Roche
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
GB9525606D0 (en) * 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
AU4988697A (en) * 1996-10-24 1998-05-15 Vion Pharmaceuticals, Inc. Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
AU1412299A (en) * 1997-11-25 1999-06-15 Protarga, Inc. Nucleoside analog compositions and uses thereof
NZ537432A (en) * 2000-10-13 2005-05-27 Shire Biochem Inc Dioxolane analogs for improved inter-cellular delivery
WO2002032920A2 (en) * 2000-10-18 2002-04-25 Pharmasset Limited Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
CN100560073C (en) * 2001-12-14 2009-11-18 法玛塞特公司 The N that is used for the treatment of viral infection 4-acyl group cytidine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043691A1 (en) * 1998-02-25 1999-09-02 Emory University 2'-fluoronucleosides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1569652A2 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094770B2 (en) 2000-04-13 2006-08-22 Pharmasset, Ltd. 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
US6914054B2 (en) 2000-05-23 2005-07-05 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus
US7157441B2 (en) 2000-05-23 2007-01-02 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus
US7169766B2 (en) 2000-05-23 2007-01-30 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus
US10363265B2 (en) 2000-05-23 2019-07-30 Idenix Pharmaceuticals Llc Methods and compositions for treating hepatitis C virus
US10758557B2 (en) 2000-05-23 2020-09-01 Idenix Pharmaceuticals Llc Methods and compositions for treating hepatitis C virus
US7105493B2 (en) 2000-05-26 2006-09-12 Idenix Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
US7163929B2 (en) 2000-05-26 2007-01-16 Idenix Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
US9968628B2 (en) 2000-05-26 2018-05-15 Idenix Pharmaceuticals Llc Methods and compositions for treating flaviviruses and pestiviruses
US8093380B2 (en) 2002-08-01 2012-01-10 Pharmasset, Inc. Compounds with the bicyclo[4.2.1]nonane system for the treatment of Flaviviridae infections
US10525072B2 (en) 2002-11-15 2020-01-07 Idenix Pharmaceuticals Llc 2′-branched nucleosides and flaviviridae mutation
US8658616B2 (en) 2006-11-24 2014-02-25 University College Cardiff Consultants Limited Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus

Also Published As

Publication number Publication date
US7105527B2 (en) 2006-09-12
AU2002364730A1 (en) 2003-06-30
KR20040094398A (en) 2004-11-09
JP2005519916A (en) 2005-07-07
US20040214844A1 (en) 2004-10-28
WO2003051306A2 (en) 2003-06-26
US6908924B2 (en) 2005-06-21
KR100978904B1 (en) 2010-08-31
US20090176730A1 (en) 2009-07-09
CA2470255C (en) 2012-01-17
EP1569652A4 (en) 2008-07-02
US20070078080A1 (en) 2007-04-05
US20030176319A1 (en) 2003-09-18
MXPA04005779A (en) 2005-05-16
US8114997B2 (en) 2012-02-14
CN100560073C (en) 2009-11-18
USRE42015E1 (en) 2010-12-28
EP1569652A2 (en) 2005-09-07
AU2002364730A8 (en) 2003-06-30
BR0214944A (en) 2005-06-07
WO2003051306A3 (en) 2003-12-18
CA2470255A1 (en) 2003-08-07
CN1617726A (en) 2005-05-18
WO2003063771A3 (en) 2005-07-07
US20120202766A1 (en) 2012-08-09
AU2002365234B2 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
US8114997B2 (en) N4-acylcytosine nucleosides for treatment of viral infections
AU2002365234A1 (en) N4-acylcytosine nucleosides for treatment of viral infections
KR101995598B1 (en) Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
FI93217B (en) Process for the preparation of esters and amides of therapeutically active nucleoside derivatives
WO2012158811A2 (en) Purine monophosphate prodrugs for treatment of viral infections
CA2685748A1 (en) Azido purine nucleosides for treatment of viral infections
WO1993022328A1 (en) Adenosine derivatives having a2 agonist activity
WO2011069294A1 (en) N6-substituted adenosine derivatives, n6-substituted adenine derivatives and uses thereof
WO2014135107A1 (en) Novel nucleoside phosphoramidate compound and use thereof
WO2010068708A2 (en) 3&#39;-azido purine nucleotide prodrugs for treatment of viral infections
JP2022531899A (en) Modified cyclic dinucleoside compound as a STING modulator
Nauš et al. Synthesis and biological profiling of 6-or 7-(het) aryl-7-deazapurine 4′-C-methylribonucleosides
RU2731385C1 (en) Macroheterocyclic nucleoside derivatives and analogues thereof, production and use
Béres et al. Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogs derived from common chiral pools:(+)-(1R, 5S)-and (-)-(1S, 5R)-2-oxabicyclo [3.3. 0] oct-6-en-3-one
Koszytkowska-Stawińska et al. Synthesis of aza-analogues of Ganciclovir
US20030162992A1 (en) Preparation of intermediates useful in the synthesis of antiviral nucleosides
Pei et al. Synthesis of 3′-C-hydroxymethyl-substituted pyrimidine and purine nucleosides as potential anti-hepatitis C virus (HCV) agents
JPH0859688A (en) 5&#39;-thioester-substituted trifluorothymidine derivative and carcinostatic agent containing the same as active ingredient
Camara et al. Synthesis of L‐Analogues of 1‐(2′, 3′‐Dideoxy‐β‐D‐glycero‐pent‐2‐enofuranosyl) thymine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/005779

Country of ref document: MX

Ref document number: 2003563467

Country of ref document: JP

Ref document number: 2470255

Country of ref document: CA

Ref document number: 1020047009263

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002365234

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002804833

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028278402

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002804833

Country of ref document: EP